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Abstract 
Like many Gram negative bacterial pathogens Enterohaemorrhagic Escherichia coli 
(EHEC) O157:H7 possesses a type III secretion system (T3SS). The T3SS translocates 
effector proteins into host cells during infection and consists of a basal apparatus that 
spans the inner and outer membranes and a needle and filament complex. The basal 
apparatus is composed of -20 proteins that are highly conserved between bacterial 
species, but despite this homology little is known about the EHEC basal apparatus. 
The aim of this project was to label inner membrane basal apparatus proteins with 
fluorescent markers or immunogenic tags in order to investigate their function, 
regulation and localization. Cloning strategies were designed to insert tags at the 3' end 
of eight genes encoding putative inner membrane proteins and to use these fusions to 
replace the wild type sequences by allelic exchange. 
From the eight strategies, escR and escU were taken forward to produce five EHEC 
O157:H7 strains. One strain contained EscR labelled at the C- terminus with an HA 
(haemagglutinin) epitope tag and the other four strains contained different labelled 
versions of EscU. Work with these strains demonstrated that the T3SS could not be 
visualized using fluorescence microscopy. However, Western blot analysis did show that 
the EscU protein was cleaved into 30kDa and 10kDa peptides, both of which localized 
to the membrane fraction of the bacterial cell. This cleavage was most likely occurring at 
the conserved cleavage site NPTH, which is present in the homologous proteins YscU 
from Yersinia pseudotuberculosis and FlhB from the flagella basal apparatus of 
Salmonella Typhimurium. 
Interestingly all the mutant strains constructed did not secrete a detectable level of EspD, 
apart from one fusion that had previously been shown to cleave the tag from EscU. This 
indicated that, despite the small size of the HA tag, all the tags interfered with the 
function of EscR or EscU. Fusions to the 10kDa fragment of EscU, along with a deletion 
of this domain, were used to elucidate its function in the T3SS. All the EscU mutants did 
xxvi 
not form EspA filaments, secrete EspD at wild type levels or secrete detectable levels of 
Tir, while the expression from the LEE1 -5 promoters remained unaffected. These 
phenotypes could not be restored upon supplying the 10kDa peptide in trans. 
Based on these results and previous work with the EscU homologues; it is proposed that 
the uncleaved EscU protein is needed to secrete EscF. After a defined period EscU is 
cleaved (possibly auto -catalytically) and this allows the secretion of EspA, B and D. The 
lack of wild type EscU in the mutant strains may not allow EscF to be secreted or 
assembled correctly and this in turn leads to the inhibition of EspA, B and D 
translocation. 
An anti EscF antibody was obtained and used to detect EscF in cell fractions of the 
mutant EscU strains. Western blot analysis with this antibody detected a protein of the 
estimated size for EscF; however, similar size bands were still detectable in a LEE4 
deletion strain (containing no escF). Progression of the research requires EscF secretion 
to be measured in order to establish whether the carboxy -terminal of EscU is essential 
for EscF export in EHEC O157:H7. 
In conclusion, the project utilized a complex strategy to produce single copy gene 
fusions to basal apparatus proteins. This approach was taken to elucidate the function, 
localization and interactions of basal apparatus proteins whilst causing minimal changes 
to sequence, expression and copy number. Even so, it was evident that even minimal 
changes were not tolerated and inhibited secretion by the system. Future research will 
have to proceed with either alternative target proteins or the generation of high affinity 





1.1 An introduction into Escherichia coli 
The genus Escherichia is a member of the Enterobacteriaceaen family that have their 
principal habitat in the bowel of humans and animals. Commensal strains of E. coli 
usually colonise the gastrointestinal tract within a few hours of birth and rarely cause 
disease (Kaper, J., et al 2004). 
E. coli are short, straight Gram negative bacilli. They are facultative anaerobes that can 
grow rapidly by respiratory metabolism and by fermentation (Nataro, J., et al 1998). 
Their serological characteristics depend on a number of antigens. The somatic 
lipopolysaccharide 0-antigen, the flagella H- antigen, and the capsular K- antigen, form 
the basis of the modified Kauffmann typing scheme where a specific combination of O 
and H antigens defines the serotype of an isolate (Nataro, J., et al 1998, Orskov, I., et al 
1977). 
1.2 Diarrhoeagenic E. coli 
As a pathogen E. coli has acquired colonisation and virulence factors, which allow it to 
cause disease in several body systems; including urinary tract infections, septicaemia, 
meningitis and diarrhoea. The E. coli that cause diarrhoea are categorised into six main 
pathogenicity groups depending on virulence properties, mechanisms of pathogenicity, 
clinical symptoms and serology (Kaper, J., et al 2004, Wasteson, Y., 2001). 
1. Enteroinvasive E. coli (EIEC) 
2. Enterotoxigenic E. coli (ETEC) 
3. Enteroaggregative E. coli (EAEC) 
4. Diffusely Adherent E. coli (DAEC) 
5. Enteropathogenic E. coli (EPEC) 
6. Enterohaemorrhagic E. coli (EHEC /STEC/VTEC) 
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1.2.1 Enteroinvasive E. coli (EIEC) 
EIEC are associated with dysentery like disease, a disease involving the inflammation of 
the lining of the large intestine, causing stomach pains and diarrhoea. It is a large 
contributor to paediatric diarrhoea and has been associated with as much as 5% of 
diarrhoea and 20% of dysentery cases in developing countries (Pacheco -Gil, L., et al 
2006). Where EIEC infections are common asymptomatic human excretors are found. In 
Western Europe EIEC is rarely isolated but the exact number of infections may be under 
estimated because of misdiagnoses due to its similarity with dysentery caused by 
Shigella (Beutin, L., et al 1997). The site of infection for EIEC is the colon and the 
diarrhoea tends to contain blood and mucus. EIEC is able to invade and multiply within 
the colonic epithelia cells (Kaper, J., et al 2004, Wasteson, Y., 2001). 
1.2.2 Enterotoxigenic E. coli (ETEC) 
ETEC strains are a major cause of disease in infants in developing countries and 
travellers. Worldwide ETEC is considered to be the most common cause of E. coli 
mediated diarrhoea. Its prevalence in the developing world results in 650 million cases a 
year and approximately 800,000 deaths (Turner, S., et al 2006). ETEC infection leads to 
a sudden onset of diarrhoea that can lead to severe dehydration and death. Where 
hygiene levels are high ETEC is not considered to be a significant pathogen, but it is a 
problem for travellers to the developing world and military personnel. ETEC also affects 
young animals such as calves, lambs and neonatal and post weaning piglets, leading to 
financial loss (Wasteson, Y., 2001). ETEC produces colonisation factors that allow the 
bacteria to attach to the intestinal mucosa. After the close contact is established ETEC 
produce one or more cytotoxin, which induce fluid secretion and /or inhibit absorption in 
the gut (Turner, S., et al 2006). These cytotoxins include: 
1.2.2.1 Heat Labile Enterotoxin 
The heat labile enterotoxin (LT) is the most characterised virulence factor of ETEC due 
to its similarity to the Vibrio cholerae enterotoxin (choleragen). Mature LT is 84kDa and 
consists of six subunits: one 28kDa A subunit and five 11.6kDa B subunits. Once in the 
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intestinal tract the B subunits mediate the entry of the A subunit into the host cell by 
binding to ganglioside receptors on the intestinal mucosal cell (enterocyte) membrane. 
Each B subunit binds to one receptor, when all five are bound the A subunit is 
internalised. Once inside the cell the A subunit is activated by proteolytic cleavage into 
two domains and becomes a functioning adenosine -ribosyl transferase. It acts by 
transferring ADP -ribose from nucleotide adenine dinucleotide (NAD) to the stimulatory 
guanine nucleotide- binding regulatory protein subunit of the adenylate cyclase system. 
This stimulates the adenylate cyclase system causing elevated levels of cyclic AMP, up 
to 100 -fold of normal levels. This leads to increased secretion of calcium ions and 
impaired absorption of sodium ions, causing water to leave the cells due to osmotic 
effects, resulting in diarrhoea. There are two main subgroups of LT: LT -I and LT -II 
(with LT -I being most closely related to choleragen). These sub groups are distinguished 
by their different B subunits that bind to different ganglioside receptors (Sussman, M., 
1997, Turner, S., et al 2006). 
1.2.2.2 Heat Stable Enterotoxin 
The heat stable enterotoxins (ST) can be categorized into two distinct groups: STa (STI) 
and STb (STII). Both types are synthesised as pre -pro -peptides of 72 amino acids that 
are processed during their export to an active toxin of just 18 or 19 amino acids (Turner, 
S., et al 2006). STa binds to host surface receptors and leads to an increase in 
intracellular cGMP levels, which activates the cystic fibrosis transmembrane 
conductance regulator chloride channel (CFTR). This activation enhances the secretion 
of water and salt and inhibits the absorption of sodium, causing secretory diarrhoea. 
STb, which is mostly associated with porcine infections, is also processed during 
translocation across the membrane from a 72 amino acid protein to a 48 amino acid 
toxin. The toxin binds to sulphatide and is internalised into the host cell where it causes 
an influx of calcium, which leads to the opening of ion channels (possibly CFTR) 
(Sussman, M., 1997, Turner, S., et al 2006). 
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1.2.3 Enteroaggregative E. coli (EAEC) 
EAEC were first characterised in 1987 when stool cultures from Chilean children helped 
distinguish the EAEC strains from EPEC (Nataro, J., et al 1987). Their characteristic 
adherence is seen on HEp -2 cells where they bind in a `stacked brick' formation. EAEC 
colonise the mucosa (most likely the colon) and enhance mucus secretion creating a 
mucus -bacterium biofilm. Their role as a causative agent of diarrhoea has been highly 
debated but studies have linked EAEC with diarrhoea in both developing and developed 
countries, particularly with persistent paediatric diarrhoea. Typically EAEC infection 
causes a watery, mucoid, secretory diarrhoea with low grade fever and little or no 
vomiting, but up to one third of all the cases can present with grossly bloody stools. 
Although some EAEC strains have been shown to contain toxins and adhesins, they are 
not found uniformly in all strains that cause diarrhoea (Wasteson, Y., 2001, Weintraub, 
A., 2007). 
1.2.4 Diffusely Adherent E. coli (DAEC) 
DAEC are named diffusely adherent due to their adherence to HEp -2 cells, where they 
do not produce microcolonies like EPEC. The association of DAEC with diarrhoea is 
not strong and only a few studies have been carried out on the clinical symptoms. 
However, there may be an age dependant susceptibility to DAEC and infection seems to 
manifests itself as watery diarrhoea with no blood in the stools (Nataro, J., et al 2004). 
Two fimbrial adhesins have been identified in DAEC which mediate the diffuse 
adherence; they are fimbrial adhesin F1845 and AIDA -I but the pathogenesis of the 
disease is still unknown (Torres, A., et al 2005). 
1.2.5 Enteropathogenic E. coli (EPEC) 
EPEC is responsible for significant mortality and morbidity worldwide as it is a leading 
cause of diarrhoea in infants under 2 years of age. It produces profuse watery diarrhoea, 
colonising the small intestine. Whilst the exact mechanism of diarrhoea remains obscure 
a three stage model of infection was proposed in 1992 by Donnenberg and Kaper 
(Donnenberg, M., et al 1992). This model used genetic evidence to upgrade the previous 
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two stage model and further dissected and separated EPEC's mode of action on 
epithelial cells. The model consists of a first stage of localized adherence, followed by a 
second stage of signal transduction and a final intimate adherence stage. Although vastly 
simplified it has proven to be robust enough to accommodate recent understandings of 
how EPEC utilises its virulence factors to colonise and cause diarrhoea (Clarke, S., et al 
2003). The intimate attachment of EPEC to the intestinal epithelium, by the type III 
secretion system (T3SS), causes disruption of the ionic balance in the intestine by 
effacing microvilli. The effacement process requires three effector proteins (Map, EspF 
and Tir) and leads to the retention of detached microvillar material (Dean, P., et al 
2006). The onset of diarrhoea in volunteers can occur as little as 2.9hr after ingestion of 
EPEC, indicating that active secretion is involved with a variety of intestinal ion 
transporters affected (Nataro, J., et al 1998). 
1.3 Enterohaemorrhagic E. coli (EHEC /STEC/VTEC) 
EHEC is the last of the six categories of diarrhoeagenic E. coli and is the organism 
studied in this project. To understand the different nomenclature (EHEC /STEC /VTEC) 
it is important to put the emergence and classification of EHEC /STEC /VTEC in 
chronological order. In 1977 Konowalchuk et al (Konowalchuk, J., et al 1977) found a 
cytotoxin present in culture filtrates in 10 of 136 E. coli strains. This toxin induced a 
cytotoxic response in Vero cells, distinct from the effect of the heat labile cytotoxin. 
Later in 1982 O'Brien et al (O'Brien, A., et al 1982) reported a cytotoxic effect of 
extracts from lysed E. coli on HeLa cells that was neutralised with anti -sera to shiga 
toxin from S. dysenteriae type I, this identified Shiga -like toxin producing E. coli 
(STEC) strains. The previous described assay (Konowalchuk, J., et al 1977) was then 
used by Karmali et al (Karmali, M., et al 1983b) in a study that linked sporadic cases of 
haemolytic uraemic syndrome (HUS) with faecal cytotoxins and cytotoxin -producing E. 
coli. Again, the cytotoxin was found to be active on Vero cells, less so on HeLa cells 
and inactive on W138 cells and termed Verotoxin (VT). The study found that 11 out of 
15 (73 %) of the HUS cases had evidence of infection by these VT positive E. coli 
(VTEC), suggesting a high association between the VT producing E. coli and the 
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disease. However, when O'Brien et al published again (O'Brien, A., et al 1983), they 
showed that a VTEC strain from the study by Konowalchuk et al in 1977 produced the 
Shiga -like toxin (Stx). After further analysis O'Brien et al deduced that the two toxins 
(the Verotoxin and the Shiga -like toxin) were the same toxin, having an identical 
molecular weight, subunit structure and cytotoxic effect on Vero cells. Late in 1983, 
Karmali et al (Karmali, M., et al 1983) proposed that it was the Verotoxin /Shiga -like 
toxin that was responsible for the clinical symptoms of haemorrhagic colitis (HC) and 
HUS and that both these conditions originated from the same disease - an infection with 
EHEC. From this publication history two terms emerged to describe the same strains of 
E. coli; Verotoxin producing E. coli (VTEC) and Shiga -like toxin producing E. coli 
(STEC) with EHEC classified as a VTEC /STEC strain that is associated with disease 
(particularly HC and HUS) and forms attaching and effacing (AJE) lesions. This is an 
important distinction as some strains of VTEC /STEC are not pathogenic, whilst by 
definition all strains of EHEC are capable of causing disease (Nataro, J., et al 1998). 
Riley et al reported the first outbreaks of EHEC O157:H7 in 1983 after investigating 
two outbreaks in 1982, one in Oregon and one in Michigan. These outbreaks were of a 
gastrointestinal illness that affected at least 47 people. It was characterised by grossly 
bloody diarrhoea and little or no fever, symptoms that were termed haemorrhagic colitis 
(HC). Riley et al traced the outbreak back to the consumption of undercooked beef patty 
in a fast food restaurant chain. Stool analysis from the patients found 9 out of 12 samples 
contained the previously rarely isolated serotype of EHEC O157:H7, which was shed 
within 4 days of the onset of HC (Riley, L., et al 1983). 
1982 and 1983 saw an eventful time for EHEC O157:H7, with the serotype being linked 
to outbreaks in America, where it was responsible for causing serious diseases. 
However, it was not until data published by the Public Health Laboratory (London, UK) 
was taken into account that the importance of these outbreaks could be interpreted. In 
1983 Day et al (Day, N., et al 1983) reported that between 1978 and 1983 the Public 
Health Laboratory had catalogued 15,000 serotypes of E. coli, of which only 28 were of 
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the serotype 0157 and only 1 of these was of the H type 7. Over the previous ten years 
(1973 - 1983) the Public Health Laboratory had received strains from 161 outbreaks of 
E. coli and non of them were attributed to 0157. It could only be concluded that 
previous to 1983 O157:H7 was not an important cause of outbreaks or sporadic cases of 
diarrhoea in the UK. This conclusion was echoed in America and Canada after similar 
reviews of previously catalogued strains. It meant that in 1983 EHEC O157:H7 was a 
new emerging pathogen (Nataro, J., et al 1998). 
1.3.1 Haemolytic Uraemic Syndrome (HUS) 
Since 1982 the reported cases of EHEC infections have increased world wide, with large 
outbreaks in Japan, Scotland and the USA. In an EHEC surveillance and prevention 
meeting (WHO; Reilly, A., 1998) outbreaks were reported in USA, Canada, England 
and Wales, Scotland, Germany, Denmark, South America and in many of the African 
countries where diagnosis and serotyping was possible. Of these outbreaks 1 -10% of all 
the cases develop HUS, a life threatening disease. Karmali et al (Karmali, M., et al 
1983) linked the cause of HUS with the production of the Stx toxin and that link remains 
today, although the exact mechanism is still unknown. However, studies of the large 
outbreaks, such as the Sakai City outbreak in Japan in 1996, where over 9000 cases were 
reported, have led to treatment plans for patients presenting with HUS and can correlate 
the progression of an EHEC infection to the HUS complication (Honda, X., et al 1999, 
Yoshioka, K., et al 1999). Complete HUS is defined by three main symptoms: 
1) Haemolytic anaemia (anaemia and fragmented red blood cells). 
2) Thrombocytopenia (platelets, 100 000 /1AL or less). 
3) Acute renal dysfunction (oliguria, anuria or increased serum creatine). 
With the associated symptoms: 
1) Central nervous system damage (loss of consciousness, convulsions, headaches 
etc). 
2) Pancreatitis. 
(Yoshioka, K., et al 1999) 
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Several risk factors have been identified that correlate with the progression of an EHEC 
infection to HUS, they include: 
1) Age: either very young or very old. 
2) Mental retardation. 
3) The presence of bloody diarrhoea. 
4) A weaker expression of P antigen on red blood cells. 
5) Anti -motility agents and anti -diarrhoeal agents. 
6) The use of antimicrobials. 
(Honda, T., 1999) 
The treatment regime of EHEC infections and HUS remains controversial, with the use 
of certain antibiotics making the illness worse. During the Sakai City outbreak the 
antibiotic fosfomycin was given to 84% of patients within 5 days of presenting with 
symptoms and found not to correlate with the progression to HUS (Honda, T., et al 
1999). However, there are reports that fosfomycin causes a 13 to 16 fold increase of the 
amount of Stx in the supernatant of cultures grown in minimum inhibitory concentration 
(Yoh, M., et al 1997). It has been documented that antibiotics such as quinolones, that 
induce the bacterial `SOS' response to DNA damage, cause an increase in the level of 
free faecal Stx in mice whilst decreasing the actual amount of faecal VTEC (Zhang, X., 
et al 2000). With antibiotics often prescribed before the cause of an infection has been 
ascertained there are concerns about the link between the antibiotic used and the onset of 
HUS. The use of anti -diarrhoeal agents and anti motility agents were also seen to 
increase the likelihood of developing HUS (Honda, T., 1999). The use of IgG, which 
contains antibodies to Stx 1, and dialysis coupled with plasma exchange have yielded 
some success in treating both complete and incomplete forms of HUS (Yoshioka, K., et 
al 1999). 
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1.3.2 Epidemiology of EHEC O157:H7 
1.3.2.1 Bovine Reservoir of EHEC O157:H7 
In 1986 60 children and 14 adults visited a dairy farm in Southwest Ontario; of these 74 
individuals, 48 became ill with abdominal cramps and watery diarrhoea. An EHEC 
0157:H7 infection was diagnosed in 43 of the cases, with significant association 
between infection and the consumption of unpasteurised milk on the farm. The faecal 
samples of 67 healthy cows from the farm were screened for the presence of EHEC, 
identifying 7 EHEC positive animals, two of which were positive for O157:H7, while 
the others were not serotyped. This was the first direct evidence that cattle were the 
primary reservoirs of EHEC O157:H7 and that colonised cattle were asymptomatic 
(Borczyk, A., et al 1987) 
Cattle are considered the main reservoir for EHEC O157:H7, with 10% of cattle 
carrying EHEC O157:H7 in their faeces. Although EHEC O157:H7 could be detected in 
the faeces of cattle there was some debate as to its localization within the bovine host as 
it was infrequently found in the gastrointestinal tract. It was later found that EHEC 
0157:H7 has a specific tropism for the recto -anal - junction (RAJ) at the terminal rectum 
(Naylor, S., et al 2003). The main area colonised was 3 -5cm proximal to the RAJ and 
explained its previous lack of detection, as this site had not been sampled before. Its 
colonisation at such high proximity to the anal opening also explained the observed 
faecal distribution of the bacteria, with more bacteria found on the surface of faeces 
compared to the core, indicating that EHEC O157:H7 lined the outside of the faeces 
during their final stages of compaction and excretion (Naylor, S., et al 2003). The RAJ 
localization was later confirmed with intact rectum samples from 267 cattle, where 35 
animals were positive for EHEC O157:H7, with a region closest to the RAJ being the 
principle site for carriage. A high level of variation of the amount of EHEC O157:H7 
detected in the faeces of individual animals was also observed, adding evidence to the 
existence of `supershedders' (Low, J., et al 2005). These supershedders are identified by 
excretion of a high level of EHEC O157:H7 in their faeces ( >104CFUmg-1) and have 
been identified in penned animals as the possible cause of infection of co- penned 
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animals (Cobbold, R., et al 2007). When considering EHEC 0157:H7 epidemiology and 
infection control strategies, the supershedders are very important. In a mathematical 
model of an EHEC 0157:H7 infected herd, supershedders account for only 20% of 
infected cattle but are responsible for 80% of the transmission of infection. Because 
these few supershedders are responsible for a disproportionate number of transmission 
events they provide a valid target for treatment. In fact, removing the suppershedding 
animals (5% of the herd) would control the spread of infection (Matthews, L., et al 
2006). Interventions need only to stop this high bacterial carriage by capping bacterial 
carriage loads to below that of a supershedder (Matthews, L., et al 2006). 
The easy access to the RAJ and the effect of eliminating high secretors from the herd in 
controlling the spread of infection has created the opportunity for easier prevention and 
detection techniques. One study used a direct application of an antiseptic to the RAJ, 
compared to orally treated calves, to great success, needing only one application to clear 
the EHEC 0157:H7 infection. Swabs directly of the RAJ were used with a rapid 
immunochemical test kit, usually used for liquid cultures, at a sensitivity that would 
detect supershedders (Naylor, S., et al 2007). In conjunction these two methods can be 
used to identify supershedders in a herd and treat their infection to control the spread of 
EHEC 0157:H7. 
EHEC 0157:H7 strains have been isolated from faeces or intestines of birds and animals 
but has only been shown as a causative agent of disease in cattle (calf dysentery) pigs 
(oedema disease) and dogs (Alabama rot), with a majority of animals carrying EHEC 
without disease (Wasteson, Y., 2001). 
1.3.2.2 EHEC 0157:17 in the environment 
In the USA there are an estimated 76 million cases of illnesses a year caused by food 
borne pathogens, costing the government approximately $6.7 billion. Of these illnesses 
more than 100,000 are estimated to be caused by EHEC 0157:H7 and other shiga toxin 
producing E. coli, with EHEC 0157:H7 causing over 250 deaths each year, although the 
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issue is made more complicated by the failure of many clinical laboratories to screen for 
this serotype (Mead, P., et al 1999, Natara, J., et al 1998, Tauxe, R., 2001). After being 
implicated in the outbreak in 1982 (Riley et al 1983) EHEC O157:H7 caused over 30 
outbreaks in the USA in the following 10yrs. In 1993 a further 15 outbreaks were 
recorded and 20 outbreaks in the first half of 1994. With the increase in outbreaks more 
novel vehicles of transmission are starting to emerge. Ground beef, raw milk and person - 
to- person transmission still account for most cases, but acidic fruits, salad vegetables, 
yogurt and water have also been implicated (Feng, P., 1995). 
There have been many cases of EHEC O157:H7 infection, some leading HUS, after 
consumption of unpasteurised apple cider. In 1996 in New Haven County, Connecticut 
14 people were taken ill after consuming unpasteurised apple cider and five went on to 
develop HUS (Hilborn, E., et al 2000). In 1998 in Ontario, 66 people consumed 
contaminated apple cider with 10 people developing illness (Tamblyn, S., et al 1999). 
Both these cases are a result of the use of `drop' apples to make apple cider. These 
apples have dropped from the tree onto the ground and cannot be marketed as fresh 
eating apples. Unfortunately, EHEC O157:H7 has been shown to persist in apple cider, 
which was previously thought to not be conducive to survival and growth of food 
pathogens due to its low pH (pH 4.0). However, EHEC O157:H7, whilst not growing 
can maintain its original population size in apple cider at pH3.7 and 8 °C for 7 -21 days. 
This timeframe can include the entire 2 -3 week shelf life of apple cider (Zhao, T., et al 
1993). It has also been shown that when faeces containing EHEC are deposited on grass 
the organism is transferred to the soil and can be detected after the faeces have 
decomposed. On soil with rooted grass EHEC O157:H7 was demonstrated to persist for 
several months (Wasteson, Y., 2001). 
Recreational use of water can cause EHEC O157:H7 outbreaks. For example, in 1992 a 
children's paddling pool in Scotland became contaminated with EHEC O157:H7 by 
child defecation, the contaminated water infected two other children who infected others 
by person to person contact (Brewster, D., et al 1994). The first, but not the largest, 
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drinking water associated outbreak was in Missouri in 1989, where 243 people were 
infected, 32 hospitalised, 4 died and 2 developed HUS. It was traced to backflow during 
a water mains break (Swerdlow, D., et al 1992). The largest outbreak due to ingestion of 
contaminated water is still the outbreak in May 2000 in Walkerton, Ontario, Canada. 
The outbreak was caused by the towns drinking wells being contaminated by cattle 
faecal matter from a neighbouring farm following five days of heavy rainfall. 2,300 
people were infected, 68 hospitalized with 4 confirmed fatalities (Hrudey, S., et al 
2003). Any use of unchlorinated water as a supply for drinking water is a risk for EHEC 
0157:H7, this includes private drinking wells (most commonly found on small cattle 
farms) which are at risk for contamination with faeces from infected humans or animals 
due to sewage overflows, polluted storm water run off, or agricultural run off (Muniesa, 
M., et al 2006). 
In 1985 chickens were put forward as a potential reservoir of EHEC O157:H7 for human 
infection. After challenging 1 day old chickens with EHEC O157:H7 the bacteria were 
still detectable in the cecae for 90 days post infection. Interestingly the infected chickens 
showed no physical response to the infection when compared to unchallenged birds. 
However, there was mild transient mucous membrane damage and A/E lesions were 
seen. The proximal end of the chicken cecae was the principle site of infection, which 
may possess specific receptors (Beery, J., et al 1985). Since then it has been shown that 
experimentally challenged chickens can shed EHEC O157:H7 up to 11 months post 
infection, possibly due to the bacteria penetrating and adhering to the epithelia of the 
ceca. EHEC O157:H7 was also detectable on 13.8% of eggs screened, coating the egg as 
the bacteria moved through the colon during faecal shedding (Schoeni, J., et al 1994). 
EHEC 0157:H7 has also been shown to be present in intensive management hen farms 
in Southern Italy with 26 of the 720 samples from three different farms being positive 
for EHEC 0157:H7 after swabs were taken from caged birds (Dipineto, L., et al 2006). 
This provides interesting evidence that poultry could have a role as a reservoir of EHEC 
0157:H7. 
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Due to its discovery in the 1980's, EHEC O157:H7 is considered to be an emerging 
pathogen. The discovery of cattle as a reservoir has meant that public health concerns 
must also include healthy animals and agricultural methods may need to be tightened 
due to the implication of contaminated fodder and water as a source of acquiring and 
transmitting EHEC O157:H7 amongst cattle (Tauxe, R., 1997). Since 1986 serological 
studies have suggested that the vast majority of cattle have been exposed to EHEC at 
some point in their lives. Although cattle appear to be the main environmental reservoir 
of O157:H7 epidemiological surveys have revealed that EHEC strains are also prevalent 
in the gastrointestinal tract of other domestic animals including sheep, pigs, goats, dogs 
and cats (Paton, J., et al 1998) and with the emergence of novel vehicles of infection this 
pathogen has become a serious threat to public heath. 
1.3.3 Virulence factors of EHEC 0157:H7 
1.3.3.1 Shiga Toxin 
As previously discussed EHEC 0157:H7 can produce Shiga -like toxins (Stx), also 
known as Verotoxins (O'Brien, A., et al 1983). These toxins are the main virulence 
factor of EHEC and one of their defining characteristics. Stx is proposed to cause the 
clinical symptoms of an EHEC infection, which include: diarrhoea (lack of epithelium 
integrity in the intestine), HC (damage to endothelium of blood vessels in the intestine) 
and HUS (O'Brien, A., et al 1987). The severity of the EHEC infection and the clinical 
outcome depends largely on the type of Stx produced by the EHEC strain and the 
presence of the gene encoding intimin (Bielaszewska, M., et al 2006). The Stx family of 
toxins contain two major antigenically distinct groups, Stx 1 and Stx2. In cross 
neutralisation experiments, with polyclonal antisera raised against the shiga toxin of S. 
dysenteriae type I, the toxic activity of Stx1 was neutralised, whilst Stx2 was not 
(Strockbine, N., 1986 et al). A single EHEC strain may express Stx 1 or Stx2, both or 
even multiple forms of Stx2, with the toxin detectable in cell lysates and supernatants 
(Scotland, S., et al 1985, Strockbine, N., et al 1986). Stxl from EHEC is homologous to 
the shiga toxin from S. dysenteriae type 1, while Stx2 has sequence variations. Whether 
a strain expresses Stxl or Stx2 or both may play an important factor in clinical 
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management of an infection. Stx2 has been demonstrated to be more toxic when 
interacting with human intestinal microvascular endothelial cells (even though Stxl 
binds at a higher affinity) and disruption of these cells may be the gateway to systemic 
circulation of Stx allowing it to reach the kidneys and brain (Jacewicz, M., et al 1999). 
Due to the importance of Stx genes in the progression of EHEC O157:H7 infections to 
HUS it is important to limit the dissemination of the Stx genes through the induction of 
the phage that carries the gene. Treatment of EHEC infections with antibiotics that 
induce the bacterial `SOS' response to DNA damage inadvertently increase the amount 
of Stx produced by inducing the phage, causing a greater likelihood of progression to 
HUS (Kimmit, P., et al 2000). This phage induction is also seen in antibiotics used in 
animal husbandry as growth promoters, where sub -inhibitory concentrations of 
antibiotics are used that lead to an increase of free phage particles in the intestine, which 
could promote the development of new VTEC pathotypes (Kohler, B., et al 2000). Free 
Stx2- encoding bacteriophages have been found in aquatic environments, but there is 
little information about the lysogenic strains and the bacteria in the environment 
susceptible to phage infection (Garcia -Aljaro, C., et al 2004). Even though it is 
conceivable that E. coli of any serotype can acquire the toxin genes it is believed the 
ability of the organism to produce the toxin alone does not confer pathogenicity, that a 
background of appropriate virulence factors is needed. In fact there is a strong 
association between Stx2 and the presence of the gene for intimin (eae) in strains of 
VTEC that cause human disease (Boerlin, P., et al 1999, Law, D., 2000). 
The Stx family have a conserved basic A -B subunit structure. The receptor binding B 
subunits of Stx are arranged in a doughnut shaped pentamer and form a non polar pore 
that can be penetrated by the enzymatically active C terminus of the A subunit (Haddad, 
J., et al 1993). The single 32kDa A subunit is proteolytically nicked to yield a 28kDa 
peptide (Al) and a 4kDa peptide (A2), which remain linked by a disulphide bond. The 
Al peptide has the enzymatic activity and the A2 peptide binds the A subunit to the 
pentamer of five identical 7.7kDa B subunits. The B pentamic ring encircles a helix at 
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the C terminus of the single A subunit (Paton, J., et al 1998) and binds the toxin to a 
specific glycolipid receptor, globotriaosylceramide (Gb3), which is present on the 
surface of certain eukaryotic cells (Lingwood, C., 1996). After binding the toxin it is 
internalised by receptor mediated endocytosis through coated pits and transported to the 
golgi apparatus and the endoplasmic reticulum (Sandvig, K., et al 1992). The A subunit 
is translocated to the cytoplasm and acts on the 60s ribosomal subunit, where the Al 
peptide (a N- glycosidase) removes a single adenine residue from the 28S rRNA of 
eukaryotic ribosomes, inhibiting protein synthesis. The resulting disruption leads to cell 
death (Law, D., 2000, Lingwood, C., 1996). 
Although very similar to the Shiga toxin from S. dysenteriae type 1, the Stx toxins from 
EHEC O157:H7 have some interesting structural differences which may account for 
their different mode of action and disease potential (Fraser, M., et al 2004). The Stxl 
and Stx2 homopentameric B subunits also differ; when compared to Stxl, the Stx2 B 
subunit pentamer formation is less thermodynamically stable, with its assembly strongly 
dependent on temperature, subunit concentration and ionic strength. Its unstable nature 
may account for Stx2's perceived increase in toxicity (Kitova, E., et al 2005). 
Stx translocates from the intestine into the blood stream and causes HUS by interacting 
with the Gb3 receptors on human renal tissue, particularly the Gb3 receptors found on 
blood vessels and capillaries (Nataro, J., et al 1998). To reach the susceptible tissues and 
cause the associated clinical symptoms of Stx positive VTEC infection, the Stx 1 and 
Stx2 toxins must first cross the epithelial barrier and enter the blood stream (Paton et al 
1998). In vitro Stxl, and to a lesser extent Stx2, can translocate across intestinal 
epithelium to reach the endothelial cell beds underneath. They translocate without 
having a cytotoxic effect on intestinal epithelium and finish the translocation process 
neither activated nor inactivated (Hurley, B., et al 1999). Evidence is conflicted in the 
significance of Stx in producing diarrhoea upon EHEC infection, Stx has been shown to 
preferentially target villus of the jejunum (due to their higher concentration of Gb3 
receptors on the cell surface) in rabbit intestine, causing villus cell death and an 
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electrolyte imbalance (Kandel, G., et al 1989). However, it was also shown that the Stx 
toxins were not necessary to disrupt ion transport and cause diarrhoea, meaning other 
virulence factors must play a role in the onset of non -bloody diarrhoea (Li, Z., et al 
1993). 
In HUS immune interactions play an important role, with certain cytokines increasing 
the sensitivity of endothelial cells in the kidney to Stx (Kaye, S., et al 1993). In the 
brain, inflammatory cytokines increase the actual amount of Gb3 receptors present on 
human brain endothelial cells (Stricklett, P., et al 2002). It is also thought that there is a 
form of molecular mimicry, where Stx closely resembles CD36, a receptor present on 
platelets and microvascular endothelial cells. Antibodies for Stx are therefore cross 
reactive with CD36 and this cross reactivity may be the cause of platelet aggregation and 
kidney damage (Rock, G., et al 2005). In the bovine host EHEC O157:H7 does not 
cause infection, this may be part explained by the lack of vascular Gb3 receptors 
(Pruimboom -Brees, I., et al 2000) and the presence of the Gb3 receptor on crypt 
epithelial cells in the small and large intestine, which absorb Stx and limit its systemic 
effects (Hoey, D., et al 2002). Once in the crypt cells the toxin is destroyed in lysosomes 
(Hoey, D., et al 2003). 
1.3.3.2. pO157 
EHEC O157:H7 has a large 60MDa (9.2Kb) plasmid (pO157), which was shown to 
increase the strains adherence to Henle 407 intestinal and HEp -2 epithelial cell lines 
(Toth, I., et al 1990). In strains cured of the plasmid the growth, metabolic reactions and 
antibiotic resistance were identical to wild type strains. However, after oral 
administration to calves the cured strains survived passage through the bovine 
gastrointestinal tract better than the wild type strains but did not colonise the RAJ as 
well. This may indicate that cell lines are not an accurate representation of in vivo 
conditions (Lim, J., et al 2007). The presence of the plasmid encoded genes has been 
linked to adhesion and virulence. Originally the plasmid was thought to increase 
adherence by containing genes for fimbriae, but after sequencing no genes related to 
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known fimbriae were identified (Makino, K., et al 1998). Among the genes on the 
plasmid are genes for potential virulence factors, including: enterohaemolysin, (Schmidt, 
H., et al 1995), toxB which is homologous to Toxin B of Clostridium difficile and efa -1 
in non- O157:H7 EHEC strains (Stevens, M., et al 2004), espP which codes for a serine 
protease (Dziva, F., et al 2007), stcE a gene for a protease that cleaves Cl esterase 
inhibitor (Lathem, W., et al 2002) and genes that are homologous to the type II section 
system (T2SS) of other Gram negative bacteria (Schmidt, H., et al 1997). 
1.3.3.2.1. Enterohaemolysin 
Haemolysins belong to the RTX toxin family, named so because of the presence of 
nonomer repeats (repeats in toxin). The enterohaemolysin on the pO157 plasmid is toxic 
against human red blood cells (Bauer, M., et al 1996) but its involvement in virulence is 
still to be determined. The enterohaemolysin is found in all O157:H7 EHEC strains and 
sporadically in other EHEC serotypes, this may indicate an association between the gene 
and greater virulence and incidence of the EHEC strain (Law, D., et al 1995). Patients 
with HUS have antibodies in their sera reactive against the enterohaemolysin, however, 
very little of the toxin is secreted as its own secretion system is defective (Schmidt, H., 
et al 1995). 
1.3.3.2.2 ToxB 
ToxB shares 28% amino acid identity with EHEC Efa -1 (not present in O157:H7 
serotypes), which is an important adherence factor to Chinese Hamster Ovary cells and 
28% amino acid identity with the EPEC LifA, which has the ability to inhibit 
lymphocyte activation ( Tatsuno, I., et al 2001). The toxB gene itself has been shown to 
be involved in full adherence to CaCo -2 cells and wild type levels of secretion and 
expression of proteins from the LEE (an important pathogenicity island in EHEC 
infection), however, a toxB mutant does not effect faecal shedding of 10 -14 day old 
calves or 6 week old sheep (Stevens, M., et al 2004, Tatsuno, I., et al 2001). 
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1.3.3.2.3. EspP 
EspP is a serine protease that cleaves pepsin and coagulation factor V. It has been shown 
to be important in the colonisation of calves by EHEC 0157:H7 and adhesion to bovine 
rectal primary cells, although its mechanism of action is unclear (Dziva, F., et al 2007). 
1.3.3.2.4 StcE 
StcE is a zinc metalloprotease that specifically cleaves Cl esterase inhibitor (C1 -INH) as 
well as mucin 7 and glycoprotein 340. The protein is secreted by the T2SS encoded on 
the pO157 plasmid and is involved in intimate adherence on HEp -2 cells (Grys, T., et al 
2005). Its expression is also regulated by the LEE regulator Ler, indicating that it may be 
important during infection and colonisation at the same time as the genes on the LEE 
pathogenicity island (Lathem, W., et al 2002). Its mechanism is unclear, but it may 
degrade protective layers of mucin on host cells as well as anchoring the active C1 -INH 
domain to the site of infection where C1 -INH reduces inflammation and inhibits the 
activation of the complement immune system cascades (Grys, T., et al 2005). 
1.3.3.2.5 Type II Secretion System (T2SS) 
Thirteen genes closely related to the T2SS are found on p0157, named etpC to etpO. 
Although not a virulence factor, the pathway is used by Gram negative bacteria to 
secrete proteins, including toxins and has already been shown to be the mechanism by 
which StcE is translocated across the bacterial cell membrane (Schmidt, H., et al 1997, 
Lathem, W., et al 2002). 
1.3.3.3 EAST1 
The enteroaggregative E. coli heat stable enterotoxin 1 (EAST1) is only 38 amino acids 
long and 4.IkDa (Menard, L., et al 2004). EAST1 is encoded by the gene astA, has 
homology with the enterotoxic domain of STa and has been shown to increase cGMP 
levels in tissues that have been exposed to it (Savarino, S., et al 1993). The gene is not 
present in all EHEC strains but is present in EHEC 0157:H7. Its link to disease has not 
been demonstrated in EHEC; however, atypical strains of EPEC with the astA gene are 
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more significantly associated with diarrhoea in children and are found in up to 15% of 
healthy cattle (Yuste, M., et al 2006). 
1.3.3.4 Fimbriae 
Although some fimbriae have been described and linked to adherence on tissue culture 
cell lines, such as Lpfl and Lpf2 (Torres, A., et al 2002, Torres, A., et al 2004) not 
many have been visualised on EHEC O157:H7 or are functional. EHEC O157:H7 
contains 16 recognisable fimbrial gene clusters, yet of 15 examined for expression only 
4 expressed under a variety of conditions. This limited repertoire of expressed and 
functioning fimbrial genes may explain the RAJ tropism (Low, A., et al 2006b). One 
fimbrial operon (F9) does increase binding of K12 strains to bovine epithelial cells in 
vitro, but deletion of the fimbrial adhesin still leads to colonisation at the RAJ (Low, A., 
et al 2006). The regulation of the fimbrial operons and their influence on colonisation, 
still needs to be elucidated for the mechanism of tropism and adherence to be explained. 
1.3.4 Type III Secretion System (T3SS) 
The type III secretion system (T3SS) is used by many bacterial pathogens (such as 
Yersinia, Salmonella, Shigella, and Pseudomonas) to secrete proteins directly into host 
cells and is found exclusively amongst Gram negative bacteria (Heuck, C., 1998, Ghosh, 
P., 2004). EHEC uses the T3SS to translocate bacterial proteins into eukaryotic host 
cells to manipulate them during infection (Gruenheid, S., et al 2003). In EHEC, proteins 
with various functions are released through the T3SS that promote and sustain the 
unique interaction between the bacterium and the host cell (Deng, W., et al 2005). In 
cattle the T3SS of EHEC O157:H7 is required to maintain colonisation at the terminal 
rectum of the bovine gastrointestinal tract (Naylor, S., et al 2003). 
The genes encoding the secretion apparatus are highly conserved among bacteria and 
may be products of horizontal transfer (Castillo, A., et al 2005). Much of what is known 
about the structure of the T3SS apparatus is based on extensive research investigating 
20 
the homologous flagellar assembly apparatus (Fig.2, C) and Yersinia T3SS (Blocker, A., 
et al 2003, Heuk, C., 1998). 
1.3.4.1 Locus for Enterocyte Effacement and Attaching and Effacing Lesions 
The genes for the EHEC and EPEC T3SS apparatus, and a series of secreted proteins 
including Tir and EspA, are situated on the locus for enterocyte effacement (LEE) 
(Goffaux, F., et al 2001). LEE sequences for EHEC and EPEC have been determined 
(Elliot, S., et al 1998, Perna, N., et al 2001, Goffaux, F., et al 1999), in EHEC the LEE 
is a large ( -40Kb) genetic element (Perna, N., et al 1998). Secretion of the effector 
proteins encoded on the LEE, via the T3SS, is essential for signal transduction in host 
cells and the formation of attaching and effacing (A/E) lesions (Frankel, G., et al 1998, 
Knutton, S., et al 1998, Knutton, S., et al 1989). A/E lesions are a histopathological 
feature observed after infection with certain pathogens, including EHEC and EPEC 
(Naylor, S., et al 2005b). The A/E lesion is characterised by localised destruction 
(effacement) of the intestinal epithelial microvilli, intimate adherence between the 
bacterium and the epithelial cell membrane and the formation of an underlying pedestal - 
like structure in the host cell consisting of polymerised actin, alpha -actinin, ezrin, talin 
and myosin (Fig.1) (Finlay, B., et al 1996). 
B 
Fig.1. A/E lesions A) Scanning electron microscopy of EPEC pedestal formation on HEL 
cells (taken from Knutton, S., et al 1998) B) transmission electron microscopy of EHEC 
A/E lesion at the terminal region of infected cattle (taken from Naylor, S., et al 2005b). 
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It is worth noting that despite the LEE being highly conserved in diarrhoeagenic E. coli 
(Wieler, L., et al 1997) there are fundamental differences. For example; the LEE 
pathogenicity island of EHEC O157:H7 has high homology with the LEE of EPEC 
0127:H6, having the same genes in identical order and orientation. However, unlike 
EPEC, the LEE from EHEC is unable to form A/E lesions when cloned into an E. coli 
K -12 background, suggesting that there are unknown functional and /or regulatory 
differences (Elliot, S., et al 1999). These differences need to be considered as the 
majority of the literature concerning the T3SS in E. coli refers to strains of EPEC. 
The LEE contains over 41 open reading frames (ORFs) of more than 50 amino acids, 
with at least five operons (LEE1 -5) (Fig.2, A) (Elliot, S., et al 1998, Perna, N., et al 
2001). Genes homologues to Yersinia T3SS genes are named `E. coli secretion' (esc) 
genes, genes without homology to Yersinia but with a defined role in secretion are 
named `secretion of E. coli' proteins (sep) genes. Genes encoding secreted proteins and 
their chaperones are called esp (E. coli secreted proteins) and ces (chaperone for E. coli 
secretion) (Creasey, E., et al 2003). The remaining genes, like eae (that encodes the 
protein intimin) (Jerse, A., et al 1990), have either maintained their original name or are 
T3SS proteins with no homologues. 
LEE1, 2 and 3 contain 22 ORFs and primarily encode proteins required for the basal 
apparatus of the T3SS, which spans the two bacterial membranes. LEE4 encodes EscF, 
SepL and the secreted proteins EspA, B, D, F (Mellies, J., et al 1999). These enable a 
translocon and pore to be formed, which secretes effector proteins into the host cell. The 
genes for the translocated intimin receptor (Tir), its chaperone (CesT) and intimin are 
located in LEES. Other small operons and ORFs are also present, including one that 



































































































































































































































































































































































































































































































































































































































































































































































1.3.4.2 The Type III Secretion System Apparatus 
The T3SS apparatus is composed of approximately 20 proteins (Blocker, A., et al 2003, 
Heuck, C., 1998, Ghosh, P., 2004). It consists of a basal apparatus that spans both the 
inner and the outer membrane with a short projecting needle composed of EscF (Sekiya, 
K., et al 2001). EscD, R, U, V, S and T, probably span the inner membrane and associate 
with a putative cytoplasmic ATPase EscN, required for the secretion of proteins. In 
EPEC, EscC is located in the outer membrane, where it is thought to form a large 
homomultimeric ring complex. Homology with Shigella, suggests the EscC ring is 
thought to project into the periplasm where it can interact with proteins to form the 
central rod (Gauthier, A., et al 2003b). The short projecting needle attached to the basal 
apparatus is composed of EscF, from which a filamentous structure composed of EspA 
extends (Ogino, T., et al 2006). The EspA filament interacts with EspB, which in turn 
interacts with EspD to form a pore in the host cell membrane (Fig.2, B) (Hartland, E., et 
al 2000, Ide, T., et al 2001). 
Translocated proteins pass from the bacterial cytoplasm as fully translated proteins or 
are translated and translocated in a coupled step at the basal apparatus (Roe, A., et al 
2003). They pass through the basal apparatus, the hollow needle and the EspA filament 
into the host cell via the EspB -EspD pore (Heuck, C., 1998). 
The T3SS is essential for the translocation of effector proteins such as Tir, Map, EspF, 
EspH and EspG into the mammalian host cell (Shaw, R., et al 2005). Upon entering the 
host cell the effector proteins affect the brush borders and form A/E lesions. 
1.3.5 LEE -Encoded Proteins 
The majority of the proteins encoded on the LEE will now be discussed. 
1.3.5.1 LEE -Encoded Regulator (Ler) 
The LEE -Encoded Regulator (Ler) is a positive regulator of the LEE, homologous to 
Histone -like non -structural proteins (H -NS) (Pallen, M., et al 2005). H -NS binds 
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strongly to curved DNA and influences gene expression (Yamada, H., et al 1990). Ler 
has been shown to be essential for the expression of multiple LEE genes including esp 
and esc genes, tir and eae. Ler is also capable of activating the LEE operon promoters in 
a K -12 strain background (Elliott, S., et al 2000). The expression of ler has been shown 
to be influenced by a number of factors, including integration host factor (IHF), a DNA 
binding protein that bends DNA to form nucleoprotein complexes. IHF binds 
specifically upstream of the ler promoter, activating expression from ler (Friedberg, D., 
et al 1999). Quorum sensing has also been implicated in expression from ler. Quorum 
sensing is a mechanism by which bacteria can sense one another by detecting 
compounds called autoinducers. Fusions to lacZ have been used to show that the gene 
luxS, which produces the autoinducer AI -2, is important in increasing ler expression 
(Sperandio, V., et al 1999), as is QseA (an intermediary transcription factor in a quorum 
sensing signalling cascade) (Sharp, F., et al 2007). It would seem that multiple factors 
effect the expression from the ler promoter to relay environmental signals to the LEE 
and other genes, to assure correct timing of expression (Laaberki, M., et al 2006). 
1.3.5.2 Orf2 
Orf2 has homology with the Yersinia T3SS protein YscE and so it has been proposed to 
name it EscE (Pallen, M., et al 2005). YscE is needed for Yop secretion, as is Orf2 for 
T3S in Citrobacter rodentium (Allaoui, A., et al 1995, Deng, W., et al 2004). YscE is 
the smallest Ysc protein and is not broadly conserved amongst T3SS. It is a dimer in 
solution and its crystal structure has been elucidated (Phan, J., et al 2005). YscE 
interacts with YscG (thought to be the chaperone for YscE) and is not secreted out of the 
bacterial cell (Day, J., et al 2000). YscE was also shown to interact with TyeA, a 
homologue for the SepL protein in EHEC (Swietnicki, W., et al 2004), which indicates 
that EscE interacts with SepL (Pallen, M., et al 2005). 
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1.3.5.3 Orf3 (CesAB) 
A yeast two -hybrid screen demonstrated an interaction between Orf3 (the protein from 
the uncharacterised orf3) and EspA and EspB (Creasey, E., et al 2003). Orf3 is now 
thought to be the chaperone for EspA and EspB and termed CesAB. A mutant in CesAB 
does not form A/E lesions, make EspA filaments or secrete EspB but expression from 
the LEE4 promoter is unaffected (Creasey, E., et al 2003b). 
1.3.5.4 Orf4 
Orf4 shows a homology to SsaK (Pallen, M., et al 2005). SsaK is a protein involved in 
the T3SS of Salmonella; it is thought to be hydrophilic with no predicted transmembrane 
helices (Hensel, M., et al 1997). 
1.3.5.5 OrfS 
OrfS (EscL) shows homology with YscL from Yersinia T3SS and FliH from the flagellar 
system (Pallen, M., et al 2005). Two molecules of F1iH bind to one molecule of Flil (the 
ATPase of the flagellar system, homologous to EscN in the EHEC T3SS) and down 
regulate the Flil ATPase activity (Auvray, F., et al 2002). YscL has a similar function as 
an ATPase regulator when it binds to YscN (ATPase of the Yersinia T3SS) it may also 
have a function in anchoring YscN to the T3SS (Blaylock, B., et al 2006). 
1.3.5.6 EscR 
EscR is predicted to be in the inner membrane basal apparatus of the EHEC T3SS 
(Ghosh, P., 2004). Little is known about EscR but it does interact with EscS, EscU, 
SepZ and EspD in yeast two -hybrid screens ( Creasey, E., et al 2003). EscR is 
homologous to FliP in the flagella system and YscR in the Yersinia T3SS. FliP has been 
localised to the basal body of the flagellar secretion system (Fan, F., et al 1997) and 
undergoes cleavage of a signal peptide (Ohnishi, K., et al 1997). 
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1.3.5.7 EscS 
EscS is predicted to he in the inner membrane, with a mass of --10kDa (Ghosh, P., 2004) 
and interacts with EscR and EscD (Creasey, E., et al 2003). Its homologous protein in 
the flagellar basal body is F1iQ (Pallen, M., et al 2005). 
1.3.5.8 EscT 
EscT is a predicted inner membrane protein of EHEC T3SS (Ghosh, P., 2004). Its 
homologous protein in the flagellar basal body is F1iR (Pallen, M., et al 2005). In the 
Salmonella flagellar export system a F1iR and F1hB (EscU homologue) fusion was made 
that could complement mutants of F1iR and F1hB, indicating they interact with each 
other on a 1:1 ratio (Van Arnam, J., et al 2004). F1iR has also been localised to the basal 
body of the flagellar secretion system (Fan, F., et al 1997). 
1.3.5.9 EscU 
EscU is a predicted inner membrane protein of the T3SS of EHEC (Ghosh, P., 2004). Its 
homologous proteins in the flagellar and Yersinia T3SS system are F1hB and YscU 
respectively. F1hB has an important role in determining hook length in flagellar (Hirano, 
T., et al 1994) through the interaction with a molecular ruler termed F1iK (Kawagishi, I., 
et al 1996). During assembly, F1hB supports the export of rod -type and hook -type 
proteins but not filament proteins, then a hook length signal is transmitted to F1hB via 
FliK and filament proteins are secreted (Minamino, T., et al 1999). The cytoplasmic 
domain of FlhB (F1hBc) is cleaved into two parts: F1hBcN and FlhBcc, which retain the 
ability to interact with each other. The interaction of F1hBcN with F1hBcc gives different 
substrate specificity to the molecule than F1hBc (Minamino, T., et al 2000). The N 
terminus of FliK senses the length of the hook and turns into an active form that binds 
F1hBc (Minamino, T., et al 2004). This binding causes a conformational change in 
F1hBc required for the switch between hook and filament proteins. The model proposed 
is that hook assembly starts very fast and slows down after the autocleavage of FlhB (a 
timing device) then the F1iK molecule passes through the hook and senses its length, 
when the hook is of the correct size it binds the F1iK N terminus leaving the C terminus 
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in close enough proximity to bind to F1hBc:F1hBN, the export specificity is changed and 
filament proteins are secreted (Moriya, N., et al 2006). YscU is proposed to act in a 
similar manner; it was shown to be necessary for T3S in Yersinia (Allaoui, A., et al 
1994) and proteolytically cleaved like F1hB (Lavander, M., et al 2002). Its cleavage 
causes a conformational change that allows it to change substrate specificity (Sorg, I., et 
al 2007). YscP (FliK homologue in Yersinia) also has a role in needle subunit secretion 
(Edqvist, P., et al 2003) and needle length; acting as a molecular ruler (Journet, L., et al 
2003). 
1.3.5.10 rOrf3 
rOrf3 is homologous to a group of enzymes known as lytic transglycosylases and so it 
has been proposed to rename it EtgA (E. coli transglycosylase) (Pallen, M., et al 2005). 
Specialized lytic transglycosylases degrade peptidoglycan in the bacterial cell allowing 
insertion of the secretion complexes into the membrane (Zahrl, D., et al 2005). 
1.3.5.11 Gr1R and Gr1A 
Gr1R (global regulator of LEE -repressor) and Gr1A (global regulator of LEE -activator) 
are LEE encoded LEE regulators that influence the expression of Ler (Deng, W., et al 
2004). Gr1R and Gr1A interact with each other (Creasey, E., et al 2003) with the 
proposed mechanism for GrIR repression is binding Gr1A, thereby not allowing GrIA to 
increase the expression of ler (Iyoda, S., et al 2006). There is a regulator loop, with ler 
required for Gr1R and GrlA expression, which get transcribed together (Barba, J., et al 
2005). Gr1A also acts as a negative regulator for flagellar gene expression (Iyoda, S., et 
al 2006). The structure of Gr1R shows that it is dimeric and contains a Glu- Asp -Glu -Asp 
motif, which is important for the GrIR -GrlA interaction (Jobichen, C., et al 2007). 
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1.3.5.12 CesD 
CesD is the chaperone for EspD. Deletion of CesD leads to no secretion of EspD and a 
reduced detection of EspB in the supernatant. The EspB decrease has yet to be fully 
explained, it may be that EspB is less stable without EspD (Wainwright, L., et al 1998). 
1.3.5.13 EscC 
EscC is an outer membrane protein that forms a ring shaped structure (Ghosh, P., 2004). 
EscC enters the outer membrane in a Sec -dependent and T3SS dependent manner, with 
the proteins EscN and EscV needed for its correct insertion (Gauthier, A., et al 2003b). 
In the T3SS apparatus EscC is associated with EscF and EscD (Ogino, T., et al 2006). 
Its homologue in the Yersinia T3SS, YscC, forms a -20nm oligmeric complex in the 
outer membrane with a central pore (Koster, M., et al 1997). 
1.3.5.14 SepD 
SepD interacts with SepL (Creasey, E., et al 2003) and is involved in a switching 
mechanism between translocator and effector proteins (Deng, W., et al 2005). A sepD 
deletion leads to no translocator proteins being secreted and an increase in the secretion 
of effector proteins (Deng, W., et al 2004). 
1.3.5.15 EscJ 
EscJ is predicted to be in the periplasm, where it forms a large 24 subunit ring sitting on 
the inner membrane (Yip, C., et al 2005) It belongs to a highly conserved YscJ /Prgk 
family of proteins, is required for T3S and is associated with EscF (Ogino, T., et al 
2006, Yip, C., et al 2005). 
1.3.5.16 rOrf8 
rOrf8 is reported to have homology with PrJ, Mxil and YscI, creating a case to rename it 
Escl (Pallen, M., et al 2005). The homologue Mxil is a minor essential component of the 
T3SS of Shigella, forming the needle with MxiH (Sani, M., et al 2007). 
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1.3.5.17 SepZ /EspZ 
EspZ is translocated into host cells via the T3SS of EPEC and accumulates in a subset of 
pedestals in regions where phosphorylated Tir has built up. Deletion of EspZ does not 
effect T3S or AJE lesion formation and its function is still unknown (Kanack, K., et al 
2005). 
1.3.5.18 Orf12 
Orf12 is homologous to SsaM from the Salmonella SPI -2 system (Pallen, M., et al 
2005). SsaM is a small protein that may interact with another SPI -2 protein (SpiC) to 
control the ordered secretion of translocators and effectors (Yu, X., et al 2004). 
1.3.5.19 EscV 
EscV is an inner membrane protein with seven predicted transmembrane domains and a 
large cytoplasmic tail (Ghosh, P., 2004). EscV is vital for T3S in EPEC, where an escV 
deletion fails to disrupt host cell signalling (Nadler, C., et al 2006). EscV is predicted to 
be 75kDa with a Sec -dependent signal sequence and is located to the inner membrane, 
even in an escN and escC mutant (Gauthier, A., et al 2003b). EscV is homologous to the 
FlhA protein in the flagellar basal body (Pallen, M., et al 2005). The crystal structure of 
FlhA has been deduced in a hope to further elucidate its function (Saijo -hamano, Y., et 
al 2005). If the large cytoplasmic domain of FlhA (FlhAc) is over produced it inhibits 
motility and flagellar substrate export in Salmonella. FlhAc is thought to interact with 
FliH (the regulator of the ATPase in flagellar export) (Kihara, M., et al 2001), it is also 
involved in flagellar and virulence gene expression in Campylobacter jejuni (Carrillo, C 
et al 2004). 
1.3.5.20 EscN 
EscN is the cytoplasmic ATPase associated with the T3SS, providing the energy for 
assembly and secretion ( Ghosh, P., 2004). EscN has been shown to directly interact with 
CesT and Tir, possibly providing the energy required for Tir secretion (Gauthier, A., et 
al 2003). EscN ATPase activity is dependent on oligomerization into a hexameric ring 
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(Zarivach, M., et al 2007) or dodecamers (two hexamers on top of one another) and 
requires the presence of magnesium ions (Andrade, A., et al 2007). 
1.3.5.21 Orfl5 
Orf15 has no known homologous proteins (Pallen, M., et al 2005). 
1.3.5.22 Orf16 
Orf16 is in the same location on the LEE and has secondary structure similarities with 
the proteins F1iK (flagellar secretion system) and YscP (Yersinia T3SS) (Pallen, M., et 
al 2005). YscP and F1iK function as molecular rulers, determining the length of the 
T3SS needle and the flagellar hook, working in conjunction with YscU and FlhB, 
respectively (Agrain, C., et al 2005, Shibata, S., et al 2007). Experimental data is 
required to validate this theory due to the low sequence homology between YscP, FlhB 
and Orf16 (Pallen, M., et al 2005). 
1.3.5.23 SepQ 
SepQ is homologous with YscQ and F1iN and it has been proposed to rename it EscQ 
(Pallen, M., et al 2005). Although little is known about SepQ, F1iN is predicted to form a 
doughnut shaped tetramer that sits at the bottom of the C ring in the flagellar export 
machinery (the bottom of the flagellar basal body) (Paul, K., et al 2006, Fadouloglou, 
V., et al 2006). F1iN is thought to be involved in switching between clockwise and 
counter -clockwise rotation of the flagellar and binding F1iH (Paul, K., et al 2006b). This 
may mean that SepQ forms a ring within the T3SS basal body (Pallen, M., et al 2005). 
1.3.5.24 EspH 
EspH is a T3SS translocated effector protein that inhibits filopodia and promotes 
pedestal formation in A/E lesions in EHEC and EPEC (Tu, X., et al 2003). Despite this, 
EspH from EHEC is not needed for A/E lesion formation in infant rabbit intestine, but is 
required for full colonisation (Ritchie, J., et al 2005). 
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1.3.5.25 CesF 
CesF is the chaperone for the translocated effector protein EspF and is required for full 
EspF function (Elliott, S., et al 2002). 
1.3.5.26 Mitochondrial Associated Protein (Map) 
Map is a T3SS translocated effector protein, which localizes to the mitochondria in the 
host cell (Kenny, B., et al 2000). It is not clear what the function of Map is at the 
mitochondria, but it does enter the mitochondria and appears to disrupt their morphology 
in yeast cells (Papatheodorou, P., et al 2006). It also stimulates the formation of 
filopodia in EPEC, a transient event that happens before the formation of pedestals 
(Kenny, B., et al 2002). EPEC is capable of invading cell culture lines, which requires 
Map, although it does not require the localization of Map to the mitochondria (Jepson, 
M., et al 2003). 
1.3.5.27 Translocated Intimin Receptor (Tir) 
Tir is an effector protein that is translocated through the T3SS. It enters the host cell 
where it localizes to the membrane, functioning as the receptor for the EHEC adhesin 
intimin (Devinney, R., et al 1999). The intimin:Tir interaction at the host -pathogen 
border leads to a cascade of signalling events in the host cell, which initiates cytoskeletal 
rearrangements promoting the formation of the pedestal and the creation of an A/E 
lesion (Goosney, D., et al 2001). 
In eukaryotic cells a critical controller of actin polymerisation at the plasma membrane 
is a heptameric actin -related protein 2/3 (Arp2 /3). The actin nucleation activity of 
Arp2 /3 can be stimulated by Wiskott- Aldrich syndrome proteins (WASPs) (Galletta, B., 
et al 2008), a member of which is neuronal (N -) WASP. 
EHEC pedestal formation does not rely on tyrosine phosphorylation or the Nck adaptor 
protein, as is the case for EPEC (Campellone, G., et al 2003). Instead three amino acid 
residues (NPY458) in Tir are necessary for recruiting the T3SS translocated effector 
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protein EspFu (encoded on a cryptic prophage) (Brady, M., et al 2007). It is EspFu that 
directly binds and activates N -WASP, leading to actin polymerisation creating the 
pedestal (Campellone, K., et al 2006). 
1.3.5.28 CesT 
CesT is a chaperone required for the stable secretion of both Tir and Map (Abe, A., et al 
1999, Creasey, E., et al 2003b). It interacts with Tir, bringing it to the T3SS in an EscN- 
dependent manner. It is also the chaperone for at least five other effector proteins 
including; SepZ, N1eA, N1eH, NleF and EspH (Thomas, N., et al 2005). 
1.3.5.29 Intimin (eae) 
Intimin binds to the receptor Tir to promote tight adherence and trigger the signalling 
events that lead to pedestal formation (Kenny, B., et al 1997, Kenny, B., et al 1997b). 
EHEC intimin is also capable of binding nucleolin (a protein involved in cell 
proliferation) that is presented on the surface of host cells (Sinclair, J., et al 2004). 
1.3.5.30 EscD 
EscD is a predicted inner membrane protein (Ghosh, P., 2004) and has been shown to 
interact with EscC (Creasey, E., et al 2003). It also interacts with EscJ and is thought to 
be located in the inner membrane with its C terminus in the periplasm where it can 
interact with EscC and EscJ to sustain the central rod (Ogino, T., et al 2006). 
1.3.5.31 SepL 
SepL interacts with SepD (Creasey, E., et al 2003) and is involved in a switching 
mechanism between translocator and effector proteins (Deng, W., et al 2005). A sepL 
deletion leads to no translocator proteins being secreted and an increase in the secretion 
of effector proteins, an identical phenotype to a sepD deletion (Deng, W., et al 2004). 
SepL is situated 58bp upstream of the start codon for espA and encodes a 351 amino acid 
protein with a predicted mass of 39.95kDa. Despite this close proximity espA, espD and 
espB genes may be transcribed as a single transcript without sepL (Beltrametti, F., et al 
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1999). However, work in our laboratory indicates that the transcript includes sepL and it 
is posttranscriptional cleavage that removes sepL mRNA from that of espA, D and B. 
The SepL protein is localized at the membrane and in the cytoplasm (Kresse, A., et al 
2000). A recent hypothesis is that SepL and SepD form a complex at the T3SS pore and 
act as a gate. This gate only allows the export of translocon proteins but dissociates or 
changes, after cellular levels of calcium drop upon translocon completion and interaction 
with the host cell (Deng, W., et al 2005). The exact mechanism of the gating activity is 
still not known as there is no direct evidence that SepL or SepD bind to any of the 
translocon proteins. Work in our laboratory has shown that SepL can bind directly to Tir 
and that Tir is displaced from SepL when SepL binds to the basal apparatus protein 
EscD (unpublished data). This binding of SepL to Tir may have a role after the SepL- 
SepD complex has dissociated, proving important in the hierarchal secretion of proteins 
through the T3SS. In EHEC O157:H7 sepL mutants have a decreased in adherence to 
epithelial cells in mouse cecum and a decreased shedding period (Nagano, K., et al 
2003). 
1.3.5.32 EspA 
EHEC produces a filamentous T3SS, as it contains a large filament made of polymerized 
EspA that extends from the needle structure (Daniell, S., et al 2001). The EspA filament 
is required for the formation of A/E lesions and full virulence, creating a direct link 
between the bacteria and the host cell (Abe, A., et al 1998, Knutton, S., et al 1998, Ebel, 
F., et al 1998). The EspA filament has polymorphisms that do not allow cross reactivity 
between antibodies raised against EspA from different strains (Neves, B., et al 2003b). 
This lack of reactivity was used to demonstrate that EspA filaments elongate from the 
tip of the growing filament (Crepin, V., et al 2005). The filaments are hollow conduits 
rising from the EscF needle of the T3SS to deliver bacterial proteins into the host cell 
(Crepin, V., et al 2005, Daniell, S., et al 2001b). 
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1.3.5.33 EspD and EspB 
EspD and EspB form the pore in the target cell membrane at the tip of the EspA filament 
(Ide, T., et al 2001) and have a role in regulating EspA filament length (Daniell, S., et al 
2001). Deletions in these proteins are unable to secrete Tir and produce A/E lesions (Lai, 
L., et al 1997) and they may have a role in initial adherence (Chiu, H., et al 2005). EspB 
is also translocated into the cytoplasm of host cells where it interacts with myosin in a 
step that is involved with effacing the microvilli in A/E lesions (Iizumi, Y., et al 2007). 
1.3.5.34 CesD2 
CesD2 is the second chaperone for EspD and is required for stabilization and secretion 
of EspD (Neves, B., et al 2003). 
1.3.5.35 EscF 
EscF forms the needle that protrudes from the basal body of the T3SS and from which 
the EspA filament extends (Sekiya, K., et al 2001, Wilson, R., et al 2001). The EscF 
needle also interacts with EscC and EscJ and may be part of the central rod that spans 
the periplasm (Ogino, T., et al 2006). 
1.3.5.36 Orf29 
Orf29 is homologous to the SsaI protein from the Salmonella T3SS, SsaI has yet to be 
characterized (Pallen, M., et al 2005). 
1.3.5.37 EspF 
EspF is a T3SS translocated effector protein that is involved in disrupting the tight 
junctions of epithelial cells (Viswanathan, V., et al 2004). EPEC EspF is targeted to the 
mitochondria in the host cell, here it disrupts the mitochondrial membrane potential and 
effects cell death, epithelial barrier dysfunction and uptake into macrophages (Nagai, T., 
et al 2005, Quitard, S., et al 2006). 
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1.3.5.38 rOrfl 
rOrfl has a domain that has homology with SdiA regulated proteins and it interacts with 
EspD (Pallen, M., et al 2005). SdiA is a signal receptor involved in quorum sensing 
(Ahmer, B., et al 2004), an SdiA homologue in Salmonella regulating genes on a 
virulence plasmid (Ahmer, B., et al 1998). Quorum sensing has already been linked to 
the expression from ler (Sperandio. V., et al 1999) and rOrf 1 may be another way in 
which quorum sensing influences LEE encoded proteins. 
1.3.5.39 EspG 
EspG is a T3SS translocated effector protein with homology to the Salmonella protein 
VirA (Elliott, S., et al 2001, Pallen, M., et al 2005). Using Citrobacter rodentium in an 
animal model EspG was shown to interact with tubulin, modulating the host cell 
cytoskeleton by destroying microtubules and polymerising actin and having an 
accessory role in colonisation (Hardwidge, P., et al 2005). 
1.3.6 Non -LEE Encoded Proteins 
Several non -LEE encoded proteins use the T3SS to be delivered into the host cell (e.g. 
EspFu) (Brady, M., et al 2007). However, only the Nle (Non -LEE encoded) proteins will 
be discussed. 
1.3.6.1 Non -LEE Encoded (Nle) Effector Proteins 
Some effector proteins have been identified that are not encoded on the LEE 
pathogenicity island, but are still secreted in a T3SS dependent manner and possibly 
influence colonisation and virulence. They have been termed non -LEE encoded (Nle) 
effector proteins (Deng, W., et al 2005). To date nine Nle proteins have been identified 
in LEE containing pathogens (N1eABCDEFGHI), some by signature- tagged transposon 
mutagenesis (Dziva, F., et al 2004, Kelly, M., et al 2006) and some by increasing 
expression of effector proteins by deleting sepD or sepL (Deng, W., et al 2005, Li, M., et 
al 2006). Although NleB and NleE have been shown to be involved in colonisation in 
the mouse pathogen Citrobacter rodentium (Kelly, M., et al 2006, Wickham, M., et al 
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2007), N1eD and NleC were not required for colonisation in lambs after infection with 
EHEC O157:H7 (Marches, O., et al 2005). It is clear that these proteins, under certain 
conditions, are translocated through the T3SS, but their contribution to virulence is still 
to be fully elucidated. This is highlighted by the fact that when the expression profiles of 
N1eA,B,C,D and E were investigated, in a wild type EHEC O157:H7 strain, only nleA 
was expressed co- ordinately with EspA filamentation and detected in the supernatant 
(Roe, A., et al 2007). 
1.4 Fluorescent and Immunogenic Tags 
Green fluorescent protein (GFP) and Haemagglutinin (HA) tag fusions will be used in 
this project for fluorescence microscopy and Western blot analysis. 
1.4.1 Green Fluorescent Protein (GFP) 
GFP originates from the bioluminescent jellyfish Aequorea Victoria. It has long been of 
interest and in 1992 Prasher et al demonstrated that the visible green fluorescence was 
genetically encoded, the chromophore being derived from a Ser- Tyr -Gly sequence in the 
protein (Prasher, D., et al 1992). The chromophore is formed auto -catalytically by a 
unique series of reactions occurring intramolecularly, with oxygen needed for the final 
step (Sullivan, K., et al 1999). 
Mature GFP is excited by photons of light with a wavelength of 395nm (ultraviolet 
light) and emits photons with a 508nm wavelength (green light) (Bongaerts, R., et al 
2002). The ultraviolet light promotes the chromophore into an excited state and the 
excited GFP emits light with a fluorescence lifetime of 3.3ns (Sullivan, K., et al 1999). 
The use of GFP has been optimised by the isolation and creation of GFP mutants with 
varied fluorescent half lives, lower and higher fluorescence quantum yields and shifted 
emission and absorbance spectra (e.g. enhanced GFP (eGFP), GFP +, YFP and CFP). 
These mutants have increased the variety of systems and techniques GFP can be applied 
to (Jung, G., et al 2005). The GFP protein can be used for monitoring gene expression in 
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both eukaryotes and prokaryotes as it requires no jellyfish specific cofactors or 
substrates (Cha, H., et al 1999, Southward, C., et al 2002). GFP fusions are also used to 
show protein localization and dynamics, allowing an insight into the spatial and 
temporal organisation of cellular processes (Mullineaux, C., et al 2006). To date 
numerous cytoplasmic protein fusions to GFP have been constructed and used in vivo, 
although export difficulties have limited its use in extra -cytoplasmic compartments. 
However, there has been success in the transport of functional GFP into the periplasm in 
bacteria using the twin arginine translocation system (Thomas, J., et al 2001). 
The main considerations when using GFP or GFP variants are false readings due to 
artefact production or cell death caused by phototoxicity (from the production of 
reactive oxygen species) (Remington, S., et al 2006). 
1.4.2 Haemagglutinin (HA) tag 
The HA tag is based on a nine amino acid immunodominant sequence from the 
influenza haemagglutinin protein (Tyr Pro Tyr Asp Val Pro Asp Try Ala) (Green, N., et 
al 1982). Monoclonal antibodies with high specificity for the sequence can be 
purchased, including dye labelled anti HA antibodies that reduce immunolocalization 
methodology to a single step (Jarvik, J., et al 1998). The antibodies raised against the 
short peptide can often recognise the sequence when it is engineered into a folded 
protein (Niman, H., et al 1983). However, care needs to be taken with the position of the 
tag (Munro, S., et al 1984) as a drawback is the possibility of the loss of protein function 
in vivo (Kolodziej, P., et al 1991) or unexpected effects on protein localization and 
function, which only the presence of the correct controls can highlight (Brother, S., et al 
2003). 
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1.5 Aims of the Thesis 
Fluorescent markers and immunogenic tags will be used to tag the T3SS apparatus in the 
EHEC O157:H7 strain Walla3 (Ostroff, S., et al 1990). The Walla3 strain is from the 
Walla Walla outbreak in 1983, it is a Stx- strain (does not produce Stx) but work in our 
laboratory has shown that the strain can cause A/E lesions in cattle. This will make the 
work containment level 2. 
Inner membrane components of the basal apparatus (EscR and EscU) will be labelled as 
full protein fusion with eGFP, GPF+ or the HA tag, to the C terminus with no linker 
region. These will be used in allelic exchange (Emmerson, J., et al 2007, Blomfield, I., 
et al 1991) to replace the native genes and allow visualisation of the basal apparatus 
using microscopy and detection by Western blot analysis. These new Walla3 strains will 
then be used as a tool to investigate the following: 
1.5.1 Localization 
Determine how many basal apparatus are in each bacterial cell 
Examine whether novel non -LEE encoded proteins can be co- localised with the 
basal apparatus in order to ascertain whether they interact with the T3SS 
Whether the mRNA transcript of espADB can be localised to the basal apparatus 
Study what happens to the basal apparatus after intimate adherence has been 
achieved by EHEC 
Use fluorescence resonance energy transfer (FRET) be to measure the proximity 
of proteins with the basal apparatus 
Use transmission electron microscopy, with gold labelled anti HA antibody, to 
localize the HA tagged basal apparatus protein to either the bacterial inner 
membrane or outer membrane to confirm its position 
1.5.2 Regulation 
Investigate whether EHEC strains that are considered to secrete a high level of 
effector proteins contain more T3SS basal apparatus units 
40 
 To elucidate whether basal apparatus are present in all EHEC cells grown in 
T3SS permissive conditions 
1.5.3 Timing 
Examine whether the formation of basal apparatus be seen in real time 
1.5.4 EscU Aims 
The fusions of eGFP and HA to EscU will also be used to further elucidate the function 
and localization of EscU. The EscU specific aims of the thesis are: 
Determine at what stage the T3S ceases formation in the EscU mutants 
Investigate the effect of mutating EscU on secretion of EspD, EspA and Tir 
Elucidate the function of EscU cleavage 
Localise both fragments of EscU to a bacterial cell fraction 
Investigate the link between EscU and the secretion of EscF 
Investigate the link between EscU cleavage and secretion of EscF 
Determine whether an EscUcc deletion or an EscU fusion can be complemented 
in trans by EscUcc 
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Chapter 2 
Materials and Methods 
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2 Material and Methods 
2.1 Bacterial Strains 
All the bacterial strains used in this study, a description of their main characteristics 
and their source or reference are listed in alphabetical order in Table 1. For long term 
storage strains were cultured for 16hr in 5m1 Luria -Bertani (LB) broth, 8O00 of the 
culture was then mixed with 2O0111 100% glycerol in a 1.5ml eppendorf and the 
strains catalogued and placed at -70 °C. 
2.2 Plasmid Constructs 
All plasmids used in this study are listed in alphabetical order in Table 2. The 
commercial vectors were either obtained directly from the supplier or from existing 
laboratory stocks. Dr. I. Blomfield kindly supplied the pIB307 plasmid and the 
pGEM -grlA plasmid was supplied by Professor H. Ando. The plasmids with the 
prefix pJRE were created as part of this study and the remaining plasmids were 
provided by other researchers in the Zoonotic Animal Pathogens (ZAP) laboratory, 
Centre for Infectious Diseases, Edinburgh: pAJRs were constructed by Dr. Andrew 
Roe, pASLs by Dr. Alison Low, pDWs by Mr. Dai Wang, pHYs by Miss Helen Yu11 
and pMTs by Dr. Makrina Totsika (where applicable a reference has been provided). 
2.3 Bacterial Growth Conditions and Media 
For the construction of strains and plasmids LB broth and LB agar (BDH Merck, 
Leicestershire, UK) were used. These were routinely supplemented with 501.1g /ml 
Ampicillin (Amp), 25µg /m1 Chloramphenicol (Cm), 101.1g /ml Tetracycline (Tc), or 
25µg /ml Kanamycin (Kn) when appropriate. Strains were also cultured in minimal 
essential medium with HEPES modification (MEM- HEPES; Sigma, Dorset, UK), a 
T3SS promoting media. This cell culture medium was supplemented with 2.5% 
glucose, micronutrients and 0.261AM ferric nitrate to facilitate bacterial growth with 
antibiotics added when necessary. All the bacterial cultures were grown at 37 °C 
unless the bacteria contained the temperature sensitive plasmid pIB307, when 
cultures were grown at 28 °C (42 °C for plasmid integration in allelic exchange). All 
cultures in liquid media were placed in shaking incubators at 200rpm with static 
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incubators used for incubating LB agar plates. Incubation times, which varied from 
42hr to 8hr, are stated in the relevant results sections. 
Table 1: A description and the source of the strains used in this study. The symbol <> 
indicates a genetic substitution on the bacterial chromosome. 
Strain Description Source /reference 
148a Partial deletion of EHEC T3SS 
apparatus structural proteins in 
strain EDL933. nucleotides 
4,668,961 - 4,670,521 (8.9Kó and 
15 ORFs) deleted 
Campellone, K., et al 
2004 
AAEC185 F ,- supE44 hsdR17 mcrA endA1 
thi -1 A fimBEACDFGH ArecA 
Blomfield, I., et al 1991 
TOP10 One shot° TOP10 chemically- 
competent E. coli cells 
Invitrogen v 
Walla3 EHEC 0157:H7 Stx2 -, Nal" Supplied by Mary 
Reynolds, Atlanta. 
(Ostroff, S., et al 1990) 
ZAP193AescN escN deletion in strain ZAP193 Roe, A., et al 2007 
ZAP632 Walla3 escRSTU < >saciKan 
complement strain 
This Study 
ZAP633 Walla3 escU < >escUAcc 
ZAP634 Walla3 escU< >escUC,,..HA 
ZAP635 Walla3 escU < >escUcf..Qfp+ " 
ZAP636 Walla3 LEE4< >saciKan 
ZAP637 Walla3 escR < >escR::HA 
ZAP1140 Walla3 escRSTU < >sac /Kan 
ZAP1141 Walla3 escU< >escUcc :1egp 
ZAP1142 Walla3 escU < >escUcc:;Qfp+ 
Table 2: A description and the source of all the plasmids used in this study. 
Plasmid name Description Source /reference 
pACYC184 Commercial cloning vector, Cm" and 
TcR 
New England Biolabs 
pAJR70 pACYC184 digested with the REase 
BamHl, egfp cloned using REases 
BamHl and Bglll 
Roe, A et a12003 
pAJR71 pAJR70 digested with BamHl and 
Kpnl; LEE1 promoter cloned in frame 
5' to egfp 
pAJR72 pAJR70 digested with BamHl and 
Kpnl; LEE2 promoter cloned in frame 
5' to egfp 
" 
pAJR73 pAJR70 digested with BamHl and 
Kpnl; LEES promoter cloned in frame 
5' to egfp 
pAJR74 pAJR70 digested with BamHl and 
Kpnl; LEE4 promoter cloned in frame 
5' to e.fp 
" 
pAJR75 pAJR70 digested with BamHl and 
Kpnl, 442óp including LEE5 promoter 
cloned in frame 5' to egfp 
Roe, A., et al 2004 
pAJR145 pACYC184 with rpsM::gfp+ 
transcriptional fusion 
ASL10 ACYC184 based plasmid with ler Supplied b Dr. Alison 
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under the expression of the pTac 
promoter 
Low, ZAP lab 
pCR°4 -TOPO° Commercial cloning vector containing 
TOPO® cloning site and T3 and T7 
_priming sites, AmpR and KnR 
Invitrogen ' 
pDWO6 pACYC184 based plasmid with LEE4 
promoter and sepL fused to egfp 
Supplied by Mr. Dai 
Wang, ZAP lab 
pGEM -grla pGEM -T -easy vector with gr/A cloned 
under the expression of the T7 
promoter 
Ando, H., et al 2007 
pHY10 pIB307 containing the sac/Kan 
cassette and flanking regions for a 
LEE4 deletion 
Naylor, S., et al 2005 
pIB307 Allelic exchange temperature- 
sensitive vector, pSC101 replicon, 
CmR 
Blomfield, I., et al 1991 
pJRE01 pIB307escRSTU This Study 
pJRE02 pCR" 4- TOPO ̀ 9escRSTU " 
pJRE03 pIB307escRSTU < >sacAKan 
pJRE04 pCR194- TOPO"escU PCR1 
pJRE05 pCR" 4- TOPOrescU PCR 2 
pJRE06 pCRr4- TOPO"escU PCR1 and 2 
pJ R E07 pC Rr4 -TO POvescUcc ::egfp 
pJ RE08 p I B307 escRSTUcc::egfp ' S 
pJ R E09 pC RN-TO PO" escUcc: :qfp+ 
pJRE10 pl B307escRSTUcc: :qfp+ 
pJRE11 pI B307escRSTU Agel removal of ler " 
pJRE12 plB307escRSTUc. :ffp+ BstElI 
pJRE13 p B307escRSTUcn ::HA BstEI I 
pJRE14 pIB307escRSTU Psti site removed 
pJRE15 pCR" 4- TOPOrescR PCR 1 
pJRE16 pCR" 4- TOPO"escR PCR 2 
pJRE17 pCRN- TOPO ®escR PCR 1 and 2 
pJRE18 pCR" 4- TOPO °escR::HA " 
pJRE19 p1B307escR( : :HA)STU 
pJRE20 pJRE10 digested with Agel to remove 
ler and the LEE1 promoter region then 
religated 
pJRE21 pJRE20 digested with BstEll and 
Aatll, Klenow treated and religated 
pJRE22 pJRE21 with the sequence from 
BstEll to the cleavage site, to create 
an escUcc deletion 
" 
pJRE23 pKC21 containing escUcc sequence 
with a 5' HA tag, downstream of the 
pTac promoter 
pJRE24 pKC21 containing the sequence for 
escUcc, downstream of the pTac 
promoter 
" 
pKC21 pACYC184 based plasmid containing 
the pTac promoter. Kpnl and Hindlll 
restriction sites are used for creating 
IPTG inducible clones of genes 
Supplied by Miss 
Kirsteen Catherwood, 
ZAP lab 
pMT01 pIB307 with papl- A'from CFT073 P1 
fused to efp 
Holden, N., eta /2007 
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2.4 Molecular Techniques and Genetic Manipulations 
Unless otherwise stated the procedures are essentially those described in Molecular 
Cloning: A laboratory Manual, 
3rd edition (Sambrook, J., et al 2001). 
2.4.1 CTAB DNA Extraction 
The CTAB DNA extraction method (Murray, M., et al 1980) was used to extract 
Walla3 genomic DNA. The CTAB method uses hexadecyltrimethyl ammonium 
bromide (CTAB) that precipitates cell debris, proteins and polysaccharides to leave 
high -molecular weight DNA, which can be recovered by isopropanol precipitation. 
In brief a 1.5ml aliquot of a Walla3 culture grown in LB broth for 16hr was 
microcentrifuged at 13,000 g for 1min and the cell pellet suspended in 567111 TE 
buffer. To the suspension 3011l 10% sodium dodecyl sulphate (SDS) and 3µl 
20mg /m1 of proteinase K (QIAGEN, West Sussex, UK) were added, this mixture was 
then incubated at 37 °C for lhr. After the incubation l00111 of 5M sodium chloride 
(NaCl) was added and gently mixed, followed by 801A 10% CTAB solution in 0.7M 
NaCl. The mixture was incubated at 65 °C for 10min, then an equal volume of 
chloroform:isoamyl alcohol (24:1) was added followed by microcentrifugation at 
13,000 g for 5min. The aqueous phase supernatant was removed and the 
chloroform:isoamyl alcohol step repeated. The genomic DNA was then precipitated 
from the remaining aqueous phase supernatant by adding 0.6 volumes of isopropanol 
and pelleted by microcentrifugation at 4 °C and 13,000 g for 10min. The DNA pellet 
was washed with 0.5ml 70% ethanol and re- suspended in 50111 TE buffer. A 1:150 
dilution of the extracted DNA was made with TE buffer for use as DNA template in 
Polymerase Chain Reactions (PCRs) and was stored, with the neat extraction, at 
-20 °C. 
2.4.2 Crude DNA Extractions from E. coli 
To prepare crude extracts of DNA for PCR a 10 [11 plastic loop was used to uplift a 
colony of bacteria from an LB agar plate. The bacteria on the loop were suspended in 
a sterile 1.5ml eppendorf tube containing l00111 MQ water (Sigma, Dorset, UK). The 
lid of the eppendorf was closed and pierced with a fine syringe needle and the 
suspension heated in a 100 °C water bath for 5min. The suspension was then 
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microcentrifuged at 13,000 g for 1 min to pellet the bacterial cell debris and stored at 
-20 °C. lµl of the crude extract was used as the DNA template for PCR screens. 
2.4.3 Polymerase Chain Reaction (PCR) 
All PCR primers used in this study are listed in numerical order in Table 3. Sterile 
0.2ml thin -walled PCR tubes were used, with a standard 50µ1 PCR reaction mixture 
containing: 
DNA template Approx. 1µg (lµl of stock solution) 
5' Primer 2mM (from a 100mM stock solution) 
3' Primer 2mM (from a 100mM stock solution) 
dNTPs 16µM (from a 0.4mM stock solution) 
10x PCR buffer 5µ1 (supplied with Taq DNA polymerase from Roche, 
Burgess Hill, UK) 
Taq DNA polymerase 2.5 units (0.150 of enzyme supplied by Roche, 
Burgess Hill, UK) 
MQ water 39.85µl 
The DNA template was either 111l of 1:150 dilution of the CTAB extracted genomic 
DNA or 111l of a crude DNA extraction. The tubes were placed in a Thermo -Hybaid 
PCR Express machine, which was programmed to cycle the PCR based on the 
following template: 
Time Temperature Number of Cycles 
4min 94 °C (DNA denaturing step) x1 
45sec 94 °C (DNA denaturing step) 
45sec 
lmin /Kb of DNA to be 
amplified 
X°C (Ta for primer pair) 
72 °C (Extension) 
x25/30 
10min 72 °C (Extension) xl 
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Negative controls for the PCR reactions had the template DNA replaced by 111l of 
MQ water. For PCR screens the volume of each PCR reaction was lowered from 
501,tl to l00, usually a master mix was made and 10µl aliquots were taken and added 
to 0.5µl of the DNA to be screened. 
2.4.3.1 Expand Long Template PCR System 
For PCR products used to construct clones a Taq DNA polymerase and Tgo DNA 
polymerase mix was used. This high -fidelity amplification was supplied in the 
Expand Long Template PCR System (Roche, Burgess Hill, UK) and used according 
to manufacturer's instructions. The high- fidelity is provided by the Tgo DNA 
polymerase enzyme that has proofreading activity, giving a lower error rate than Taq 
DNA polymerase. The reaction mixture for 50µ1 and the Thermo -Hybaid PCR 
Express machine cycling template are as follows: 
DNA template Approx. 1µg (10 of stock solution) 
5' Primer 2mM (from a 100mM stock solution) 
3' Primer 2mM (from a 100mM stock solution) 
dNTPs 17.611M (from a 0.4mM stock) 
10x PCR buffer 5p1 (supplied with Taq DNA polymerase from 
Roche, Burgess Hill, UK) 
Taq/Tgo DNA polymerase mix 3.75 units (0.75µl of enzyme mix) 
MQ water 39.05µ1 
Time Temperature No. of Cycles 
4min 94 °C (DNA denaturing step) xl 
lOsec 94 °C (DNA denaturing step) 
30sec X°C (T, for primer pair) x10 
/min /Kb of DNA to be 68 °C (Extension) 
amplified 
lOsec 94 °C (DNA denaturing step) 
30sec X°C (Ta for primer pair) x20 
/min /Kb of DNA to be 68 °C (Extension) 
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amplified ( +20sec every 
cycle) 
7min 68 °C (Extension) x 1 
2.4.3.2 Overlapping Site Directed Mutagenesis 
For overlapping site directed mutagenesis the expand long template PCR system was 
used to produce two PCR products with overlapping ends. The two PCR products 
were produced separately using PCR primers that are sense and antisense versions of 
one another (primers c and b in Fig.3). The two PCR products are then purified, 
using the QlAquick PCR purification kit (QIAGEN, West Sussex, UK). The purified 
PCR products were used in a further expand long template PCR reaction as the DNA 
template - usually in varying concentrations to increase the chances of a successful 
PCR. Negative PCRs were set up with no DNA template and only one PCR product 
as DNA template. The second PCR was carried out with the outside primers (primers 
a and d from Fig.3). This created a PCR product, identical in sequence to the wild 
type DNA apart from the added mutation (contained in PCR primers b and c Fig.3). 
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r 
Two expand long template 
PCRs create two PCR 
products with an added 
mutation (40). Primers b 
and c are sense and 
antisense of one another - 




The two PCR products are purified and 
mixed in varying concentrations to act as the 
DNA template for a PCR reaction using 
primers a and b 
\d 
The overlapping PCR are used as a PCR 




Fig.3 Diagram of overlapping site directed mutagenesis. Primers are labelled with lower 
case letters. PCR products are named by pairs of uppercase letters (corresponding to the 
primers used to generate them). Two PCR products are created, using primers (b and c) that 
are sense and antisense of one another. These primers are identical to the wild type 
sequence, except specific base changes to add a mutation. The two PCR products are 
purified and mixed. A further PCR reaction with the outside primers (a and d) create a final 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2.4.4 DNA Agarose Electrophoresis 
PCR products were separated and visualised on agarose gels stained with ethidium 
bromide. Either medium (100m1) or small (50m1) agarose gels were made with lx 
TBE buffer containing 0.7-1% agarose (depending on the size of the PCR product) 
and 1111 of 1M ethidium bromide. The Bio -rad (Hertfordshire, UK) electrophoresis 
system was used and electrophoresis was carried out at a constant 100v, until the dye 
front had migrated 3/4 of the way down the gel. The gels were imaged by UV 
illumination in a Flowgen MultilmageTM light cabinet (Shenstone, UK) and pictures 
taken and stored using the Chemilmager 4000i v.4.04 software. The PCR product 
samples run on the gels contained lx DNA loading buffer (Invitrogen, Paisley, UK) 
and were run alongside either the 1 OObp DNA ladder, the 1Kb DNA ladder or the X 
HindIll DNA ladder (Invitrogen, Paisley, UK) for sizing. 
2.4.4.1 Purification of DNA from Agarose Gels 
Agarose gels were used to purify DNA from either a PCR or a plasmid DNA REase 
mixture. A 50m1 0.7% agarose gel was made using the Bio -rad system 
(Hertfordshire, UK). The comb used created wells that held 60µ1 of sample, allowing 
the whole PCR reaction /plasmid DNA REase mixture with loading buffer to be 
loaded. The gel was run as before and the band(s) excised with a scalpel after 
visualisation on a UV transilluminator (SLS, Nottingham, UK). The DNA was then 
extracted from the agarose gel using the QlAquick gel extraction kit (QIAGEN, West 
Sussex, UK) according to the manufacturer's instructions. The purified DNA was 
reconstituted in 301A1 of MQ water. 
2.4.5 Preparation of Plasmid DNA 
For pACYC 184, pCR4 ® -TOPO and pGEM -T -easy based plasmids (medium and 
high copy number plasmids) the plasmid DNA was extracted from bacterial cultures 
grown for 16hr at 37 °C and 200rpm in 5m1 LB broth with the appropriate antibiotic. 
The QIAprepTM spin plasmid miniprep kit (QIAGEN, West Sussex, UK) was used 
according to manufacturer's instructions (with all the buffers supplied with the kit) 
and the plasmid DNA was eluted in 500 MQ water. For pIB307 based plasmids 
(low copy number plasmids) four 5m1 LB cultures grown at 28 °C and 200rpm for 
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16hr were pooled into a single QIAprepTM spin column and eluted in 35µ1 MQ water. 
Alternatively, if a large amount of the plasmid was required then the QIAGENTM 
spin plasmid midiprep kit (QIAGEN, West Sussex, UK) was used according to 
manufacturer's instructions, which yielded 20 -10Ong of low copy plasmid DNA in 
250µ1 of MQ water. 
2.4.6 Restriction Enzyme Digestion 
All the REases used in restriction digestions were purchased from New England 
Biolabs (NEB; Hertfordshire, UK) and used according to their instructions. Typically 
2.50 of the REase and 5µl of the corresponding NEB 10x enzyme buffer were added 
to a 500 reaction volume that contained a varying concentration of DNA suspended 
in MQ water (depending on the concentration of DNA in the original sample). The 
reaction mixture was left for approximately 2.5hr at the recommended temperature 
for optimum enzyme activity (usually 37 °C). In diagnostic digestions the reaction 
mixture volume was decreased to 200, of which 1111 was the REase and 2111 the 
corresponding NEB 10x enzyme buffer. After an hour incubation 2.2p1 of 10x 
loading buffer (Invitrogen, Paisley, UK) was added and the whole sample loaded 
onto an agarose gel. When two REases were used which were compatible for a 
double digestion only 2111 of each were added to a 50µ1 reaction with 5111 of 10x 
bovine serum albumin (BSA; NEB, Hertfordshire, UK). For diagnostic digests lµl of 
each REase was added and the reaction volume increased to 25µl with no BSA. 
2.4.7 DNA Fragment Purification 
DNA fragments from PCR (100bp - 10Kb) and DNA from 50111 REase digestion 
mixtures were purified from the reaction mixture using the QlAquick PCR 
purification kit (QIAGEN, West Sussex, UK) following the manufacturer's 
instructions. Purified DNA was eluted from the spin column in 30 -50111 MQ water. 
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2.4.8 Klenow Treatment of Digested DNA 
The DNA polymerase I, large (Klenow) fragment (NEB, Hertfordshire, UK) was 
used to form blunt ends after restriction enzyme digestion with REases that produced 
non compatible sticky ends. It was used according to manufacturer's instructions but 
briefly 2.50 of Klenow was added to a 500 reaction mixture containing the DNA 
suspended in MQ water, 5p1 10x NEB REase buffer 2 and 41l 0.4mM dNTPs. After 
a 2.5hr incubation the reaction was stopped by either heat inactivation (75 °C for 
10min) or by using the QlAquick PCR purification kit (QIAGEN, West Sussex, UK) 
to purify the DNA from the reaction mixture. 
2.4.9 Ligation of DNA Fragments 
Vector and insert DNA were restricted with the appropriate REase(s) to form 
compatible ends for ligation. 1µl of Antarctic alkaline phosphatase (AAP; NEB, 
Hertfordshire, UK) was added to the REase reaction mixture containing the vector 
DNA for the final 30min of the incubation. This dephosphorylated 5' restricted 
termini to prevent the vector from religating. The digested vector and insert were 
visualised on an agarose gel with the 2 Hindlll DNA ladder, which was used to 
quantify the amount of DNA in the samples: 
DNA ng/p1= Brightness factor x Size factor x ng of DNA in A Hindill DNA band 
Where the brightness factor is: 
Brightness of insert or vector DNA band 
Brightness factor = 
and the size factor is: 
Size factor = 
% Brightness of DNA ladder band 
Size of insert or vector DNA band 
Size of DNA ladder marker band 
The amount of insert (ng) to be used in the ligation reaction with 50 -10Ong of vector 
DNA was calculated using the equation: 
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Insert (ng) _ 
ng of vector x size of insert (bp) 
Size of vector (bp) x Insert : Vector Ratio 
(Where the ratio of insert to vector is 3:1) 
The DNA fragments (suspended in MQ water) were mixed with 111l T4 DNA ligase 
(NEB, Hertfordshire, UK) and 1m1 IOx ligase reaction buffer (NEB, Hertfordshire, 
UK) to a final volume of 10[11 (made up with MQ water). For ligations with 
complementary sticky ends the ligation mixture was incubated at 4 °C for 16hr and 
for blunt end ligations the mixture was incubated at 16 °C for 16hr. 
2.4.10 TOPO TA Cloning 
The TOPO TA cloning® kit (Invitrogen, Paisley, UK) was used to clone PCR 
products for sequencing and for sub -cloning into low copy number vectors. The kit 
provides a method of non -directionally inserting a PCR product into the pCR4"- 
TOPO" vector, without the need for restriction digestion or purification of the insert 
DNA from the PCR mixture. Taq DNA polymerase has a non -template dependent 
terminal transferase activity that produces PCR products, which contain poly -A 3' 
overhangs (the addition of single deoxyadenosine (A) to the 3' end of PCR 
products). These overhangs are fragile and can easily be lost by mechanical shearing 
from procedures like purification from agarose gels. The PCR product with the poly - 
A 3' overhangs is ligated with linearized pCR4®-TOPO®, which contains poly -T 3' 
overhangs, by the enzyme topoisomerase. This ligation reaction was carried out 
according to manufacture's instructions with the kit containing the vector, enzyme 
and the buffer. PCR products generated by the expand long template system (Roche, 
Burgess Hill, UK) lack the poly -A 3' overhangs due to the proof reading activity of 
the Tgo DNA polymerase. Before these products can be TOPO TA cloned poly -A 3' 
overhangs are added after amplification by incubating the PCR reactions with 1 unit 
of Taq DNA polymerase and 2µl dNTP (0.4mM stock) at 72 °C for 10min. The 
ligation mixtures were transformed into One shot" TOP 10 chemically competent E. 
coli cells (Invitrogen, Paisley, UK). 
56 
2.5 Transformations 
2.5.1 Preparation and Transformation of Chemically Competent Cells 
5m1 LB broth was inoculated with the E. coli K -12 strain to be made chemically 
competent. This was incubated for 16hr at 37 °C and 200rpm and 1 ml used to 
inoculate 100m1 LB broth. The 100m1 culture was grown under the same conditions 
until its optical density, measured at 600nm (0D600 °m), was 0.4 -0.6. The culture was 
then centrifuged at 4 °C and 3220 g for 10min. The cell pellet was gently suspended 
in 40m1 (0.4 volume) ice -cold transformation buffer I (TFBI) and incubated on ice 
for at least 15min. After the incubation the cells were harvested by an 8min 
centrifugation at 4 °C and 3220 g. The harvested cells were suspended in 1.6ml (0.04 
volume) ice -cold transformation buffer II (TFBII). The cells were incubated on ice in 
TFBII for 15min before aliquoting into l00111 volumes and storing at -70 °C. 
To transform chemically competent cells, a l00µ1 aliquot of the cells was mixed by 
gentle pipetting with 1111 purified plasmid DNA or the l0111 of a ligation reaction 
mixture and incubated on ice for 30min. After the incubation the mixture was heat - 
shocked in a 42 °C water bath for 45sec. The transformations were incubated on ice 
for lmin immediately after heat -shocking and then 3500 of room temperature Salt - 
Optimised and Carbon medium (SOC; Invitrogen, Paisley, UK) was added. 
Transformants containing the temperature sensitive plasmid 03307 were incubated 
at 28 °C and 80rpm for 2hr. For all other plasmids, transformants were recovered for 
lhr at 37 °C and 80ipm. After the recovery period a 20011 aliquot of the culture was 
plated on LB agar supplemented with the relevant antibiotic(s) and incubated for 
16hr at the appropriate temperature (for pIB307 based plasmids a 48hr incubation at 
28 °C was often required before colonies could be seen). 
2.5.2 Preparation and Transformation of Electro- Competent Cells 
Electroporation was used to transform plasmids into all non laboratory strains. 
Firstly a 100m1 culture of the bacteria was grown in LB broth in an identical manner 
to the preparation of chemically competent cells. The bacteria were pelleted out of 
the LB broth by centrifugation for 10min at 4 °C and 3220 g and the pellet suspended 
in 100m1 ice -cold MQ water. The centrifugation step was repeated for 8min and the 
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pellet washed with 50m1 ice cold 10% glycerol (0.5 volume). The suspended bacteria 
were then harvested by another 3220 g centrifugation at 4 °C for 8min and the pellet 
suspended in 25ml (0.05 volume) of ice -cold 10% glycerol. This suspension was 
centrifuged for a further 8min and the pellet suspended in 500111 (or less) ice -cold 
10% glycerol, to produce a thick slurry. This suspension could be divided into 100µl 
aliquots and stored at -70 °C, however electro- competent cells transformed at a higher 
efficiency if they were used on the same day they were prepared. 
To transform electro- competent cells a 750 aliquot of the cells was mixed with 1111 
of purified plasmid DNA and incubated on ice for 1min. The mixture was then 
transferred to a 1.5ml ice -cold electroporation cuvette (Flowgen, Shenstone, UK). 
Before electroporating with a 2.5KV pulse the cuvette was wiped dry and air bubbles 
removed by tapping the bottom of the cuvette against the laboratory bench. After 
electroporating lml of room temperature SOC medium was immediately added. The 
SOC was mixed with the transformed cells by pipetting, removed and placed in a 
sterile 1.5ml eppendorf and recovered at 37 °C for ihr and 200rpm or 28 °C for 2hr 
and 200rpm (depending on the plasmid being transformed). After the incubation a 
20011l aliquot of the transformation mixture was plated onto an LB agar plate 
containing the relevant antibiotic(s) and incubated for 16hr at the appropriate 
temperature (for pIB307 based plasmids a 48hr incubation at 28 °C was often 
required before colonies could be seen). 
2.6 Allelic Exchange 
All gene replacements and deletions in the Walla3 strain were created using a 
temperature- sensitive plasmid based allelic exchange system as described in 
Blomfield, I., et al 1991 and Emmerson, J., et al 2006 (which contains a detailed 
protocol). 
Integral to the method is the sac/Kan cassette, a genetic element consisting of the 
sacB gene from Bacillus subtilis and the neomycin (KnR) gene from Tn5. This 
cassette was cloned between two homologous regions of flanking DNA (sequence 
either side of the region to be substituted on the chromosome) in the temperature 
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sensitive plasmid pIB307. This plasmid was electro- transformed into the strain to be 
manipulated. Incubation and successive passage at 42 °C in LB broth (with 
chloramphenicol) promoted plasmid integration. This was followed by incubation 
and successive passage at 28 °C in LB broth (with kanamycin) to promote plasmid 
backbone excision. This produced a mixed population of bacteria, some of which had 
excised the pIB307 plasmid in an event that had substituted the genetic material on 
the chromosome for the sac/Kan cassette. These bacteria were kanamycin resistant 
and chloramphenicol sensitive. Successful integrants were screened by PCR using 
primers specific for the pIB307 backbone, the sac/Kan cassette and the region of 
genetic material substituted (Fig.4, A). 
The successful integration event creates an intermediate strain that can be used to 
create clean deletions or genetic modifications of the sequence substituted. For this 
the 013307 plasmid containing the flanking regions is used with either no genetic 
sequence between the two flanking regions (to create a clean deletion) or genetic 
modifications of the sequence between them. This plasmid is electro- transformed 
into the intermediate strain and grown at 42 °C in LB broth containing 
chloramphenicol, followed by incubation at 28 °C in LB broth containing no 
antibiotics, to promote integration and excision of the plasmid. This creates a 
proportion of bacteria that have the sac/Kan cassette on the chromosome replaced 
with the sequence between the flanking regions of the plasmid. The removal of the 
sac/Kan cassette can be screened for as its presence in the intermediate strain makes 
the strain sensitive to growth on agar plates containing 6% sucrose (and no NaC1). 
This is due to the sacB gene, which produces levansucrase that polymerizes sucrose 
to create levans. These levans build up in the bacterial cell causing an osmotic 
imbalance, leading to bacterial cell death (Emmerson, J., et al 2006, Blomfield, I., et 
al 1991). Successful integrations are sucrose tolerant and chloramphenicol and 
kanamycin sensitive. Any positive clones are then screened by PCR using primers 
specific for the pIB307 backbone, the sac/Kan cassette and the sequence 







Sac /Kan Cassette 
1: Plasmid Integration: Inserting the sacB -Kan Cassette: 
Grown at 42 °C in 
LBC. This is not 
permissive to 
Plasmid 
replication so it 







Step 2: Plasmid Excision: 
(Shown from integration B. from step 1) 
X X ---- 
1. 1 or 2. 
Successful allelic 
exchange 
Grown at 28 °C in 
LBK. 
The plasmid is 
able to replicate so 




Step 3 & 4: Plasmid Curing and selection of the mutant: i 
Grown at 28 °C in LBK. Selected on 
LBK and LBC agar plates. Bacteria 





Genetic Material to be deleted 
Homologous regions of flanking DN 
Fig.4 Diagram of allelic 
exchange A) (Taken from 
Emmerson, J., et al 2006) 
The transfer of the sacB -Kan 
cassette into the chromosome 
requires two recombination 
events leading to plasmid 
integration followed by plasmid 
excision. Step 1: plasmid 
integrates into the wild -type 
strain at the non permissive 
temperature for plasmid 
replication (42 °C). Steps 2 and 
3: plasmid integrates are 
grown at 28 °C in the presence 
of kanamycin to enrich for 
bacteria that have excised and 
cured the plasmid, leaving the 
cassette on the chromosome. 
Step 4: Growth on media 
containing LBC or LBK. 
Bacteria that can only grow on 
LBK are successful constructs 
of the intermediate strain. 
Grown at 28 °C on 
LBK and LBC 
agar plates. 
Positive clones are 







Sac /Kan Cassette 
1: Plasmid Inte rag tion: Removing the saca -Kan Cassette: 
A. x x B. 
Grown at 42 °C in 
LBC. Temperature 
sensitive plasmid 
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2.7 Methods for Protein Analysis 
2.7.1 Whole Cell Protein Preparations 
Bacteria were grown for 16hr in 5m1 MEM -HEPES supplemented with 0.5% 
glucose, micronutrients and 0.26µM ferric nitrate at 37 °C and 200rpm. This culture 
was used to inoculate 50m1 supplemented MEM -HEPES to a starting OD600nm of 
0.01 and grown at 37 °C for -8hr until it had reached an OD600nm of 0.8 -0.9. Once this 
OD600nm was reached the culture was transferred to ice -cold 50m1 falcon tubes and 
centrifuged at 3220 g for 30min at 4 °C and the pellet suspended in 0.5ml ice -cold 
sonication buffer. The suspension was then placed on ice and sonicated three times 
for 15sec at 5 microns amplitude using a Soniprep 150. After sonication cell debris 
was removed by two rounds of microcentrifugation at 13,400 g and 4 °C for 10min. 
The final supernatant was used as a preparation of whole cell proteins and could be 
aliquoted and stored at -20 °C until needed. 
2.7.2 Supernatant Protein Preparations 
For supernatant protein preparations the cultures were grown in an identical manner 
to the whole cell protein preparations. After they reached an OD600nm of 0.8 -0.9 the 
cultures were transferred to ice -cold 50m1 falcon tubes and centrifuged at 3220 g for 
30min at 4 °C and the supernatant decanted and transferred to a sterile ice cold 50m1 
falcon tube. The supernatant was then filtered through a low protein binding 0.45µm 
PVDF filter (Millex -HV filter; Millipore, Watford, UK) and BSA was added to a 
final concentration of 4µg /ml. The supernatant was then made to 10% trichloroacetic 
acid (TCA acid) and incubated at 4 °C for 16hr. After the incubation the solution was 
centrifuged at 3220 g for 30min at 4 °C and the pellet suspended in a volume of 
sonication buffer that was adjusted according to the final OD600nm reached by the 
culture; typically pellets for samples that reached an OD600nm of 0.8 were suspended 
in 250111 of sonication buffer. 
2.7.3 Cytoplasmic and Membrane Protein Preparations 
The method for whole cell protein preparations was followed. When the final 
supernatant containing the whole cell samples had been obtain it was centrifuged in a 
Sorvall Discovery Ultra Centrifuge for lhr at 4 °C and 50,000 g. Following the ultra 
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centrifugation step the supernatant, containing the cytoplasmic proteins, was 
decanted into a chilled eppendorf and could be aliquoted and stored at -20 °C. The 
pellet, containing the membrane proteins, was suspended in half the volume of the 
cytoplasmic samples (- 250µ1) in SDS gel loading buffer (not sonication buffer). This 
made the membrane samples twice as concentrated as the cytoplasmic samples and 
they did not need dilution with SDS gel loading buffer before running on SDS PAGE 
gels, so potentially more sample could be loaded. 
2.7.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS 
PAGE) 
Samples for SDS PAGE were obtain by either whole cell, supernatant, cytoplasmic 
or membrane protein preparations. The whole cell, cytoplasmic and membrane 
protein preparations, which had not been adjusted for the OD600nm of the original 
culture, had variable amounts loaded onto the gel. Typically l20 was loaded of a 
protein preparation from a sample which had originated from a culture that had 
reached an OD600nm of 0.8; this ratio was used to adjust all the samples that were 
loaded onto the gel. For membrane protein preparations 6111 was loaded for a culture 
that had grown to an OD600nm of 0.8, as these samples were twice as concentrated as 
their corresponding cytoplasmic protein preparations. The supernatant protein 
preparations did not need adjusting for their OD600nm so 14,l was loaded. 8111 SDS 
gel loading buffer was added to all the samples (except to the membrane protein 
preparations). All the samples for SDS PAGE mixed with the loading buffer were 
placed in 1.5 or 0.5ml eppendorfs, which had their lids pierced by a fine syringe 
needle, and were incubated in a water bath set to 100 °C for 5min to denature the 
proteins. After the incubation the samples were centrifuged in a microcentrifuge at 
13,000 g for 30sec and loaded onto the SDS PAGE gel. 
The SDS PAGE BIO -RAD Mini -protean II gel apparatus (Bio -rad, Hertfordshire, 
UK) system was used to construct and run the SDS PAGE gels. Firstly the 12% 
resolving gel solution was prepared and applied to the vertical electrophoresis 
apparatus and allowed to polymerase (approx. 30min at room temperature). Once 
polymerised the 5% SDS PAGE stacking gel was prepared and the solution applied 
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on top of the polymerised resolving gel. Immediately after the stacking gel's 
application a 10 well comb was placed into the stacking gel. It was then allowed to 
polymerise. Once polymerised the BIO -RAD Mini -protean II gel apparatus for 
running the gel was assembled and the gel placed into the electrophoresis tank. SDS 
PAGE running buffer was added to the inner and outer compartments and the well 
comb removed. The boiled samples were loaded into the wells alongside 5.t1 of the 
molecular weight marker (Rainbow marker; Amersham Pharmacia Biotech, 
Buckinghamshire, UK). A constant voltage of 100V was used until the dye in the 
loading buffer had reached the bottom of the gel. Gradient gels of 10 -20% (Bio -rad, 
Hertfordshire, UK) and gels of 18% (Bio -rad, Hertfordshire, UK) were used in an 
identical manner. However, these were purchased as pre -cast gels and so did not 
need any preparation before being placed in the BIO -RAD mini gel system. 
2.7.5 Coomassie Blue Staining of SDS PAGE Gels 
Polyacrylamide gels were stained with Coomassie blue (Colloidal blue; Invitrogen, 
Paisley, UK) according to manufacturer's instructions. Gels were then de- stained for 
16hr in dH2O and transferred onto two 3MM Whatman paper squares. Gel images 
were captured using a Flowgen MultilmageTM cabinet after 
dried at 75 °C for at least 180min in a vacuum and heated gel drier (Bio -rad, 
Hertfordshire, UK). 
2.7.6 Tricine SDS PAGE 
Tricine gels were purchased from Bio -rad (Hertfordshire, UK). They were placed 
into the BIO -RAD Mini- protean II gel apparatus and the outside chamber was filled 
with the cathode buffer and the inside chamber with the anode buffer. The samples 
were loaded in the same manner as for SDS PAGE protocol (section 2.7.4) and the 
gels run at a constant voltage of 30V until the samples had reached the bottom of the 
gel (-6hr). 
2.7.7 Antibodies 
All antibodies used, their application and incubation time are listed in Tables 4. 
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1:2000, 1 hr - 




1:4000, 1 hr - 
OmpA (Dr. J. Leong, USA) Polyclonal Rabbit 1:4000, 1 hr - 
EspA Polyclonal Rabbit 1:2000, 1 hr 1:250, 1.5hr 
EspD Monoclonal 
Mouse 
1:2000, 1 hr - 
HA (Sigma, Dorset, UK) Monoclonal 
Mouse 
1:1000, 2hr - 




1:1000, 2hr - 
EscJ (Prof. Abe, Japan) Polyclonal Rabbit 1:2000, 1 hr 1:250, 2hr 
EscF (Prof. Abe, Japan) Polyclonal Rabbit 1:1000, 1 hr 1:250, 2hr 




Western blotting: dilution 
factor and incubation 
time 
Microscopy staining: 
dilution factor and 
incubation time 





anti mouse IgG 
1:4000, 1 hr - 





anti rabbit IgG 
1:4000, 1 hr - 




anti rabbit IgG 
- 1:1000, 2hr 
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2.7.7.1 Absorbing Antibodies with a Mutant Strain 
Two cultures of the relevant strain for absorption were grown in 50m1 supplemented 
MEM- HEPES. At an OD600nm of 0.8 both the cultures were centrifuged at 3220 g for 
15min and 4 °C. One of the bacterial pellets was suspended in lml of a 1:250 dilution 
of the relevant antibody in lx phosphate buffer saline (PBS; Oxoid, Hampshire, UK). 
This was incubated for 2hr on a rocking platform at 4 °C. After 2hr the mixture was 
centrifuged at 13,000 g for 5min at 4 °C and the supernatant used to suspend the 
bacterial pellet from the second 50m1 MEM -HEPES culture. This was incubated for 
2hr on a rocking platform at 4 °C and then centrifuged at 13,000 g for 5min at 4 °C. 
The supernatant was filtered through a low protein binding 0.45µm PVDF filter 
(Millex -HV filter; Millipore, Watford, UK). The filtrate was used in Western blot 
analysis as primary antibody diluted 1:10. 
2.7.8 Western Blotting 
Proteins separated by SDS PAGE and Tricine SDS PAGE were transferred from the 
polyacrylamide gel onto a nitrocellulose membrane (Amersham Pharmacia Biotech, 
Buckinghamshire, UK) using the Bio -rad transfer apparatus (Bio -rad, Hertfordshire, 
The nitrocellulose membrane and 4 pieces of 3MM Whatman paper were cut to 
the size of the gel and soaked in transfer buffer with two sponges. The wells on the 
polyacrylamide gel were removed and the transfer apparatus constructed with the gel 
and the membrane between the 4 pieces of Whatman paper (two either side) and the 
two sponges (one either side). These were held together in the plastic clamp and 
placed into the transfer tank with an ice pack (Bio -rad, Hertfordshire, UK) and filled 
with transfer buffer. The transfer was performed at a constant voltage of 60V for 
100min. Upon completion of the transfer the nitrocellulose membrane was removed 
and blocked in blocking buffer at 4 °C for 16hr. Excess blocking buffer was removed 
by three 10min washes with washing buffer and the membrane was immersed in 
primary antibody solution and incubated at room temperature on a rocking platform. 
After the incubation the excess primary antibody was removed by three 10min 
washes in washing buffer, following which the membrane was incubated in 
secondary antibody solution at room temperature on a rocking platform. Excess 
secondary antibody was then removed with a final set of three 10min washes in 
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washing buffer. The membrane was then incubated in 10m1 ECL solution and left on 
the bench for 5min. The chemiluminescence from the ECL reaction was detected 
using HyperfilmTM ECL chemiluminescence film (Amersham Pharmacia Biotech, 
Buckinghamshire, UK) and developed in a Protec automatic film processor 
(Optimax, Nottingham, UK). After developing, the film and the membrane were 
lined up and the Rainbow marker bands were marked onto the film with a permanent 
marker pen. 
2.7.8.1 Quantification of Western Blot bands using ImageJ software 
The ImageJ software (National Institute of Health, USA) was used to quantify the 
amount of signal from Western blot X -ray films. The film, once developed, was 
scanned as a high resolution image file and loaded into the ImageJ software. The 
software tools were used to invert the image and draw a box around the band to be 
measured. The box was then copied and placed over an area of film containing no 
sample. The analysis function was used to measure the amount of pixilation in each 
box. The value for the background was subtracted from the value for the sample band 
giving an approximation of the signal from the sample. This was repeated for the 
number of bands to be measured, using the same drawn box and background reading. 
2.8 Fluorescence Microscopy 
2.8.1 Immunofluorescence Antibody Staining 
Samples for antibody staining were grown in 5m1 supplemented MEM -HEPES for 
16hr. This was used to inoculate 10m1 or 50m1 supplemented MEM -HEPES to a 
starting OD600nm of 0.01. At an OD600,,,,, of 0.8 the bacteria were placed on ice and 
aliquots of the culture were fixed for microscopy. 
2.8.1.1 Paraformaldehyde (PFA) Fixation 
A sample of the culture was mixed with 4% paraformaldehyde (PFA) in a ratio of 
1:4. The suspension was inverted to gently mix the bacteria and incubated for 16hr at 
4 °C or for 15min at room temperature. 200 of the sample was spotted into a well on 
a 10 well glass microscope slide and dried at 37 °C. 
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2.8.1.2 Methanol Fixation 
Methanol fixation was used to fix and permeabilise bacteria for antibody staining 
within the cell. A sample of the culture was mixed with 99% ice -cold methanol in a 
ratio of 1:1. After gentle mixing the suspension was immediately incubated at -20 °C 
for at least 10min. Once incubated 200 of the sample was spotted into a well on a 10 
well glass microscope slide and dried at 37 °C. 
The dried slides were heat fixed with a Bunsen burner flame to ensure the bacteria 
were not dislodged from the slide during the antibody staining technique. Then the 
slides were washed with lx PBS (Oxoid, Hampshire, UK) by pipetting 20µ1 of PBS 
into each well and removing it, this was repeated three times. After this the wells 
were incubated in 20µ1 of primary antibody solution and placed on a rocking 
platform at room temperature inside a sealed box containing wet tissue (to stop the 
slides from drying). The slides were then washed three times with lx PBS to remove 
the primary antibody and the wells were incubated in 20111 of secondary antibody 
solution and placed on a rocking platform inside the sealed box. Following this 
incubation the slides were washed with lx PBS for a final three times and mounted 
fluorescence mounting medium (Dako; Glostrup, Denmark). Cover slips were 
placed on the slides and they were allowed to dry for 48hr in the dark before 
visualising them on a DM LB2 microscope (Leica, Milton Keynes, UK) using a 100x 
objective lens with image acquisition and analysis performed using OpenLab 
software (Improvision, Coventry, UK) 
2.8.2 GFP Slide Preparation 
Slides that were made with strains containing GFP fusions (i.e. strains that did not 
need antibody staining to be visualised by fluorescence microscopy) were fixed by 
the PFA fixation method. Once dry they were mounted with the fluorescence 
mounting medium (Dako; Glustrop, Denmark), left to dry for 48hr in the dark and 
visualised on the Leica DM LB2 microscope. 
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2.8.3 Improvision OpenLab Software 
The Improvision (Coventry, UK) OpenLab software was used to control the 
exposure time of a captured image and to contrast enhance the image to the 
software's `best guess' parameter. Both the exposure time and whether the image has 
been contrast enhanced is stated in the relevant results sections. 
2.9 Whole Population Fluorescence Measurements using the FLUOstar 
OPTIMA Apparatus 
To measure whole population fluorescence the bacteria were grown in an identical 
manner as for fluorescence microscopy. During their growth from an OD600nm of 0.01 
to 0.8, -5 FLUOstar OPTIMA readings were taken. For each reading three 2000 
aliquots were taken and placed in three wells of a black 96 well plate. This was 
assayed in a Flurostar fluorimeter (FLUOstar OPTIMA, Bath, UK), using 485nm 
absorbance and 520nm emission, at a gain of 1750. The results were expressed in 
relative fluorescence units (rfu) and plotted against the OD600nr measured at the time 
the samples were taken. 
2.10 DNA Sequencing 
All DNA sequencing for this study was performed by MWG- Biotech, London, UK 
(single read DNA sequencing services), with forward and reverse sequencing primers 
designed and sent to MWG- Biotech according to the company's guidelines. 
All the recombinant vectors constructed from the ligation of a PCR product to a 
plasmid were sequenced. Clones into the pCRe-TOPO® vector were sequenced 
using the T3 and T7 primers, which flank the TOPO® cloning site. 
A double- stranded DNA sequence for each plasmid was assembled by aligning 
contigs obtained from MWG -Biotech using ContigExpress, a component of Vector 
NTI Suite 8.0 (Invitrogen, Paisley, UK). Sequence chromatograms were viewed with 
CodonCode Aligner v.1.3.4 when any variations between the sequence and the 
reference strain were observed to ensure the variation was genuine. 
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2.11 Solutions 
All chemicals are from Sigma Aldrich (Dorset, UK) unless otherwise stated. 
2.11.1 Media 
2.11.1.1 LB Broth: 
For 1L: 10g Tryptone 
5g Yeast extract 
5g NaC1 
Dissolved in distilled water (dH7O) to make 1L and autoclaved. 
2.11.1.2 LB Agar: 
For 1L:10g Tryptone 
5g Yeast extract 
5g NaCl 
15g Bacto agar 
Dissolved in dH2O to make IL and autoclaved. 
2.11.1.3 Supplements 
2.11.1.3.1 MEM -HEPES - Ferric Nitrate: 
0.4g dissolved in 100m1 dH2O and filter sterilised to make a stock solution of 10mM. 
Store at 4 °C and add 130 to 500m1 MEM -HEPES. 
2.11.1.3.2 MEM -HEPES - Micronutrients: 
100m1 of 1000x Micronutrients: 
30111 1mM Ammonium molybdate 
400111 1mM Boric acid 
3000 1mM Cobolt chloride 
100µl 1mM Copper sulphate 
8000 1mM Manganese chloride 
l000 1mM Zinc sulphate 
Make to 100m1 with dH2O and store at -20 °C protected from light. 
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2.11.1.4 Antibiotics (1000x stocks) 
50mg /m1 Ampicillin: lg dissolved in 20m1 dH2O, aliquoted and stored at -20 °C. 
25mg /m1 Chloramphenicol: 0.5g dissolved in 20m1 100% ethanol, aliquoted and 
stored at -20 °C. 
25mg /m1 Kanamycin: 0.5g dissolved in 20m1 dH2O, aliquoted and stored at -20 °C. 
10mg /m1 Tetracyclin: 0.2g dissolved in 20m1 1:1 ethanol:dH2O, aliquoted and stored 
at -20 °C. 
2.11.2 CTAB DNA Extraction 
2.11.2.1 TE buffer: 
10mM Tris -HC1 (pH 8.0) 
1mM Ethylinediamine tetraacetic acid (EDTA) 
lml 1M Tris -HCL (pH8.0) added to 2000 0.5M EDTA and made up to 100m1 with 
MQ water. 
2.11.2.2 5M NaCI: 
292.2g NaCI dissolved in 1L dH2O and autoclaved. 
2.11.2.3 CTAB /NaC1 -10% CTAB in 0.7M NaCI: 
4.1g NaC1 dissolved in 80m1 dH2O and 10g CTAB slowly added whilst heating and 
stirring (if necessary heat to 65 °C to dissolve). dH2O added to 100m1. 
2.11.3 PCR 
2.11.3.1 dNTP mix: 
0.404 of dATP, dCTP, dTTP, and dGTP (Roche, Burgess Hill, UK) in MQ water 
(40 of 100mM dNTP solutions dissolved in 984tl MQ water, aliquoted and stored 
at -20 °C). 
2.11.3.2 10 x PCR Reaction Buffer (Roche, Burgress Hill, UK): 
100mM Tris -HCI (pH8.3 @ 20 °C) 
15mM Magnesium chloride (MgC12) 
500mM Potassium chloride (KC1) 
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Supplied with Taq DNA polymerase enzyme (Roche, Burgess Hill, UK). 
2.11.3.3 Expand Long Template PCR System (Roche, Burgess Hill, UK) 
2.11.3.3.1 10x Expand Long Template PCR System Buffer: 
100mM Tris-HC1 (pH8.3 @ 20 °C) 
17.5mM MgCl2 
500mM KCl 
Supplied with Expand Long Template PCR System (Roche, Burgess Hill, UK). 
2.11.4 DNA Agarose Electrophoresis 
2.11.4.1 TBE Buffer: 
89mM Tris (hydroxymethyl) aminomethane (Fisher, Leicestershire, UK) 
89mM Boric acid 
2mM EDTA 
10x TBE buffer was purchased from Fisher (Leicestershire, UK). 
2.11.5 NEB Buffers (Supplied with NEB Enzymes) 
2.11.5.1 10x NEB Buffer 1: 
10mM Bis Tris Propane -HC1, 10mM MgCl, 1mM dithiothreitol (pH7.0 at 25 °C). 
2.11.5.2 10x NEB Buffer 2: 
50mM NaC1, 10mM Tris-HC1, 1mM dithiothreitol (pH7.0 at 25 °C). 
2.11.5.3 10x NEB Buffer 3: 
100mM NaC1, 50mM Tris -HCI, 10mM MgCI7, 1mM dithiothreitol (pH7.9 at 25 °C). 
2.11.5.4 10x NEB Buffer 4: 
50mM potassium acetate, 20mM Tris- acetate, 10mM magnesium acetate, 1mM 
dithiothreitol (pH7.9 at 25 °C). 
2.11.6 Transformations 
2.11.6.1 Transformation Buffer I (TFB I): 
For 1L: 30mM (2.94g) Potassium acetate 
10mM (1.47g) Calcium chloride 
100mM (7.45g) Potassium chloride 
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15% (150m1) Glycerol 
Dissolved in 900m1 dH2O, autoclaved and added to 100m1 of autoclaved 500mM 
manganese chloride (9.9g/100m1). Aliquoted and stored at -20 °C. 
2.11.6.2 Transformation Buffer II (TFB II): 
For 1L: 75mM (11.03g) Calcium chloride 
10mM (0.75g) Potassium chloride 
15% (150m1) Glycerol 
100mM (2.09g) MOPs 
Made to pH7.0 with 10M sodium hydroxide and autoclaved. Aliquoted and stored at 
-20 °C. 
2.11.7 6% Sucrose Plates: 
For 1L: 14g Bacto agar 
10g Tryptone 
5g Yeast extract 
Dissolved in 850m1 dH2O and autoclaved. Add 150m1 of 40% sucrose stock solution 
(filter sterilised), plates poured and stored at 4 °C. 
2.11.8 Sonication/Protein Buffer: 
For lOmis: 10mM (200) Sodium chloride 
50mM (5000) Tris -HC1 pH7.6 
1mM (20111) EDTA 
0.1mM (10) Dithiothreitol (DTT) 
0.001mM (1µl) Phenylmethylsulphonyl fluoride (PMSF) 
Made to 10m1 with dH7O, filter sterilized and stored at 4 °C 
2.11.9 SDS PAGE 
2.11.9.1 12% SDS PAGE Resolving Gel: 
3m1 Acrylamide / N,N'- methylenebisacrylamide (bisacrylamide) (37.5:1) 
4.3m1 dH2O 
2.5m1 1.5M Tris -HCI pH8.8 
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0.1m1 10 %SDS 
0.1m1 10% Ammonium persulphate 
10µ1 N, N, N ',N'- Tetramethylethylenediamine (TEMED) 
2.11.9.2 5% SDS PAGE Stacking Gel: 
0.625ml Acrylamide / N,N'- methylenebisacrylamide (bisacrylamide) (37.5:1) 
3m1 dH2O 
1.26m1 0.5M Tris -HCI pH6.8 
5O0 10% SDS 
5O0 10% APS 
5µl TEMED 
2.11.9.3 10x SDS PAGE Running Buffer: 
For 1L: 30g Tris 
144g Glycine 
Dissolved in dH2O to make 1L, should have pH8.8, heat and stir to dissolve. 
PAGE Loading 
For 20m1: 8ml 10% SDS 
2.4ml Glycerol 
0.4ml ß- mercaptoethanol 
lml 1M Tris -HC1 pH6.8 
Small spatula of brilliant blue granules to colour 
6.5ml dH2O 
Aliquoted and stored at -20 °C. 
2.11.10 Tricine SDS PAGE 
2.11.10.1 5x Anode Buffer: 
For IL: 121.1g Tris 
Dissolved in 1L dH2O (adjusted pH to 8.9). 
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2.11.10.2 Cathode Buffer: 
For IL: 12.11g Tris 
17.92g Tricine 
lg SDS 
Dissolved in 1L dH2O (adjusted pH to 8.2 if necessary). 
2.11.11 Western Blotting 




dH2O added to 1L. 
2.11.11.2 Blocking buffer: 
lx PBS (Oxoid, Hampshire, UK): 2 tablets dissolved in 200m1 dH2O and autoclaved. 
8% Dried semi -skimmed milk (Marvel): 16g dissolved in 200m1 lx PBS. 
2.11.11.3 Washing Buffer: 
2.11.11.3.1 Low Stringency Blots: 
For 1L: lx PBS (10 Oxoid PBS tablets in 1L dH7O) 
0.05% Tween 20 (0.5ml in 1L). 
2.11.11.3.2 High Stringency Blots: 
Same as low stringency but with 1% dried semi -skimmed milk (Marvel) added. 
2.11.11.4 Enhanced Chemiluminescence ECL Reagent 
2.11.11.4.1 ECL Solution 1: 
lml Stock luminol 
0.44m1 Stock p- courmaric acid 
10m1 1M Tris -HC1 pH8.5 
Added dH7O to 100m1. 
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2.11.11.4.2 ECL Solution 2: 
64111 30% Hydrogen peroxide 
10m1 1M Tris -HCL pH8.5 
Added dH2O to 100m1 
Store both ECL 1 and 2 at 4 °C for up to one month. One Western blot from an SDS 
PAGE mini gel required 5m1 of solution 1 added to 5m1 of solution 2 immediately 
before use, mixed and applied to blot. 
2.11.11.4.3 Stock Luminol: 
Luminol (Fluka; Sigma, Dorset UK) dissolved in 250mM dimethyl sulfoxide DMSO 
(0.886g/20m1), stored at -20 °C. 
2.11.11.4.4 Stock p- Coumaric Acid: 
p- Coumaric acid (Sigma, Dorset, UK) dissolved in 90mM DMSO (0.296g/20m1), 
stored at -20 °C. 
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3 Strategy and Cloning 
This chapter describes the strategy employed to create tagged proteins in the basal 
apparatus of the T3SS. The initial description is generic, describing a method devised to 
create the tagged proteins which, in theory, could be transferred to any genes in E. coli 
requiring genetic manipulation to add a tag with minimal changes to the wild type 
sequence. The chapter goes on to describe specific details relating to the strategy 
surrounding the esc genes that have been chosen for this project, followed by the proof of 
constructs and strains made and the problems and solutions encountered when 
manipulating these genes. 
The T3SS basal apparatus proteins that are predicted to be in the inner membrane are Esc 
D, V, R, S, T, U, and the associated cytoplasmic ATPase EscN (Fig.2, B). In the EHEC 
0157:H7 LEE pathogenicity island the genes escV and escN are situated next to each other 
on the LEE3 operon and the genes escR, S, T, and U are next to each other on the LEE1 
operon (Fig.2, A). These two sets of genes are two distinct targets. EscD is upstream from 
the LEE4 operon, isolated from the genes for the other predicted inner membrane basal 
apparatus proteins. This project will not focus on escD as the two sets of genes on LEE1 
and LEE3 offer the opportunity to manipulate six esc genes with related intermediate 
steps. The strategies for LEE3 were devised but not implemented, and can be seen in 
Appendix 1. 
For the strategy and cloning sections all the primers have been given a number, which is 
referred to throughout the results chapters. Table 3 contains the sequence of all the primers 




3.1.1 Site Directed Mutagenesis 
3.1.1.2 Principle 
A cloning strategy was created for the addition of REase recognition sites at the 3' end 
of the genes escN, V, R, S, T, and U. Only the strategies for escR and escU will be taken 
forward, the rationale for this will be explained under the relevant results section. EscR 
and escU will have the genes for fluorescent proteins or antigenic peptides cloned into 
the sites to create C terminal protein fusions detectable by immunochemistry techniques 
or by direct visualisation with fluorescence microscopy. Fundamental to the strategy is 
using allelic exchange to create Walla3 strains where the genes escRSTU are substituted 
with the sac/Kan cassette. The intermediate strain created allows for a second round of 
allelic exchange in which the sac/Kan cassette is replaced by an esc gene fused to the 
gene for the fluorescent protein or the antigenic peptide. The EHEC O157:H7 strain will 
now have a single copy of the escR or escU fusion gene on the chromosome in its 
original genetic context, being expressed under its natural promoter. 
3.1.1.2.1 Creating an escRSTU < >sac /Kan Strain 
Creating a sac/Kan substitution for groups of genes (escRSTU) means the cloning 
strategy can be designed to manipulate more than one gene at a time, for example: 
creating a Walla3 strain where both the genes escR and escU have a tag at their 3' end, 
allowing detection of both proteins in the same strain. 
In the strategy the allelic exchange method will be used to create the initial deletions of 
the LEE1 genes. Instead of amplifying 1Kb flanking regions from either side of the 
chosen gene cluster and cloning them into an exchange vector (as described in Roe, A., 
et al 2007), the whole of the sequence for escRSTU will be amplified with -1Kb of 
homologous sequence either side and cloned into the exchange vector. The two 
sequences to be amplified will be chosen to contain unique REase sites that, following 
digestion, removes the genes of interest, leaving the 1 Kb of flanking sequence needed to 
create the substitution to form the intermediate strain (Fig.6). The sac/Kan cassette will 
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be ligated into the restricted plasmid replacing the esc genes. This creates the plasmid 
for the first round of allelic exchange. In this round the esc genes that are removed from 
the plasmid after restriction digestion (escRSTU) will be substituted on the Walla3 
chromosome by the sac/Kan cassette. This will create an intermediate strain which is 
sucrose sensitive, kanamyacin resistant and lacks the esc genes R, S, T, U or N, V 
(Fig.7). The next stage of the strategy is to use the original plasmid containing the esc 
genes to add unique REase sites at the 3' end of the gene(s) of interest, then to use these 
REase recognition sites to add the genes for the fluorescent protein or antigenic peptide, 
creating the gene fusions. This plasmid can then be used in the second round of allelic 
exchange in the intermediate strain to replace the sac/Kan cassette with the tagged esc 
gene. 
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p I B307 
1Kb 1 Kb 
PCR of escRSTU from Wallaa chromosomal 
DNA 
PCR of esc genes is digested and ligated to the 
temperature sensitive plasmid plB307 
Restriction digested 
with unique REases, 
the recognition sites 
for which 
CmR 
This plasmid will be used 
to create a plasmid for 
allelic exchange and later 
to create gene fusions 
are found within the PCR product 
sequence. Digestion excises a 
fragment containing the genes of 
interest, leaving 1 Kb flanking 
regions 
R 
1 Ko Flanking 
region 
Fig.6 Schematic diagram showing the creation of a plasmid 
containing the esc genes and its restriction with unique REases (R) 
to leave 1Kb of flanking DNA. The plasmid is now ready to have the 




The sac/Kan Cassette is 
ligated into the restricted 
plasmid on the unique 
y restriction sites 
sac/Kan 
1st round of allelic exchange to replace 
the esc genes on the chromosome 




Successful allelic exchange creates an 
intermediate strain with the sac/Kan cassette 
replacing the esc genes. 
Intermediate strain 
Fig.7 Schematic diagram showing the creation of the exchange plasmid 
used in the first round of allelic exchange to create the intermediate strain. 
82 
3.1.1.2.2 Addition of 3' REase Recognition Sites 
After the PCR products for the esc genes are cloned into the pIB307 vector two unique 
restriction sites will be chosen that are situated -1Kb either side of the 3' end of escR 
and escU gene. A 5' and 3' primer will be designed over these sites (creating a 2Kb 
product when they are used in a PCR). Over the 3' end of the gene two more primers 
will be designed. These two primers will overlap one another but are not identical to the 
wild type sequence, using overlapping site directed mutagenesis to add a new REase 
recognition site (see Chapter 2 for overlapping site directed mutagenesis method and 
diagram). The overlapping primers are paired with either the 3' or 5' primers designed 
over the unique restriction sites -1Kb up or down stream. PCR with these two sets of 
primers creates two 1Kb products with the 5' end of one product identical to the 3' end 
of the other. These two products, after PCR purification, will be used as the DNA 
template in a third PCR reaction, using the two outside primers (sitting over the wild 
type unique restriction sites) to create one product of -2Kb. This product is identical to 










numbered F1, F2, 
R1 and R2. 
REase 
recognition sites 
labelled A, B and 
C 
Primers F1 and R2 are designed over unique REase recognition 
sites (A and C) on the chromosome. Primers F2 and R1 are 
overlapping and paired with R2 and F1 respectively. The 
overlapping primers contain base changes that introduce a novel 
REase recognition site (B) at the 3' end of the gene (marked with 
a star) 
PCR: F1 + Ri PCR: F2 + R2 
PCR using the two PCR 
products as DNA template 
and the primers F1 and R2. 
V 
Fig.8 Diagram showing the creation of two PCR products that 
overlap at their 3' and 5' ends. The overlapping region contains 
sequence changes added to the primers which introduce a 
unique REase recognition site (B). These two products are 
used in a PCR reaction as the DNA template with the primers 
F1 and R2. This PCR creates a 2Kb PCR product that is 
identical to the wild type sequence except for the added 
restriction site. 
The 2Kb product will then be restricted by the unique REases whose recognition sites are 
present in the wild type sequence. The plasmid containing the escR or escU gene PCR 
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product is restricted with the same REases and the 2Kb fragment removed is replaced by 
the 2Kb PCR product containing the added REase recognition site. The resulting plasmid 
is identical to the parent plasmid apart from a unique restriction site added to the 3' end of 
the esc gene. This site is then used in non -directional cloning to add the gene for either a 
fluorescent protein or an antigenic peptide. A second round of allelic exchange is 
performed in the intermediate strain with this plasmid, now containing a tagged gene, to 
replace the sac/Kan cassette (Fig.9). 
The restricted PCR product is ligated with the plasmid on the unique restriction 
sites A and C, replacing the wild type sequence with the sequence containing 





The REase recognition site B is used to 
add the genes for a fluorescent protein 
or an antigenic peptide. The genes are 
cloned into the plasmid to produce an 
in -frame C terminal fusion to the Esc 
protein. The plasmid is used in a round 
of allelic exchange in the intermediate 
strain to replace the sac/Kan cassette 
on the chromosome with the esc genes 
on the plasmid, including the gene 
fusion. 
Allelic Exchange 
Single copy gene fusion 
created to escR or escU 
Fig.9 The addition of a unique REase recognition site allows for the non -directional 
cloning of a chosen tag at the 3' end of the esc gene. This plasmid can be used in a 
round of allelic exchange to replace the sac/Kan cassette from the intermediate strain 
with the esc genes on the plasmid. 
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To enable the tagging of more than one esc gene at a time the added REase recognition 
site has to be unique and only used for one esc gene. Bearing this in mind, whilst trying to 
create minimal changes in the wild type sequence, strategies to add a 3' endonuclease 
recognition site were designed for all six esc genes in LEE1 and LEE3. Only the strategies 
for escR and escU are shown, but strategies for escS, T, V, N can be seen in Appendix 1. 
3.1.4 Strategy for escR 














5 amino acids to 
stop codon of escR 
A T T C G A A I I I 
Sequence changed byTGG CAA AAA I I 
overlapping primers 
Leu 




Fig.10 Diagram showing the REases to be used in the strategy for escR to add a 
Swal recognition site. The nucleotides in blue will be changed in the wild type 
sequence to form the recognition sequence for Swal (shown in red). 
For escR, primer 9 (primer F1) sits over the unique REase recognition site for Nsil and 
primer 10 (primer R2) is designed over the recognition site for PstI. A PstI recognition site 
is also present in the pIB307 plasmid, meaning that either a partial digest is required for 
successful cloning or the Pstl site in the pIB307 backbone has to be removed. The site 
added by the overlapping primers 11, 12 at the 3' end of escR is SwaI (Fig.10). Although 
this site has been used for escV it can be used for escR as the two genes will not be cloned 
together on the same allelic exchange plasmid. The start codon for escS is 19bp beyond 
the added Swal site. Again this is designed to minimise interference with the transcription 
and translation of escS. However, it means the sequence for the last 6 amino acids of escR 
will be added in the tail of the 5' primer used in the PCR for the tag. 
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3.1.7 Strategy for escU 
Wild type sequence (sense 
strand). - 
Sequence changed by 
overlapping primers 
A B C 




Asp Tyr Stop 
ATA GAC CTT GAT TAT TAA 
ATA GAC CTT 1GAC GTCI TAA 
Asp Val 
Aatll site 
Fig.11 Diagram showing the REases to be used in the strategy for escU to add an 
Aatll recognition site. The nucleotides in blue will be changed in the wild type 
sequence to form the recognition sequence for Aatl l (shown in red). 
Primer 19 sits over the REase recognition site BstEII and primer 20 over Bsal. Primers 21, 
22 overlap and contain the changes to add the REase recognition site for AatII (Fig.11). 
The strategy for escU is the only strategy that changes the last six nucleotides of the gene 
into the added REase recognition site. It is designed this way because the downstream 
gene (rorf3) is transcribed in the opposite direction. The stop codon for rorf3 is UAA 
comprised of the last T from the tyrosine (the last amino acid in EscU, Fig.12) and the first 
two nucleotides of the escU stop codon TA, making TTA; this transcribed on the antisense 
strand is the stop codon UAA. The AatII restriction site was chosen as it changes the EscU 
amino acid sequence from a tyrosine to a valine. This changes the stop codon of the 
downstream gene from UAA to the stop codon UAG. Therefore, the addition of the AatII 
site has a minimal effect on both genes and requires no added nucleotides to either end of 
the primers used to PCR amplify the tags. 
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3.2 Cloning 
Although strategies for LEEI genes escRSTU and LEE3 genes escNV were designed only 
the LEE! clone was created. The decision was made because the LEEI clone offered the 
opportunity to manipulate four basal apparatus proteins, while there are only two on the 
LEE3 clone. As the strategies for tagging escN and escV have been designed it can be 
revisited at a later date if required. 
Every strain made throughout the project was stored in 20% glycerol at -70 °C. The 
plasmids constructed were also stored in this way, either in the strain TOP10 or the strain 
AAEC185, the plasmids were also extracted using the QlAprepTM spin plasmid miniprep 
kit (QIAGEN, West Sussex, UK) and stored at -20 °C. 
3.2.1 Creating the Strain Walla3 escRSTU < >sac /Kan (ZAP1140) 
3.2.1.1 Constructing the pJRE01 Plasmid 
The section of the LEEI operon containing the genes escRSTU and -1Kb of left and right 
flanking sequence was amplified using expand long template PCR system (Roche, 
Burgess Hill, UK) and the primer pair 23, 24 (Fig.12). 
Annealing Temperature °C 
1 2 3 4 5 6 7 8 9 10 
-- 6.3Kb 
2Kb- 
Fig.12 Expand long range template escRSTU product. The annealing 
temperature was a gradient from 60 °C to 70 °C with approximately one -degree 
increments. The DNA template for the reaction was 1µ1 of a 1:150 dilution of 
Walla3 DNA extracted by the CTAB method. 
Lane1: 1Kb DNA ladder 
Lane2 -11: PCR product for escRSTU on temperature gradient 60 -10 °C 
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The escRSTU PCR product was cloned into the pCR4 ® -TOPO® vector creating the 
plasmid pJRE02. The pCR4®-TOPO® cloning step was added to facilitate the final cloning 
step into pIB307 as it generates high quantities of the digested escRSTU fragment, 
following restriction digestion with XmaI (primer 23) and XbaI (primer 24) and gel 
extraction. 
The creation of pJRE02 was confirmed by restriction analysis with the REase EcoRI. 
The QIAprepTM spin plasmid miniprep kit (QIAGEN, West Sussex, UK) was used to 
extract plasmid DNA from recovered TOP10 colonies (Fig.13, A). The pJRE02 plasmid 
was then digested with the REases XbaI and XmaI to remove the 6.3Kb escRSTU 
fragment. 




1 2 3 
Linearized pJRE02 
_ vector 
6Kó - ---; ` } escRSTU Restricted 
4Kb = ':.1,, DNA 
pCR4®-TOPO DNA 
: .:::.. 
Fig.13, A) EcoRI digest of pJRE02 - expected band sizes for pJRE02 are 
4.1 Kb, 3.9Kb, and 2.2Kb 
Lane1: 1Kb DNA ladder 
Lane2: pJRE02 clone digested with EcoRl 
(expected size of bands: 4118bp, 3936óp, 2192bp) 
B) pJRE02 digested with Xmal and Xbal removal of the 6.3Kb escRSTU 
fragment 
Lane1: 1Kb ladder 
Lane2: pIB307 vector digested with Xbal and Xmal 
Lane3: pJRE02 clone digested with Xbal and Xmal 
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This fragment was purified from an agarose gel and ligated to Xmal and Xbal digested 
pIB307 vector (Fig.13, B. Lane2). The ligation mixture was transformed into chemically 
competent AAEC185 cells. The colonies were screened for successful ligations by Kpnl 
digestion of plasmid DNA (Fig.14) extracted by the QIAprepTM spin plasmid miniprep kit 
(QIAGEN, West Sussex, UK). 





positive for pJRE01. 
Lane1: 1Kb DNA ladder 
Lane2: pIB307 vector (control). Expected band size: 4.2Kó 
Lane3 -8: pJRE01 clones. Expected band size: 8.1 Kb and 2.3Kó 
3.2.1.2 Constructing the pJRE03 Plasmid 
The PCR of the genes escRSTU was designed to include the REase recognition sites for 
HpaI (Fig.17). This enzyme digests the plasmid at two sites to remove the esc genes and 



















Fig.15 Vector NTI map of 
pJRE01 plasmid showing Hpal 
sites and Xmal and Xbal site. 
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1 2 3 4 
j, 7Kb 
Fig.16 pJRE01 digested with Hpal and the sac/Kan cassette after 
Klenow treatment and extracted from a 0.8% agarose gel - To be 
ligated together at 4 °C for 16hr. The ligation mixture was then 
transformed into chemically competent AAEC185 cells, recovered for 
40hrs at 28 °C and plated on LBC plates. 
Lane1: 1Kb DNA ladder. 
Lane2: pJRE01 plasmid Hpal digested, gel extracted and religated. 
Then Hpal digested again. Expected band size 6.9Kb 
Lane3: sac/Kan cassette BamHl digested, Klenow treated. Expected 
band size 3.8Kb 
Lane4: Hindi! DNA ladder 
The sac/Kan cassette was restricted with BamHI, treated with DNA polymerase, large 
fragment (Klenow) and gel extracted. The cassette was ligated to pJRE01 which had been 
restricted by the REase HpaI, the esc genes removed and the 7.2Kó backbone gel 
extracted (Fig.16). The fragments were ligated together and recovered colonies were 
patched on LBK plates to screen for the insertion of the sac/Kan cassette, which confers 
kanamyacin resistance. The resulting plasmid (pJRE03) contains the flanking regions (for 
creating the escRSTU substitution) and the sac/Kan cassette. 
Kanamycin resistant clones were screened by restriction digest analysis with the REase 
Rsal, the digest shows which plasmids are positive for insertion of the sac/Kan cassette 
and the orientation the sac/Kan cassette is in. Either orientation can be used in the allelic 
exchange process (Fi g.17). 
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1 2 3 4 5 6 7 8 9 10 11 12 
Fig.17 Rsal digest of possible pJRE03 clones for allelic exchange process. 
Orientation one has the band pattern 2.8Kb, 1.4Kb, 1.4Kb, 1Kb, 859bp, 
713bp, 706bp, 635bp, 538bp, 377bp, and 187bp and orientation two has 
the band pattern 2.8Kb, 2Kb, 1Kb, 859bp, 827bp, 713bp, 706bp, 635bp, 
538bp, 377bp, 187bp 
Lane1: 1Kb DNA ladder. 
Lane4,7,9,10: pJRE03 plasmids containing the sac/Kan cassette in 
orientation one. 
Lane8: pJRE03 plasmid with the sac/Kan cassette in orientation two. 
Lane12: 100bp DNA ladder 
A pJRE03 plasmid with the sac/Kan cassette in orientation one was used in allelic 
exchange to replace the genes escRSTU with the sac/Kan cassette in the EHEC 0157:H7 
Walla3 strain to create the strain ZAP1140. A schematic diagram for creating the 






Sac /Kan Cassette 
1: Plasmid Integration: Inserting the sacB -Kan Cassette: 
Grown at 42 °C in 
LBC. This is not 
permissive to 
plasmid 
replication so it 




Step 2: Plasmid Excision: 






Grown at 28 °C in 
LBK. 
The plasmid is 
able to replicate so 




Step 3 & 4: Plasmid Curing and selection of the mutant: 
'UM= 
Grown at 28 °C in LBK. Selected on 
LBK and LBC agar plates. Bacteria 
that only grow on LBK have been 




Genetic Material to be deleted 
Homologous regions of flanking DNA 
Fig.18 Diagram of allelic 
exchange method creating 
an intermediate strain (Taken 
from Emmerson, J., et al 2006) 
The transfer of the sac/Kan 
cassette into the chromosome 
requires two recombination 
events leading to plasmid 
integration followed by plasmid 
excision. Step 1: plasmid 
integrates into the wild -type 
strain at the non permissive 
temperature for plasmid 
replication (42 °C). Steps 2 and 
3: plasmid integrates are 
grown at 28 °C in the presence 
of kanamycin to enrich for 
bacteria that have excised and 
cured the plasmid, leaving the 
cassette on the chromosome. 
Step 4: Growth on media 
containing LBC or LBK. 
Bacteria that can only grow on 
LBK are successful constructs 
of the intermediate strain. 
Grown at 28 °C on 
LBK and LBC 
agar plates. 
Positive clones are 
verified by PCR. 
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3.2.2 Screening the Strain Walla3 escRSTU < >sac /Kan (ZAP1140) 
Walla3 colonies with the correct resistance profiles for the successful chromosomal 
insertion of the sac/Kan cassette and excision of the pIB307 plasmid were screened by 
PCR (Fig.19). A PCR was also designed with the 5' primer (primer 25) sitting outside the 
left flanking region on the bacterial chromosome paired with a 3' primer (primer 27) 
specific for the sacB gene. This PCR will only work, giving a product of 3.4Kó, if the 
sac/Kan cassette has been inserted into the correct place on the chromosome. Fig.19, 
Lane9 contains the correct PCR product from this reaction in the ZAP1140 strain. 
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Fig.19 PCR screening of Walla3 escRSTU < >saclKan (ZAP1140). strain Primer pairs 
10, 11 and 20, 21 for escR (1.4Kb product) and escU (572óp product) were used with a 
blank DNA negative control, 1µ1 of a CTAB Walla3 DNA extraction (diluted 1:150) as a 
DNA template for a positive control and crude DNA lysate from the ZAP1140 strain 
being screened 
Lane1: 1Kb DNA ladder 
Lane2: escU PCR 2 DNA blank negative 
Lane3: escU PCR 2 Walla3 DNA template positive 
Lane4: escU PCR 2 ZAP1140 strain 
Lanes: escR PCR 2 DNA blank negative 
Lane6: escR PCR 2 Walla3 DNA template positive 
Lane7: escR PCR 2 ZAP1140 strain 
Lane8: Outside left flanking region PCR DNA blank negative (55 °C) 
Lane9: Outside left flanking region PCR ZAP1140 strain (55 °C) 
Lane10: Outside left flanking region PCR DNA blank negative (56 °C) 
Lane11: Outside left flanking region PCR ZAP1140 strain (56 °C) 
Lane12: Inside left flanking region PCR DNA blank negative (55 °C) 
Lane13: Inside left flanking region PCR pJRE01 DNA positive (55 °C) 
Lane14: Inside left flanking region PCR ZAP1 140 strain (55 °C) 
Lane15: Inside left flanking region PCR DNA blank negative (56 °C) 
A PCR with a 5' primer situated in the left flanking region and a 3' primer specific for 
sacB was also used to screen the Walla3 escRSTU< >saclKan (ZAP1140) strain (primers 
28, 27) giving a 1.4Kb product (Fig.19, Lane12 -17). 
The Walla3 escRSTU < >sac /Kan strain was screened for the absence of the esc genes escR, 
escS, escT, and escU (Fig.20). 
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Fig.20 PCR screening of Wallaa escRSTU < >saclKan (ZAP1140) strain (cont.). 
Screening for the absence of the esc genes escR (primers 9, 12 giving a 
957óp product), escS (primers 13, 10 giving a 1.2Kb product and primers 14, 9 
giving a 1Kb product), escT (primers 15, 18 giving a 1Kb product and primers 
16, 17 giving a 670bp product) and escU (primers 19, 22 giving a 346bp 
product) 
Lane1: 1Kb DNA ladder 
Lane2: escR PCR DNA blank negative 
Lane3: escR PCR Walla3 DNA template positive 
Lane4: escR PCR ZAP1140 strain 
Lanes: escS PCR DNA blank negative 
Lane6: escS PCR Walla3 DNA template positive 
Lane7: escS PCR ZAP1140 strain 
Lane8: escS PCR 2 DNA blank negative 
Lane9: escS PCR 2 Walla3 DNA template positive 
Lane10: escS PCR 2 ZAP1140 strain 
Lane11: escT PCR DNA blank negative 
Lane12: escT PCR Walla3 DNA template positive 
Lane13: escT PCR ZAP1140 strain 
Lane14: escT PCR 2 DNA blank negative 
Lane15: escT PCR 2 Walla3 DNA template positive 
Lane16: escT PCR 2 ZAP1140 strain 
Lane17: escU PCR DNA blank negative 
Lane18: escU PCR Walla3 DNA template positive 
Lane19: escU PCR ZAP1140 strain 
Lane20: 1Kb DNA ladder 
The Walla3 escRSTU < >sac /Kan strain was also screened with primers specific for the 
sacB gene and primers specific for the pIB307 plasmid backbone (Fig.21, Lane5-l0). 
These PCR products confirmed the observed resistance profile for the strain ZAPI 140 
97 
(kanamycin resistant and chloramphenicol sensitive). Another PCR screening for the 
absence of the escR gene was also carried (Fig.21, Lane2 -4). 
1 2 3 4 5 6 7 8 9 10 11 
Fig.21 PCR screening of Walla3 escRSTU<>saclKan (ZAP1140) strain (cont. Il). 
Screening with primers specific for the sacB gene (primers 26, 27 to give a 230bp 
PCR product) and primers specific for the plB307 plasmid backbone (primers 29, 30 to 
give a 520bp PCR product) and escR gene using primers 31, 32 to give a product of 
270bp 
Lane1: 1Kb DNA ladder 
Lane2: escR PCR 3 DNA blank negative 
Lane3: escR PCR 3 Walla3 DNA template positive 
Lane4: escR PCR 3 ZAP1140 strain 
Lanes: sacB gene PCR DNA blank negative 
Lane6: sacB gene PCR pJRE03 DNA template positive 
Lane7: sacB gene PCR ZAP1140 strain 
Lane8: plB307 specific PCR DNA blank negative control 
Lane9: pIB307 specific PCR pJRE03 DNA template positive 
Lane10: pIB307 specific PCR ZAP1140 strain 
The resistance profile of the strain and the PCR results confirm that the ZAP1140 stain is a 
successful substitution of the escRSTU genes for the sac/Kan cassette. 
3.2.3 Creating the Walla3 escRSTU<>sac/Kan Restored Strain (ZAP632) 
The next stage was to manipulate the pJREOI plasmid to add REase recognition sites at 
the 3' end of the esc genes. First the pJRE01 plasmid was sent to MWG for sequencing to 
check that the expand long template PCR system (Roche, Burgess Hill, UK) did not 
introduce any errors into the escRSTU sequence. The sequencing results showed that, 
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when compared to the available sequence for the EHEC O157:H7 strain EDL933, there 
were three base changes. One was a silent mutation in ORF5, another changed a valine 
into an alanine in ORF3, and the third change was in EscU changing a phenylalanine to a 
serine. At this stage it was impossible to tell, without repeating the PCR and sending it for 
sequencing again, whether these were errors or true base changes in the Walla3 strain 
when compared to the EDL933. 
The pJRE01 plasmid was used in the allelic exchange process with the intermediate strain 
Walla3 escRSTU < >sac /Kan (ZAP1140) to replace the sac/Kan cassette with the esc genes 
on the plasmid to create the restored Walla3 strain - with a restored T3SS. This was an 
important check for the pJRE01 plasmid; if it was able to restore T3S in the ZAP1140 
strain by producing a functioning basal apparatus then the plasmid could be used to 
manipulate the LEE1 sequence to add the tags. It also meant the pJRE01 plasmid could be 
verified despite the two amino acid substitutions in the amplified sequence. 
3.2.4 PCR Screen of the T3SS Restored Strain (ZAP632) 
The Walla3 escRSTU< >sac /Kan restored strain (ZAP632) was screened in a similar way 
to the Walla3 escRSTU< >sac /Kan strain. Colonies with the correct resistance profiles 
were patched and crude DNA extracts made. They were screened using the PCR primers 
used to detect the absence of the esc genes in the strain Walla3 escRSTU< >sac /Kan and 
the primers specific for the pIB307 and sacB gene (Fig.22, A, B, C). All the PCR products 
confirmed that the restored T3SS strain contained the esc genes and had excised and cured 
the pIB307 plasmid with the sac/Kan cassette. 
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A 






Fig.22 For each set of PCR primers there was a positive control of 1µl of a 1:150 dilution of 
CTAB extracted Walla3 DNA or a positive control of pJRE03 plasmid DNA, a negative control 
containing no template DNA and crude DNA extracted from the ZAP632 strain being screened. 
For PCR products escS PCR 1 and 2, escR PCR 2 and escT PCR 2 the ZAP1140 strain was 
also used as a negative control. 
A) PCR screen of restored T3SS ZAP632 strain. 
Lane1: 1Kb DNA ladder 
Lane2: escR PCR Walla3 template DNA positive control 
Lane3: escR PCR DNA blank negative control 
Lane4: escR PCR ZAP632 strain DNA template 
Lane5: escS PCR Walla3 template DNA positive control 
Lane6: escS PCR DNA blank negative control 
Lane7: escS PCR ZAP632 strain DNA template 
Lane8: escS PCR 2 Walla3 template DNA positive control 
Lane9: escS PCR 2 DNA blank negative control 
Lane10: escS PCR 2 ZAP632 strain DNA template 
Lane11: escS PCR 2 ZAP1140 strain DNA template 
Lane12: escT PCR Walla3 template DNA positive control 
Lane13: escT PCR DNA blank negative control 
Lane14: escT PCR ZAP632 strain DNA template. 
Lane15: 1Kb DNA ladder 
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Fig.22 B) PCR screen of ZAP632 strain with a restored T3SS (cont.). 
Lane1: 1Kb DNA ladder 
Lane2: escT PCR 2 Wallaa template DNA positive control 
Lane3: escT PCR 2 DNA blank negative control 
Lane4: escT PCR 2 ZAP632 strain DNA template 
Lanes: escT PCR 2 ZAP1140 strain DNA template 
Lane6: escU PCR Walla3 template DNA positive control 
Lane7: escU PCR DNA blank negative control 
Lane8: escU PCR ZAP632 strain DNA template 
Lane9: escU PCR 2 Walla3 DNA positive control 
Lane10: escU PCR 2 DNA blank negative control 
Lane1 1: escU PCR 2 ZAP632 strain DNA template 
Lane12: escR PCR 2 Walla3 template DNA positive control 
Lane13: escR PCR 2 DNA blank negative control 
Lane14: escR PCR 2 ZAP632 strain DNA template. 
Lane15: escR PCR 2 ZAP1140 strain DNA template 
Lane16: 1Kb DNA ladder 
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Fig.22 C) PCR screen of ZAP632 strain with a restored T3SS (cont. II). 
Lane1: 100bp DNA ladder 
Lane2: escR PCR 3 Walla3 template DNA positive control 
Lane3: escR PCR 3 DNA blank negative control 
Lane4: escR PCR 3 ZAP632 strain DNA template 
Lane5: sacB gene pJRE03 DNA template positive control 
Lane6: sacB gene PCR DNA blank negative control 
Lane7: sacB gene PCR ZAP632 strain DNA template 
Lane8: pIB307 specific PCR pJRE03 DNA template positive control 
Lane9: pIB307 specific PCR DNA blank negative control 
Lane10: plB307 specific PCR ZAP632 strain DNA template 
Lane11: 100bp DNA ladder 
3.3 Western Blot Detection of EspD from the Strains Walla3, Walla3 
escRSTU < >sac /Kan (ZAP1140) and the T3SS Restored Strain (ZAP632) 
After the creation and PCR verification of the ZAP632 strain it was checked for its ability 
to secrete EspD. Walla3, Walla3 escRSTU< >sac /Kan and T3SS Restored Strain 
supernatants and whole cell proteins were run on a SDS PAGE gel. After transfer to a 
nitrocellulose membrane the blot was incubated with in EspD antibody. Western blot 
analysis demonstrated that when the sac /Kan cassette was substituted for the escRSTU 
genes (strain ZAP1140) EspD secretion does not occur, while the wild type phenotype is 
restored in the ZAP632 strain (Fig.23). Interestingly the whole cell fraction for the 
ZAP1140 strain contains EspD at wild type levels, indicating that having no EscR, S, T, U 
proteins in the basal apparatus does not feedback on the production of EspD inside the 
cell. The Western blot demonstrates that the escRSTU genes on pJRE01, when exchanged 
back into the LEE1 locus, can restore EspD secretion, an indication that the strain is now 
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producing a functional T3SS. This plasmid can now be used to engineer REase 
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Fig.23 Western blot analysis with a 1:2000 dilution of EspD primary antibody on 
supernatant and whole cell proteins from Walla3, Walla3 escRSTU < >sac /Kan and the 
restored T3SS ZAP632 strain (12% SDS PAGE gel) 
Lane1: Walla3 supernatant 
Lane2: ZAP1140 supernatant 
Lane3: ZAP632 supernatant 
Lane4: Walla3 whole cell 
Lane5: Zap1140 whole cell 
Lane6: ZAP632 whole cell 
3.4 Addition of 3' REase Recognition Sites 
Due to time restraints escR and escU were chosen as the genes to manipulate by adding 
the REase site at their 3' end. EscU was chosen as its homologous proteins in the flagellar 
system (F1hB) and the Yersinia TTSS (YscU) have large cytoplasmic domains. EscU also 
has a unique restriction site (BstEII) upstream from the 3' end of the gene. This restriction 
site was also used to add tags to create EscU fusion proteins. These tags were embedded in 
the cytoplasmic domain rather than inserted into the C terminal amino acids. EscU is also 
the only gene which was planned to have the added REase recognition site in its last six 
nucleotides of the gene. This meant the primers used to PCR amplify the tags did not need 
to include any escU sequence in their non complementary tails, as was the case for the 
other esc genes. 
EscR is a smaller protein than EscU and is predicted to have its C terminus in the 
periplasm. Although this limits the tags that are able to be added to its restriction site, due 
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to the different environment in the periplasm compared to the cytoplasm, it did offer the 
opportunity to tag a periplasmic tail. 
3.4.1 Overlapping Site Directed Mutagenesis 
For escR, the PCR products escR PCR 1 and escR PCR 2 were used as the DNA template 
for the overlapping PCR with primers 9, 10. Five PCR mixtures were set up as seen in 
Fig.24: 
Lanel: 1Kb DNA ladder 
Lane2: 2111 of escR PCR 1 and 2111 of escR PCR 2 as DNA template 
Lane3: 51d of each escR PCR product as template. 
Lane4: 2111 of escR PCR 1 for DNA template as a negative control 
Lanes: 2111 of escR PCR 2 for DNA template as a negative control 
And Lane6: A positive control containing 10 pJRE01 DNA for template. 
Fig.24 shows that the PCR needed a lot of optimisation; the predominant band is a 1Kb 
non specific product, the main product when only using escR PCR 1 as DNA template. 
The positive control (containing pJRE01) also worked poorly. The need for optimisation 
of the overlapping PCR meant a second technique to add the REase sites to the 3' end of 
escR and escU was required. This technique involved cloning the PCR 1 and PCR 2 
products into pCR4®-TOPO® vectors, then combining both PCR products into a single 
pCR4 ® -TOPO® vector. The tag was then added to this plasmid and the whole section 
removed and cloned into the pJRE01 plasmid replacing esc gene sequence. 
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Fig.24 Expand long range template PCR using overlapping PCR products 
1 and 2 for escR (obtained using the primer pairs 9, 12 and 10, 11 
with lµ1 of CTAB extracted Walla3 DNA [1:150 diluted]). 
Lane1: 1Kb DNA ladder 
Lane2: Over lapping PCR containing 2µI of each PCR 1 and 2 products 
as DNA template 
Lane3: Over lapping PCR containing 50 of each PCR 1 and 2 products 
as DNA template 
Lane4: Over lapping PCR containing 50 of escR POR 1 product as DNA 
template as negative control 
Lanes: Over lapping PCR containing 50 of escR PCR 2 product as DNA 
template as negative control 
Lane6: Over lapping PCR containing 111l pJRE01 DNA template as 
positive control 
3.4.2 pCR4®-TOPO® Cloning 
The PCR product can be ligated into the pCRe-TOPO® in either orientation. The 
orientation of the pCR4®-TOPO® cloned PCR products was deduced by digesting the 
clones with the REase PstI and the endonuclease for the added restriction site. This either 
linearized the pCR4®-TOPO® clone or removed the PCR product that was added. To 
combine the two PCR products into one pCR42-TOPO® plasmid, one pCR49-TOPO® 
clone was digested with either the restriction endonuclease Pinel or SnaBI (depending on 
the orientation) and the added restriction site in the PCR product to linearise the plasmid. 
The second pCR4®-TOPO® clone was digested with Pinel or SnaBI (depending on 
orientation) and the added restriction site to remove the PCR product (Fig.25). The two 
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fragments were ligated together on the overhangs left after digestion with the added REase 
site and the blunt ends left by restriction with Priel or SnaBI. The resulting clone 
contained both PCR products for the esc gene with the added restriction site. This REase 
recognition site was then used to add the tag, before the entire esc section and the tag were 





Eco RI (284) 
Eco RI (302) 
Sna BI (502) 
Fig.25 Vector NTI map of pCR4"- TOPO" plasmid. The map shows the EcoRI 
recognition sites, in between which the poly -A tailed PCR product is inserted. It also 
shows the position of the recognition sites for the blunt- cutting REases Pmel and 
SnaBl. 





with escU PCR product 1) was digested with AatII and SnaBI to 
linearise the plasmid (4.2Kó) and pJRE05 (pCR4®-TOPO® with escU PCR 2) was 
digested with AatII and SnaBI to remove the PCR fragment (700bp) (Fig.26). The 
digested pJRE05 plasmid was gel extracted. This fragment was ligated to the digested 
pJRE04 plasmid and the ligation mixture transformed. The plasmid DNA was removed 
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from the recovered colonies by the QIAprepTM spin plasmid miniprep kit (QIAGEN, West 
Sussex, U.K). The clones were screened by restriction digestion with EcoRI to excise the 
whole fragment (giving two bands at 4Kb and 933óp) and a double restriction digestion 
with Ndel, a REase that has a recognition site in the cloned fragment, and Pstl which 
digests the DNA in the pCR4®-TOPO® backbone (to give 4Kb and a 843bp fragment) 
(Fig.27). A positive clone for pJRE06 was selected and sent for sequencing before adding 
the tag into the AatII restriction REase site. The clone had three sequence changes 
introduced by PCR. One created a silent mutation in rORF3 changing the codon for an 
alanine, another in rORF3 changed a threonine to an alanine and in EscU a glycine was 
mutated to a glutamic acid. 
1 2 3 4 
Fig.26 pJRE04 digested with Aatll and SnaBI and the escU PCR product 2 
removed from pJRE05 by restriction digestion with the enzymes Aatll and SnaBI - 
viewed by negative exposure . The fragments were ligated together and the 
ligation mixture transformed into TOP10 chemically competent cells and 
recovered on LBA plates at 37 °C 
Lane1: 1Kb DNA ladder 
Lane2: pJRE04 containing escU PCR 1 
Lane3: escU PCR 2 
Lane4: Hindlll DNA ladder 
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Fig.27 Diagnostic restriction digest for screening successful construction of pJRE06. 
Digested with EcoRl and Pstl and Ndel 
Lane1: 1Kb DNA ladder 
Lane2 -7: Positive clones digested with EcoRI (expect 4Kb and 933bp bands) 
Lane8 -13: Positive clones digested with Pst' and Ndel (expect 4Kb and 847óp bands) 
Lane14: 100bp DNA ladder 
None of the sequence changes matched those in the sequenced pJRE01 plasmid, and all 
the remaining sequence matched that of the EDL933 sequence. 
3.5 EscUcc::eGFP 
pJRE06 was digested with the REase AatII. A PCR for the egfp gene was carried out and 
the PCR product digested with the REase AatII (Fig.28) and ligated with the digested 
pJRE06, transformed into chemically competent TOP10 cells and recovered on LBA 
plates at 37 °C, to create pJRE07. 
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Fig.28 Agarose gel showing Aatll digested PCR product for 
egfp (using the primers 33, 34 [both containing the AatlI site 
in their non complementary tails], with 10 of pMT01 plasmid 
DNA as template) and pJRE06. to be ligated overnight at 
16 °C 
Lane1: 100bp DNA ladder 
Lane2 -3: egfp PCR restricted with Aatll 
Lane4 -5: pJRE06 restricted with Aatil 
Lane6: 1Kb DNA ladder 
Potential clones of pJRE07 were screened by restriction analysis with the REase Rsal. The 
egfp PCR product could be ligated into the plasmid in one of two orientations. Only one 
orientation gave the translational fusion, in the other orientation egfp would not be 
transcribed (Fig.29). 
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Fig.29 Agarose gel showing Rsal digestion analysis of clones for pJRE07. The 
band pattern for the restriction fragments of the pJRE06 plasmid is 3.2Kó, 1.1 Kb, 
1Kb and 60bp (Lane2), for pJRE07 (containing egfp in the correct orientation) the 
bands are 2.7Kb, 1.1 Kb, 1Kb 957bp, 282bp and 60bp (Lane3), and for pJRE06 
with egfp in the incorrect orientation the bands are 2.2Kb, 1.3Kb, 1.1 Kb, 1Kb, 
282bp, and 60bp 
Lane1: 1Kb DNA ladder 
Lane2: pJRE06 
Lane3: pJRE07 egfp in correct orientation 
Lane4:pJRE08 egfp in wrong orientation 
Lane5: 100bp DNA ladder 
The plasmid pJRE07 was then used to replace the wild type sequence on the pJRE01 
plasmid between the REase recognition sites BstEII and Bsal. pJRE01 was restriction 
digested with BstEII and BsaI, removing a 1.6Kb fragment. This fragment was discarded 
and the pJRE01 backbone gel extracted. The pJRE07 plasmid was digested with BstEII 
and BsaI, which excises two fragments of 1.6Kb, one fragment is escU::egfp, and the 
other is made entirely of pCR4"- TOPO11 plasmid DNA. The pCR4®-TOPO® 1.6Kb 
fragment contains an EagI REase recognition site, so further digestion with EagI is 
necessary. The 1.6Kb fragment that remains, after EagI digestion, is the escU::egfp 
fragment and was gel extracted and ligated (Fig.30). 
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Fig.30 pJRE01 digested with Bsal and BstEll and pJRE07 digested with 
BstEll, Bsal and Eagl. Both were gel extracted and ran on an agarose gel 
then ligated at 16 °C and transformed into TOP10 cells. 
Lane1: 1Kb marker 
Lane2: pJRE01 BstEll and Bsal digested 
Lane3: Fragment of pJRE07 after restriction with the REases Bs/Ell, Bsal 
and Eagl after gel extraction 
Lane4: 1Kb marker. 
The colonies obtained after 40hrs growth at 28 °C had their plasmid DNA extracted using 
the QIAprepTM spin plasmid miniprep kit (QIAGEN, West Sussex, UK) and the clones 
screened for the creation of pJRE08 by AatII restriction digestion and Rsal restriction 
digestion (Fig31). In pJRE08 the AatII digest should remove the egfp gene from the 
plasmid (Fig.31, Lane3 contains the 723bp egfp band). 
After the creation of pJRE08 (Fig.32) was confirmed with restriction analysis the plasmid 
was used in allelic exchange in the intermediate strain ZAP1140. 
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Fig.31 Restriction analysis of pJRE08 - After Rsal digestion the pJRE01 
plasmid gave the banding pattern 2.8Kb, 2.3Kó, 1.5Kb, 1.1Kb, 859bp, 713bp, 
635bp, 538bp, 39bp and 26bp (Lane4) and the pJRE08 plasmid the pattern 
2.8Kb, 1.8Kb, 1.5Kb, 1.1Kb, 906bp, 859bp, 713bp, 635bp, 538bp, 282bp, 
39bp and 26bp (Lane 5) 
Lane1: 100bp DNA ladder 
Lane2: pJRE07 Aatll restriction digest 
Lane3: pJRE08 Aatll restriction digest 
Lane4: pJRE07 Rsal restriction digest 
Lanes: pJRE08 Rsal restriction digest 




















Fig.32 Vector NTI map 
of pJRE08 
The resulting strain is Walla3 escU< >escU,,..egt1, (ZAP1141) and now contains all the esc 
genes on the chromosome, replacing the sac /Kan cassette, with the escU gene fused to 
egfp. Walla3 escU < >escUcc.;.egfp was screened using the primers for the PCR products escR 
PCR 1 and 2, escS PCR 1 and 2, and escT PCR 2 (Fig.33, A, B, C). A PCR screen using 
primers 35, 36 was used to confirm the presence of the egfp gene (Fig.33, D). Also the 
PCR using primers specific for the sacB gene and the pIB307 plasmid was carried out to 
confirm the resistance profile (Fig.33, E). 
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Fig.33 In each PCR a DNA blank was used as a negative control, 11..11 of CTAB 
extracted Walla3 DNA (1: 150 dilution) was the template for the positive control 
as was the pJRE08 plasmid 
A) PCR screen of Walla3 escU < >escUcc ::egfp(ZAP1141) strain 
Lane1: 1Kb DNA ladder 
Lane2: escR PCR DNA blank negative control 
Lane3: escR PCR Walla3 DNA template positive control 
Lane4: escR PCR pJRE08 DNA template positive control 
Lane5: escR PCR ZAP1141 strain DNA template 
Lane6: escS PCR DNA blank negative control 
Lane7: escS PCR Walla3 DNA template positive control 
Lane8: escS PCR pJRE08 DNA template positive control 
Lane9: escS PCR ZAP1141 strain DNA template 
Lane10: escR PCR 2 DNA blank negative control 
Lane11: escR PCR 2 Walla3 DNA template positive control 
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Fig.33 B) PCR screen of Walla3 escU < >escUcc::egfp(ZAP1141) strain 
Lane1: 1Kb DNA ladder 
Lane2: escR PCR DNA blank negative control 
Lane3: escR PCR Walla3 DNA template positive control 
Lane4: escR PCR pJRE08 DNA template positive control 
Lanes: escR PCR ZAP1141 strain DNA template 
Lane6: escS PCR DNA blank negative control 
Lane7: escS PCR Walla3 DNA template positive control 
Lane8: escS PCR pJRE08 DNA template positive control 
Lane9: escS PCR ZAP1141 strain DNA template 
Lane10: escR PCR 2 DNA blank negative control 
Lane11: escR PCR 2 Walla3 DNA template positive control 
Lane12: escR PCR 2 pJRE08 DNA template positive control 
Lane13: escR PCR 2 ZAP1141 strain DNA template 
Lane14: 1Kb DNA ladder 
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Fig.33 C) PCR screen of Walla3 escU < >escUcc: :egfp(ZAP1141) strain (cont.) 
Lane1: 1Kb DNA ladder 
Lane2: escS PCR 2 DNA blank negative control 
Lane3: escS PCR 2 Walla3 DNA template positive control 
Lane4: escS PCR 2 pJRE08 DNA template positive control 
Lanes: escS PCR 2 ZAP1141 strain DNA template 
Lane6: escT PCR 2 DNA blank negative control 
Lane7: escT PCR 2 Walla3 DNA template positive control 
Lane8: escT PCR 2 pJRE08 DNA template positive control 
Lane9: escT PCR 2 ZAP1141 strain DNA template 
Lane10: Lane14: 1Kb DNA ladder 
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Fig.33 D) PCR screen of Walla3 escU < >escUcc::egfp (ZAP1141) strain (cont. 
lI) 
Lane1: 100bp DNA ladder 
Lane2: egfp PCR DNA blank negative control 
Lane3: egfp PCR Walla3 DNA template negative control 
Lane4: egfp PCR pJRE08 DNA template positive control 
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Fig.33 E) PCR screen of Walla3 escU < >escUcc.:egfp (ZAP1141) strain (cont. Ill) 
Lane1: 100bp DNA ladder 
Lane2: sacB specific PCR DNA blank negative control 
Lane3: sacB specific PCR Walla3 DNA template negative control 
Lane4: sacB specific PCR pJRE03 DNA template positive control 
Lanes: sacB specific PCR ZAP1141 strain DNA template 
Lane6: pIB307 specific PCR DNA blank negative control 
Lane7: pIB307 specific PCR Walla3 DNA template negative control 
Lane8: pIB307 specific PCR pJRE03 DNA template positive control 
Lane9: pIB307 specific PCR ZAP1141 strain DNA template 
Lane10: 100bp DNA ladder 
3.6 ESCUCC::GFP+ 
The pJRE06 plasmid was used to create a gfp+ fusion in the same way the egfp fusion was 
created; using primers 37, 38 to PCR amplify gfp+ from 1111 of pARJ145 purified plasmid 
as DNA template. The gfp+ PCR product was cloned into the pJRE06 plasmid to create 
pJRE09. pJRE09 was digested with the REases Bsal, BstEII and Eagl and the 1.6Kó 
fragment gel extracted and ligated to the large fragment of pJRE01 after digestion with 
Bsal and BstEII. This was carried out with identical steps to the creation of pJRE08. When 
ligated together the two fragments created the plasmid pJRE10, which was screened by 
restriction analysis with the REase Rsal (Fig.34). 
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Fig.34 Rsal restriction analysis of pJRE10 clones. The Rsal restriction banding pattern for the 
pJRE10 plasmid is 2.8Kb, 1.7Kb, 1.4Kó, 1.2Kb, 1.1 Kb, 713óp, 538bp, 249bp, 39bp and 26bp 
Lane1: 100bp DNA ladder 
Lane2 -3: Negative clones for pJRE10 
Lane4 -7: Positive clones for pJRE10 
Lane8: 100bp DNA ladder 
Lane9: 1Kb DNA ladder 
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Fig.35 Vector NTI map 
of pJRE10 
The pJRE10 plasmid (Fig.35) was used in the allelic exchange process in the intermediate 
strain to replace the sac/Kan cassette. The resulting strain Walla3 escU < >escU .::4t),+ was 
screened using the same PCR screens used to screen the Walla3 escU< >escUc.c;:eo, strain. 
The PCR screening primers used to screen for the presence of egfp were used as they sit in 
the escU sequence so are not specific for egfp but for addition of DNA in the AatII site 
(primers 35, 36). The gels are not shown. 
3.7 Agel ler Deletion 
Despite the construction of two mutant strains the plasmid pJRE01 proved difficult to 
work with. The pIB307 plasmid is a low copy number plasmid, but the plasmid yield 
decreased significantly when the PCR product containing the genes escRSTU was cloned 
into the plasmid. The colony morphology also changed with the TOP10 cells growing to a 
smaller colony size when carrying the plasmid. One possibility for the poor growth of the 
bacteria was expression of the esc genes from the pIB307 plasmid. This could be due to 
the expression of ler from the LEE1 promoter; pJRE01 contains ler and the LEE) 
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promoter up to the sequence for the -10 region. To solve this problem the pJRE01 plasmid 
was digested with the REase Agel. This restriction reaction removes 1.5Kb of sequence; 
1Kb of flanking region sequence and 500bp of pIB307 sequence. This leaves 700óp as the 
left hand side flanking region, enough for the allelic exchange protocol, but removes all 
the LEE1 promoter sequence, ler and the first three and a half genes on the LEE1 operon. 
After digestion with Agel the large 9Kb fragment was gel extracted and ligated on the 
Agel site, while the 1.5Kb fragment was discarded. The ligation mixture was transformed 
into TOP10 chemically competent cells and recovered on LBC plates. Colonies recovered 
had their plasmid DNA extracted and were screened with an Rsal REase digest to confirm 
the removal of the LEE] sequence (Fig. 36) and the creation of pJREI l (Fig.37). 





Fig.36 Rsal digest of pJRE11 has the banding pattern of 2.8Kb, 2.3Kb, 1.4Kó, 1.1 Kb, 
713bp, 538bp, 39óp and 26óp on an agarose gel (Lane1). 
Lane1: pJRE11. 
Lane2: 100bp DNA ladder 
Lane3: 1Kb DNA ladder 
The pJREI l plasmid was grown in TOP10 cells, which are more robust than the K12 
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Fig.37 Vector NTI map of the removal of LEE1 sequence by digestion of the pJRE01 
plasmid with Agel, showing the Rsal sites. The plasmid is religated after the 
sequence is removed to create pJRE11. 
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3.8 ESCUCN::GFP+ 
In the escU sequence there is a natural recognition site for the REase BstEII, 685óp from 
the ATG start of the gene and 344bp from the stop codon. The BstEII recognition site sits 
in the cytoplasmic domain of EscU, 117 amino acids from the C terminus were the AatII 
site was added. The gfp+ gene will be cloned into the BstEII recognition site, as will the 
sequence for the HA tag. 
The primers 39, 40 were used to PCR amplify the gfp+ gene (with 1111 of the pMT01 
plasmid DNA as template). The PCR product and the pJREl l plasmid were both digested 
with BstEII. They were purified using the QlAquick PCR purification kit (QIAGEN, West 
Sussex, UK), ligated together and transformed into the AAEC185 strain which had been 
made chemically competent. The colonies had their plasmid DNA removed by the 
QIAquick PCR purification kit (QIAGEN, West Sussex, UK) and were screened for the 
successful creation of pJRE12 by restriction analysis with the REases HindIII, EcoRV and 
SacI, EcoRV (Fig.38). 
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Fig.38 Hindi'', EcoRV and Sad, EcoRV restriction analysis of possible clones for pJRE12. 
After restriction digestion with Hindlll and EcoRV the pJRE12 plasmid has a banding pattern 
of 4.2Kb, 2.6KB, 2.1 Kb, 291 bp and two bands at 234bp (Lane2,5,6,7) and after Sacl and 
EcoRV digestion the banding pattern is 6Kb, 2.6Kb, 820bp, 291 bp 234bp (Lane8,11,12,13) 
Lane1: 1Kb DNA ladder 
Lane2,5,6,7: Positive Hindlll, EcoRV REase digests on pJRE12 
Lane3,4: Negative Hindlll, EcoRV REase digests 
Lane8,11,12,13 Positive Sad, EcoRV REase digests on pJRE12 
Lane9,10: Negative Sad, EcoRV REase digests 













Fig.39 Vector NTI map of pJRE12 
pJRE12 (Fig.39) was used in the allelic exchange process in the intermediate strain Walla3 
escRSTU<>saclKan to replace the sac/Kan cassette with the esc genes on the plasmid, 
including escUe ...xtl, + The resulting Walla3 escU< >escUc ;;çtp+ (ZAP635) strain was 
screened using the same PCR primers used to screen the strains Walla3 escU< >escUcc;.eKÍÍ, 
and Walla3 escU < >escUc,.. xfp+ plus a PCR with the primers 41, 42 to screen for insertion 
in the BstEII site. The PCR products confirmed the esc genes were present, with gfp +, and 
the sacB gene and the pIB307 backbone had been lost (gels not shown). 
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3.9 EscUcN::HA 
The HA tag was inserted into pJRE1 1 at the BstEII REase recognition site. Two 
oligonucleotides were ordered from Sigma Genosys (Cambridge, UK) (oligonucleotides 
43 and 44 in Table 3), these contained the sequence for the HA tag, flanked by the BstEII 
recognition sequence. The oligonucleotides were -35óp in length and complementary to 
one another. 50 of each oligonucleotide were mixed together and heated to 95 °C, the 
mixture was allowed to cool to room temperature and then digested by the REase BstEII. 
The HA tag was PCR purified and ligated with BstEII restricted pJRE1 1 plasmid. The 
ligation mixture was transformed and recovered. The recovered colonies had their plasmid 
DNA removed by the QIAprepTM spin plasmid miniprep kit (QIAGEN, West Sussex, UK) 
and PCR screened for the presence of the HA tag (Fig.40). 




Fig.40 PCR screen for positive pJRE13 clones - primers 41, 42 with crude 
DNA extract from the possible clones of pJRE13 
Lane1: 100bp DNA ladder 
Lane5,11: Positive clones 
Lane2 -4,6- 10,12 -15: Negative clones 
Lane16: 100bp ladder 
The clone in Fig.40, LaneS was positive for the HA tag by PCR, and sent to MWG for 
sequencing. 
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The pJRE13 plasmid (Fig.41) was used in allelic exchange in the intermediate strain 
Walla3 escRSTU < >sac /Kan to replace the sac/Kan cassette from the chromosome. The 
resulting strain Walla3 escU< >escUU,,..HA (ZAP634) was checked by PCR to confirm the 
presence of the esc genes, the HA tag (primers 41, 42) and the absence of the sacB gene 
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Fig.41 Vector NTI map of pJRE13 
3.10 Removing the REase Recognition Site Pstl 
The cloning strategy for escR uses the REase Pstl, which has a recognition site in the escU 
sequence that will be used to transfer tagged versions of escR into the pJREI 1 plasmid. 
The enzyme Pstl also has a recognition site in the pIB307 plasmid backbone. Instead of 
carrying out a partial digest, to digest only one of the Pstl recognition sites, the PstI site in 
the pIB307 backbone was removed. The site in the pIB307 sequence is flanked by HindlIl 
and Xbal. After restriction digestion with these enzymes and treatment with the Klenow 
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fragment, the pJREI 1 plasmid lost the sequence containing the Pstl recognition site and 
was ligated with itself to form pJRE14. Fig.42 shows the screening for successful clones 
of pJRE14. The pJRE14 plasmid can now be used in the escR cloning strategy. 
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Fig.42 Restriction analysis of possible clones for the removal of a Pstl site in the 
pJRE14 plasmid digested with Pstl and Nsil. Lane3 contains a positive clone that, 
after restriction digestion with Pstl and Nsil, a 2Kb fragment is removed instead of a 
2Kb fragment and a 2.2Kb fragment (Lane1,4, -8). 
Lane1: 1Kb DNA marker 
Lane2,4 -8: Negative clones for pJRE14 
Lane3: Positive clone pJRE14 
Lane9: 1Kb DNA marker 
3.11 EscR:: HA 
The recognition site for the REase Swal was added to the 3' end of escR by the pCR4"- 
TOPO" cloning technique used for escU. EscR PCR 1 and escR PCR 2 products were 
pCR4"- TOPO" cloned creating the two plasmids pJRE15 (containing escR PCR 1) and 
pJRE16 (containing escR PCR 2). The pJRE15 plasmid was linearized by digestion with 
the REases Swal and Pmel and the pJRE16 plasmid was restriction digested with Swal and 
Pmel to excise the fragment containing the escR sequence. This fragment was gel 
extracted and ligated to the linearized pJRE15. The ligation reaction mixture was 
transformed into chemically competent TOP10 cells. Successful ligations created the 
plasmid pJRE17 and the HA tag was cloned into the added SwaI recognition site. Instead 
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of adding the HA tag as a small oligonucleotide (as was the case for escU) the HA tag was 
added in a PCR reaction. Primer 45 was designed to incorporate the HA tag in its 3' tail. 
This was used in a PCR reaction with primer 10 to remake the escR PCR 2 product, 
containing the HA tag. The PCR product was digested with the REases SwaI and PstI and 
used to replace the escR PCR 2 portion of the pJRE17 plasmid. The new pCR4®-TOPO® 
plasmid (pJRE18) was sent for sequencing. The pJRE18 plasmid was digested with the 
REases Pstl and Nsil, the 2.1Kó fragment was gel extracted and ligated with the pJRE14 
plasmid that had also been restriction digested with Nsil and Pstl and the 6.9Kb backbone 
gel extracted. The ligation was carried out and the mixture transformed and cells 
recovered. Successful ligations created pJRE19; the pJRE14 plasmid containing escR 
labelled with the HA tag. A PCR screen was used to screen for pJRE19 (Fig.43) 
1 2 3 4 5 6 7 
4- 200bp 
4--- 100bp 
Fig.43 PCR screen of pJRE19 using the primers 46, 47 
Lane1: HA screen PCR DNA blank negative control 
Lane2: HA screen PCR Walla3 DNA template negative control 
Lane3: HA screen PCR pJRE17 DNA template negative control 
Lane4: HA screen PCR pJRE01 DNA template negative control 
Lanes: pJRE18 DNA template positive control 
Lane6: pJRE19 clone 
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Fig.44 Vector NTI map of pJRE19 
pJRE19 (Fig.44) was used in the allelic exchange process to replace the sac/Kan cassette 
in the intermediate strain Walla3 escRSTU< >sac /Kan. The resulting strain contains EscR 
with a C terminal HA tag (ZAP637). PCR was used to verify the strain with the primers 
for the esc genes and the HA tag (primers 46, 47) and the sacB and pIB307 specific 
primers (gels not shown). 
3.12 Discussion 
This chapter describes the creation of five strains of EHEC 0157:H7 (Walla3), in which 
one of the predicted inner membrane proteins of the T3SS basal apparatus has been 
tagged. The fusion gene, encoding the tagged basal apparatus protein, is single copy on 
the chromosome, replacing the wild type gene. This means the fusion is expressed in the 
correct genetic background, under its natural promoter and in its original genetic 
context. 
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Four of the strains created contain a tagged version of EscU. In each of these strains 
either the tag used is different or its location within the protein has changed. The fifth 
stain contains a tagged version of EscR (see Table 6) 
Table 6. Table showing the fusion proteins created in the Walla3 strain. 
Protein Tagged Tag Used and Position of Tag 
EscU C Terminal Fusion to eGFP 
EscU C Terminal Fusion to GFP+ 
EscU HA tag Inserted into the Cytoplasmic Domain 
EscU GFP+ Inserted into the Cytoplasmic Domain 
- EscR C Terminal Fusion to HA tag 
To create these five strains an intermediate strain had to be made. This strain (ZAP1140) 
has the genes escRSTU replaced with the sac/Kan cassette. The plasmid pJRE01 was 
used to complement this strain by replacing the sac/Kan cassette with the cloned 
escRSTU genes. The resulting strain (ZAP632) provided evidence that the genes on the 
pJRE01 plasmid were capable of restoring T3SS function to the ZAP1140 strain. The 
pJRE01 plasmid could then be manipulated to add the tags to escR and escU. 
The experiment was designed to add restriction sites at the 3' end of the esc genes by an 
overlapping PCR technique. This technique failed to be successful, requiring 
optimisation. The failure of the overlapping PCR required a second method involving 
the commercial cloning vector pCR42-TOPO®. This technique added the restriction site 
by combining the two PCR products for each gene in a cloning step. This enabled the tag 
to be added in the 3' REase recognition site and the whole section used to replace the 
wild type sequence in the pJRE01 plasmid. All the tags were created in this way, except 
two strains labelled with GFP+ and HA tags in the cytoplasmic domain of EscU at the 
BstEII REase recognition site. 
During construction of the strains it became apparent that plasmid purification of 
pJRE01 was not giving the expected yield. The plasmid pJRE01 contains the gene for 
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the LEE1 regulator Ler and some of the sequence for the LEE1 promoter. If Ler was 
being produced, causing the expression of the esc genes from the plasmid, this could 
prove toxic for the AAEC 185 or TOP10 strains used to harvest the plasmid. To 
overcome this problem 1.5Kó of sequence was removed from this plasmid, which 
included the regulator Ler and any LEE1 promoter sequence. After its removal the yield 
of the plasmid increased, determined by gel electrophoresis of plasmid DNA after 
plasmid purification and digestion with a restriction enzyme, and the plasmid was used 
for the creation of three of the five strains. 
To allow successful cloning of the escR tagged fragment into the pJRE1 1 plasmid, the 
PstI REase recognition site had to be removed from the pIB307 sequence. This was done 
by restriction digestion with enzymes that flanked the PstI recognition site. Upon 
digestion with these flanking enzymes the PstI recognition site was removed and the 
plasmid ligated with itself to create the plasmid pJRE14. 
Although EscR and EscU are the two proteins that have been tagged, strategies for 
another four predicted inner membrane have been devised, these strategies can be 
revisited at a later date if required. 
With EscR and EscU successfully tagged the next stage of the project was to localise the 
tagged proteins by Western blot analysis and directly with fluorescence microscopy. 
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Chapter 4 
Microscopy and Western Blot Analysis of Strains Containing 
Tagged Proteins 
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4 Microscopy and Western Blot Analysis of Strains Containing Tagged Proteins 
4.1 FLUOstar OPTIMA with Strains Walla3, Walla3 escU< >escUcc::eb;ip (ZAP1141), 
Walla3 escU< >escU cc: :gjP +(ZAP1142) and Walla3 escU < >escUc :: jp +(ZAP635) 
FLUOstar OPTIMA was carried out on 10m1 cultures of the strains Walla3, Walla3 
escU < >escUcc::egfi, (ZAP1141), Walla3 escU < >escU,.c.::stp+ (ZAP1142) and Walla3 
escU < >escUc,,::gtp+ (ZAP635) grown in supplemented MEM -HEPES (as described in 
section 2.9). Approximately five FLUOstar OPTIMA readings were taken between an 
OD600nm of 0.1 and I for each strain and the fluorescence readings plotted against the 
OD600nm of the culture (Fig.45). 
The graph (Fig.45) shows that the wild type Walla3 strain (containing no fluorescent 
tag) has a population fluorescence that is consistently lower than the strains containing a 
GFP variant. The fluorescence of the tagged strains remains similar to one another until 
an OD600nm of 0.6. At this OD600nn, the strain ZAP1142 (Walla3 escU < >esc ULc.:: , +) starts 
to fluoresce at a higher intensity than the other two GFP tagged strains, with a 
fluorescence that peaks at 4,500rfu; over 500rfu more than strains Walla3 
escU < >escUc.c::egh, (ZAP1141) and Walla3 escU< >escU, .gtp+ (ZAP635) and 1,000rfu 
more than the Walla3 strain. 
4.2 Microscopy with Strains Walla3 escU < >escUCc : :egfp (ZAP1141), Walla3 
escU < >escUcc : :gjn +(ZAP1142) and Walla3 escU< >escUc : :gfn +(ZAP635) 
Microscopy slides were made from the cultures after the final FLUOstar OPTIMA 
reading was taken. Five of the 10 wells on the glass microscope slides contained culture 
from Walla3 escU < >escUc.e.::e, /J, (ZAP1141), Walla3 escU < >escU(.,.::çh,+ (ZAP1142) and 
Walla3 escU < >escUe,...4p+ (ZAP635) with the remaining five wells containing Walla3 
(as a negative control). For the positive control a pACYC 184 based plasmid with the 
gene sepL fused to egfp under the LEE4 promoter (pDW6) was electrotransformed into 
the Walla3 strain. A colony from the successful transformations was grown in 5m1 of 
supplemented MEM -HEPES and chloramphenicol and used to create microscope slides 
in an identical manner to the mutant strains. This was used as a positive control for the 
132 
expression and visualization of eGFP when attached to a T3SS protein in the Walla3 
strain. 
Fig.46 depicts five selected microscope images that summarize the microscopy results. 
The image of the Walla3 strain containing the SepL -eGFP fusion was captured after 
500ms exposure and needed no contrast enhancement to visualize the fluorescence from 
the eGFP fusion. The strains Walla3 escU < >escUcc : :egfp, Walla3 escU < >escUcc..gñ,+ and 
Walla3 escU < >escUc,t : :gfp+ had images captured after 1000ms (Isec) and needed contrast 
enhancement to visualize the bacteria. Discrete foci of fluorescence were seen in the 
strains Walla3 escU < >escUc : :gf,,+ and Walla3 escU < >escUGc : :gt¡,+ but not the eGFP EscU 
tagged strain Walla3 escU < >escUce : :egfp. However, when the same microscopy 
parameters were used on the wild type Walla3 strain (which contains no GFP) the 
fluorescent foci were also seen. Because of their presence in the Walla3 strain, the 
fluorescent foci were attributed to auto fluorescence of unknown protein(s) and not from 
fluorescence of the GFP fusions to EscU in the tagged strains. The detection of the foci 
is likely to be due to the long exposure time and the use of the contrast enhancement as 
































































































































































































































































































































































































































4.3 Increasing the Expression of escU with Ler 
An attempt to increase the fluorescence of the tagged strains was made by increasing the 
expression of the genes on the LEE pathogenicity island. Although artificially increasing 
expression does not give an accurate measure of the level of wild type expression from 
the basal apparatus genes, it would allow localization of tagged basal apparatus proteins 
with other fusion proteins. It would also allow the production of the tag protein from the 
single copy gene fusion to be verified by microscopy. To increase the expression from 
genes on the LEE pathogenicity island (including the EscU::GFP fusions) pASL10, a 
pACYC 184 based plasmid containing the LEE regulator ler under the regulation of an 
isopropyl ß -D -I- thiogalactopyranoside (IPTG) inducible promoter (pTac), was 
electrotransformed into the strains Walla3 escU < >escUcc::est¡, (ZAP1141), Walla3 
escU < >escUcc ::,0,+ (ZAPI 142), Walla3 escU< >escUc,,...0,+ (ZAP635) and Walla3. 
A colony from each strain containing pASL10 was grown for FLUOstar OPTIMA 
measurements. To induce expression from the pASL10 plasmid IPTG was added to the 
cultures during their final growth stage when they reached an OD600nm of 0.1. The IPTG 
was added to a final concentration of 1 mM. During their growth five FLUOstar 
OPTIMA readings were taken at regular intervals. The four strains Walla3 
escU < >escU,.c.11Gçt1 Walla3 escU < >escU,.c...Lf » +, Walla3 escU < >escU,,, :.,tp+ and Walla3 
not containing the plasmid pASL10 were also grown in an identical manner (with IPTG 
added at an OD600n,,, of 0.1) as negative controls for the experiment. 
The polynomial trend lines added to the FLUOstar OPTIMA data for the four strains 
with and without the pASL10 plasmid (Fig.47 and Fig.48) showed little difference in the 
level of fluorescence after the expression of ler. The Walla3 strain had the least amount 
of detectable fluorescence, with the GFP+ fusion to the EscU C terminus having the 
most detectable fluorescence from an OD600nn, of 0.5 - 0.6. The initial high values of 
fluorescence from the Walla3 strain in both Fig.47 and Fig.48 is fluorescence carried 




































































































































































































































































































































































































































































































































































































4.4 Increasing EscU Expression with Gr1A: FLUOstar OPTIMA 
The pASL10 plasmid had not been previously used in the laboratory to increase the 
expression of genes on the LEE 1 operon. The paper published by Ando, H., et al 2007 
describes the successful use of a plasmid containing the gene for the positive regulator 
Gr1A to increase the expression of T3SS basal apparatus genes in the EHEC 0157:H7 
strain EDL933, which were grown in LB broth. 
The Gr1A plasmid (pGEM -grlA) was kindly supplied by Hiroki Ando and transformed 
into the strains Walla3 escU < >escULc...ed, (ZAP1141), Walla3 escU < >escUc.c.::X,+ 
(ZAP1142), Walla3 escU < >escUe,7.. »+ (ZAP635) and Walla3. The transformants were 
grown in supplemented MEM -HEPES (with ampicillin for strains with pGEM -grlA) and 
IPTG (to a final concentration of 1mM) for FLUOstar OPTIMA measurements. After 
the final FLUOstar OPTIMA reading was taken microscopy slides were made as before. 
The general trend is repeated, as in all the FLUOstar OPTIMA results: The Walla3 strain 
has the lowest detectable fluorescence levels, followed by the strain ZAP1141 (Walla3 
escU < >escUcc.::egh,), then the strain ZAP635 (Walla3 escU< >escUc,,:, ,.) and finally the 
highest detectable fluorescence in the strain ZAP1142 (Walla3 escU < >escUc.c....gt¡, +). 
When the FLUOstar OPTIMA data is plotted and compared (Fig.49 and Fig.50) there is 
little difference in the population levels of fluorescence between strains with and strains 
without the pGEM -grlA plasmid. Microscopy slides were visualized by fluorescence 
microscopy (pictures not shown) and showed no difference between strains with or 











































































































































































































































































































































































































































































































































































































4.4.1 Increasing escU Expression with Gr1A: SDS PAGE of Secreted Proteins 
Secreted protein preparations were made from Walla3, Walla3 escU< >escUcc: :egfi 
(ZAP1141), Walla3 escU < >escUcc. : :gt¡,+ (ZAP1142) and Walla3 escU < >escUcn :gfi,+ 
(ZAP635) with and without the grlA plasmid (grown in the presence of 1mM IPTG). 
Secreted protein pellets (after TCA precipitation) and Coomassie staining of secreted 
proteins on an SDS PAGE gel showed a promising increase in the amount of protein 
secreted by the strains containing the plasmid. Western blot analysis with the anti GFP 
antibody was then used to determine whether the level of detectable GFP (fused to 
EscU) had increased. 
4.4.2 Increasing escU Expression with Gr1A: Western Blot Analysis with Anti GFP 
Antibodies 
To determine whether artificially increasing the levels of Gr1A increased the expression 
of the EscU GFP fusions, Western blot analysis was carried out. This analysis used anti 
GFP antibodies (J -L8; Table 4) on whole cell fractions of the strains Walla3 
escU < >escUcc : :egfp (ZAP1141), Walla3 escU < >escUcc. : :gj,+ (ZAP1142), Walla3 
escU and Walla3, with Although 
FLUOstar OPTIMA results and microscopy did not show a difference when the strains 
carried the plasmid, Western blot analysis is more sensitive and can be quantified to 
highlight any increase. 
The whole cell preparations of the strains with and without the gr/A plasmid were run on 
a SDS PAGE gel and Western blott analysis carried out with anti GFP monoclonal 
antibody - in high stringency conditions. Western blot analysis showed the strains with 
and the strains without the pGEM -glrA plasmid had little difference in the amount of 
GFP being expressed (Fig.51). The intensities of the bands show a 1.5 times increase in 
eGFP detected in the strain ZAP1141 (with eGFP at the C terminus of EscU) with 
pGEM -grlA compared to without. For GFP+ fused to the EscU C terminus (ZAP1142) 
the intensities are almost identical, with a 0.03 times decrease when the Gr1A plasmid is 
expressed. Interestingly the GFP+ at the C terminus gives a 1.8 times stronger band than 
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eGFP without the grlA plasmid. This increase in the amount GFP+ detected by Western 
blot analysis and its brighter fluorescence properties could explain the increase in 
fluorescence measured by the FLUOstar OPTIMA apparatus for this GFP+ strain. 
50 kDa - 
35 kDa 
30 kDa - 
25 kDa - 
1 2 3 
41111dVel. 
4 5 6 
Fig.51 Western blot analysis to determine the effect of increased amount of GrIA 
on the expression of escU::gfp fusions (Walla3 escU < >escUcc::egfp [ZAP1141], 
Walla3 escU < >escUcc::gfp +[ZAP1142] and Walla3 escU < >escUcn::gfp +[ZAP635]). 
Run on a 12% SDS PAGE gel and detected using a 1:2000 dilution of anti GFP 
antibody on whole cell samples. 
Lane1: ZAP1141 without pGEM -gr/A 
Lane2: ZAP1142 without pGEM -gr1A 
Lane3: ZAP635 without pGEM -gr /A 
Lane4: ZAP1141 with pGEM -gr/A 
Lanes: ZAP1142 with pGEM -gr /A 
Lane6: ZAP635 with pGEM -gr /A 
4.4.3 Increasing escU Expression with GrIA in non TTSS Promoting Conditions 
The paper by Ando, H., et al 2007 detailed the plasmids use in LB broth to increase the 
expression of the T3SS apparatus proteins. A possible explanation for the higher levels 
of GrlA not increasing the amount of the EscU GFP fusion could be due to the fact that 
the Walla3 strain is a high secretor and the experiment is performed under conditions 
that promote secretion. This may mean that the TTSS will not be affected by the 
presence of extra Gr1A because it is already expressing the LEE genes at maximal 
efficiency. The growth of Walla3 in LB media leads to a significant decrease in the 
expression of T3SS genes, which is thought to be due to a lack of the correct 
environmental signals. If increased Gr1A is produced in the Walla3 strain grown in LB 
media then the need for the environmental signals may be by- passed and the genes on 
the LEE expressed at a higher level leading to a detectable increase (measured by EspD 
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secretion). This would validate the pGEM -grlA construct's ability to increase the 
expression of T3SS genes situated in the LEE. 
Secreted protein preparations were made from the Walla3 strain grown in 1) 50m1 
supplemented MEM -HEPES 2) 50m1 LB broth and 3) TheWalla3 strain with the grlA 
plasmid grown in 50m1 LBA broth (with IPTG added to a final concentration of 1mM 
when the culture reached an OD600n,,, of 0.1). The secreted protein preparations under 
went Western blot analysis with anti EspD antibody (Fig.52). When Walla3 is grown in 
supplemented MEM -HEPES EspD is secreted into the supernatant at high levels. When 
grown in LB broth the secretion of EspD decreases dramatically (Fig.52, Lane2). When 
the grlA plasmid is added the levels do not increase to that observed in the MEM media, 
but secretion is increased 1.4 times. This is not a large increase, especially when 
comparing the amount of EspD produced in favourable conditions (Fig.52, Lanel ). The 
grlA plasmid appears to be having little effect on the expression of the LEE genes espD 
and escU. 
1 2 3 
Fig.52 Western blot analysis showing the effect of increased levels of GrIA on Walla3 
secretion of EspD after growth in LB broth - run on a 12% SDS PAGE gel and Western 
blot analysis carried out with a 1:2000 dilution of anti EspD antibody 
Lane1: Walla3 EspD secreted after growth in supplemented MEM -HEPES 
Lane2: Walla3 EspD secreted after growth in LB broth 
Lane3: Walla3 with pGEM -gr/A EspD secreted after growth in LB broth 
4.5 EscU Cleavage 
The GFP detected in the Western blots in Fig.60 showed that the GFP fusions were 
resolving on a 12% SDS PAGE gel at a much lower molecular mass than 66kDa, as 
would be expected from a fusion to the whole of EscU (39kDa of EscU and 27kDa of 
GFP, Fig.54 and 55). Fig.53 shows that in Lane2 there is some cleaved GFP+ detected 
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between the 25kDa and 30kDa marker bands. However, the main product in Lane2 and 
the only product in Lanel are detected at -37kDa. This is most likely 27kDa of the GFP 
protein and 10kDa of EscU, with the protein fusion being cleaved inside the EscU 
sequence. 
35 kDa - 
30 kDa 
25 kDa 
1 2 3 
'tor.. . 
Fig.53 Western blot showing the cleavage of EscU GFP fusions (Walla3 
escU < >escUcc::egfp[ZAP1141], Walla3 escU < >escUcc :.gp+ [ZAP1142] and Walla3 
escU < >escUcn::gfp +[ZAP635]), detected by anti GFP antibodies on whole cell samples. 
Lane1: ZAP1141 whole cell sample 
Lane2: ZAP1142 whole cell sample 
The EscU Homologous proteins F1hB (from the flagellar system in Salmonella 
Typhimurium) and YscU (from the Yersinia pseudotuberculosis T3SS) have been shown 
to cleave a 10kDa fragment from their C terminus during the process of switching from 
making the needle to making the filament (Minamino, T., et al 2000, Lavander, M., et al 
2002). This cleavage has not been observed in EscU from EHEC, but an alignment of 
the protein sequence from these three proteins (Fig.54) shows that the cleavage sequence 
NPTH is conserved. Cleavage of the homologous proteins, which is thought to be 
autocatalytic, can be stopped by mutating the NPTH cleavage site (Minamino, T., et al 
2000, Lavander, M., et al 2002). The tagging of the C terminus in strains Walla3 
escU < >escULc. : :eçti, and Walla3 escU< >escUe,,::xfi,+ is after this conserved cleavage site. It 
is reasonable to conclude that the 37kDa protein detected in Lanel and Lane2 of the 
Western blot in Fig.53 is the 10kDa of the EscU cleaved C terminus attached to the 
27kDa of the GFP variant. 
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The Vector NTI (Invitrogen, Paisley, UK) program was used to demonstrate this point as 
it was possible to create hypothetical proteins that have cleaved at different sites and 
calculate their molecular weight (Fig.55 and Fig.56). Fig.55 shows how cleavage at the 
NPTH site leads to the bands observed on the Western blot in Fig.53, Lane1 and 2. 
Fig.56 illustrates that the band detected in the Western blot in Fig.53, Lane3, when 
GFP+ was fused before the NPTH cleavage site, is most likely GFP+ cleaved from EscU 
but attached to the 34 amino acids from the GFP+ to the cleaved NPTH sequence 
(31kDa). The eGFP protein has the same molecular mass as GFP+ (27kDa) so the 
expected band sizes were the same. N- terminal protein sequencing could have been used 
to confirm the cleavage of EscU was happening at the NPTH cleavage site, however, 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































Molecular Weight 66kDa 
NPTH 
Analysis EscU Protein 
After Cleavage at 
NPTH 
Length 261 as 
Molecular Weight 30kDa 
NP 
DV DV 
Analysis Cleaved EscU 
Peptide and GFP+ 
Length 324aa 
Molecular Weight 37kDa 
TH 
Analysis GFP+ Protein 
Length 240aa 
Molecular Weight 27kDa 
DV DV 
DV 
Fig.55 A schematic diagram showing some possible proteins created by the cleavage of the 
EscU fusion protein to GFP+ at the Aatil site. EscU is shown in blue, GFP+ is shown in green 
and the NPTH cleavage site is shown in red with the Aatll sites shown in purple (translated 
amino acids). The mass in kDa is estimated by the Vector NTI program (Invitrogen, Paisley, UK) 
and rounded up to the nearest kDa. The diagram shows that if cleavage only happens at NPTH 






Molecular Weight 66kDa 
GNP GNP 0 NPTH 
Analysis EscU BstEII::GFP+ 
After Cleavage 
Length 504aa 
Molecular Weight 57kDa 
GNP GNP I l NP 
Analysis GFP+ and part 
of EscU 
Length 470aa 
Molecular Weight 53kDa 
GNP GNP 
Analysis GFP+ Protein 
Length 242aa 
Molecular Weight 27kDa 
GNP GNP 
Analysis GFP+ and part of 
EscU 
Length 276aa 
Molecular Weight 31 kDa 
GNP GNP 0 NP 
Analysis GFP+ and Part of 
EscU with No 
Cleavage at NPTH 
Length 357aa 
Molecular Weight 40kDa 
GNP GNP NPTH 
Fig,56 A schematic diagram showing some possible proteins created by the cleavage of the 
EscU fusion protein to GFP+ at the BstEll site. EscU is shown in blue, GFP+ is shown in green 
and the NPTH cleavage site is shown in red with the BstEll sites shown in purple (translated 
amino acids). The mass in kDa is estimated by the Vector NTI program (Invitrogen, Paisley, UK) 
and rounded up to the nearest kDa. The diagram shows that if cleavage only happens at the 
NPTH then the expected detectable protein would be 57kDa in mass. However, the fifth protein 
(marked with a yellow star) is most likely the one being detected. 
The fusion of GFP+ in the BstEII site of escU is before the cleavage sequence NPTH 
and gives an unexpected band on the Western blot. If the cleavage of EscU is happening 
at the NPTH site then the fusion in strain Walla3 escU < >escUc,. ,+ should give a band 
at 57kDa (30kDa of the large fragment of EscU after cleavage and 27kDa of GFP +). It is 
likely that this is not seen because the cleavage of EscU is not happening properly. 
Previous studies have shown that when the cleavage site is removed from YscU the 
protein cleaves randomly due to an altered conformation (Lavander, M., et al 2002). It is 
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likely that the addition of the large GFP+ protein in the cytoplasmic tail of EscU before 
the cleavage site distorts the proteins conformation and leaves EscU vulnerable to 
cleavage at alternative sites. This may not have been seen with the EscU C terminal 
fusions because the addition of the tags at the C terminus or N terminus are generally 
considered to interfere less with the protein they are labelling (Margolin, W., et al 2000). 
4.6 EscU Localization 
Because fluorescence microscopy could not localise the GFP fusions Western blot 
analysis was carried out using the anti GFP monoclonal antibody on bacterial cell 
preparations, which separate cytoplasmic, membrane and supernatant proteins. It was 
expected that the EscU protein localised to the membrane fraction, however, after 
cleavage the EscU C terminal peptide may leave the T3SS and be released into the 
cytoplasm to be degraded or carry out another function. 
Western blot analysis carried out with the J -L8 anti GFP antibody. The samples run on 
the gel were cytoplasmic, membrane and supernatant preparations of the bacterial strain 
Walla3 escU < >escU...e,St¡,. The gel (Fig.57) also contained a positive control, which was 
a cytoplasmic fraction of the Walla3 strain expressing the pDW6 plasmid (Fig.57, 
Lane7). The highest band on the Western blot in the positive control is the GFP fusion to 
SepL, the middle band is degraded SepL fusion protein, and the lowest band is that of 
eGFP cleaved from the SepL fusion. Membrane, cytoplasmic and secreted protein 
preparations were also made from the Walla3 strain to act as a negative control. The 
Western blot (Fig.57) shows that eGFP can only be detected in the strain Walla3 
escU< >escUe(. : :egtp and only in Lane2 and Lane4. Lane2 is the cytoplasmic fraction of the 
strain Walla3 escU < >escUc.e ::exf, and Lane4 is the membrane fraction. There is 3.6 times 
more eGFP detected in the membrane fraction of the Walla3 escU< >escU(.(.. este, strain. 
This indicates that the cleaved fragment is localised to the membrane, either directly 
anchored to it or via a protein that is. 
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The membrane preparations were validated by a Western blot on the same samples using 
the GroEL antibody. The Western blot (not shown) has 1.6 times more GroEL present in 
the cytoplasmic protein fraction compared to the membrane fraction, as GroEL is a 
cytoplasmic protein this result validates that the cytoplasmic fraction is biased to 
cytoplasmic proteins. 







Fig.57 A 12% SDS PAGE gel was run and Western blot analysis showed the localisation 
of the cleaved fragment of the EscU eGFP fusion in the strain Walla3 
escU < >escUcc.: :est¡,, (ZAP1141) detected by anti GFP antibody 
Lane1: Walla3 cytoplasmic fraction 
Lane2: ZAP1141 cytoplasmic fraction 
Lane3: Walla3 membrane fraction 
Lane4: ZAP1141 membrane fraction 
Lane5: Walla3 supernatant proteins 
Lane6: ZAP1141 supernatant proteins 
Lane7: Walla3 containing pDW6 as a positive control. 
The Western blot was repeated with new protein fractions prepared in an identical 
manner to confirm the result (Fig.58). This Western blot showed 3.3 times more eGFP 
detected in the membrane preparation of the Walla3 escU < >escU(.c..egt» (ZAP1141) strain 







Fig.58 Repeat Western blot showing the localization of the cleaved fragment of the EscU 
eGFP fusion in the strain Walla3 escU< >escUcc....egf¡, (ZAP1141), detected by anti GFP 
antibodies. 
Lane1: Walla3 cytoplasmic fraction 
Lane2: ZAP1141 cytoplasmic fraction 
Lane3: Walla3 membrane fraction 
Lane4: ZAP1141 membrane fraction 
Lanes: Walla3 supernatant proteins 
Lane6: ZAP1141 supernatant proteins 
Lane7: Walla3 containing pDW6 as a positive control. 
4.7 HA Tag Detection in Strains Walla3 escU < >escUe,, : :HA (ZAP634) and Walla3 
escR < >escR :: HA (ZAP637) 
The strains Walla3 escU< >escUc,,::HA and Walla3 escR < >escR : :HA contain the fusions 
EscU::HA and EscR::HA, respectively. The HA tag is an antigenic peptide that does not 
have intrinsic fluorescence properties, like GFP, so its detection requires conjugated 
antibodies. Before attempts were made to visualise the proteins via fluorescence 
microscopy the ability for the HA tag to be detected by antibodies was tested by Western 
blot analysis and EscR and EscU's localisation within the bacterial cell determined. 
The Vector NTI (Invitrogen, Paisley, UK) program was used to predict the expected 
molecular weight (kDa) of the EscU::HA fusion protein, before and after cleavage at the 
NPTH site (Fig.59) and the EscR::HA fusion protein (Fig.60). 
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Analysis EscU::HA Fusion 
(at BstEll Site) 
Length 358aa 
Molecular Weight 41 kDa 
GNP YPYDVPDYAS GNP D NPTH 
Analysis EscU:HA Fusion After 





r I GNP YPYDVPDYAS GNP D NP 
Analysis Cleaved Peptide 
Length 82aa 
Molecular Weight 10kDa 
TH 
Fig.59 A schematic diagram showing the proteins created by the cleavage of the EscU::HA 
fusion at the NPTH cleavage site. EscU is shown as blue rectangles, the HA tag is shown as 
amino acids (dark blue letters), the NPTH cleavage sequence is shown in red and the BstEll 
restriction sites shown in purple (translated amino acids). The mass in kDa is estimated by the 
Vector NTI program (Invitrogen, Paisley, UK) and rounded up to the nearest kDa. The diagram 
shows that if cleavage happens at the NPTH then the expected detectable protein would be 




Molecular Weight 26kDa 
LFK YPYDVPDYAS FLLVVN 
Fig.60 A schematic diagram showing the construction of the EscR::HA fusion protein. EscR is 
depicted as a blue rectangle, the HA tag is shown as amino acids (dark blue letters) and the 
Swal restriction site is in purple (translated amino acids). The mass in kDa is estimated by the 
Vector NTI program (Invitrogen, Paisley, UK) and rounded up to the nearest kDa. There are no 
suspected cleavage sites in EscR so the detectable fusion protein should be approximately 
26kDa. 
Cytoplasmic, membrane and supernatant protein preparations were made of the strains 
Walla3 escU< >escUc,,.:HA and Walla3 escR < >escR::HA. Two Western blots were 
carried out - one with anti HA monoclonal antibody supplied by Sigma (Dorset, UK) 
and the other with anti HA monoclonal antibody supplied by Abcam (Cambridge, UK). 
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Both Western blots were carried out in high stringency conditions. This level of 
stringency was too high to see any bands that may have been present; after an hour 
exposure no bands were detected on the X ray film. The stringency was lowered and the 
amount of antibody used was raised. The Western blots then developed multiple non 
specific bands whilst still having no unique bands at the predicted size (Fig.61). When 
using the two different brands of anti HA antibodies the non specific bands were not the 
same (Fig.61, A and B). 
A 
ZAP634 ZAP637 
Sup. Mem. Cyt. Sup. Mem. C 
-105 kDa 
75 kDa 
- 50 kDa 
- 35 kDa 
I 
30 kDa 




B Cyt. Mem. Sup. Cyt. Mem. Sup. 
105 kDa - 
75 kDa - 
50 kDa - 
35 kDa - 
30 kDa 
25 kDa - 
15 kDa - 
Fig.61 Western blot analysis to detect the HA tag in the strains Walla3 
escU < >escUcn.:HA(ZAP634) and Walla3 escR < >escR::HA (ZAP637) in cytoplasmic 
fraction (Cyt.), membrane fraction (Mem.) and supernatant fraction (Sup.) using two 
different commercially available antibodies A. Anti HA antibody from Sigma B. Anti 
HA antibody from Abcam. The boxed areas encompass the expected size for the 
EscU and EscR HA fusions. 
4.7.1 Increasing Protein Load for HA Tagged Strains Walla3 escU < >escUc,,::HA 
(ZAP634) and Walla3 escR < >escR::HA (ZAP637) 
The previous work had already demonstrated that the GFP fusions were not present in 
high enough quantity to be detected by fluorescence microscopy and the GFP bands 
detected on the Western blots were faint. The lack of HA bands detected could, 
therefore, have been due to low levels of EscU translation. The growth conditions were 
changed to increase the quantity of EscU::HA or EscR::HA protein that was present in 
the strains Walla3 escU< >escUc.,,.;HA and Walla3 escR< >escR::HA. Instead of preparing 
the protein preparations from 50m1 supplemented MEM -HEPES the preparations were 
made from strains grown in 500m1. Although the bacterial pellet for the cytoplasmic and 
membrane fractions were resuspended in 1ml of sonication buffer, twice as much of the 
sample was loaded onto the 12% SDS PAGE gel. This equated to 10 times more protein 
loaded into the wells on the SDS PAGE gel. Both the Sigma (Dorset, UK) and the 
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Abeam (Cambridge, UK) antibodies were used to detect the HA tags and the presence of 
the Walla3 strain preparations on the blot enabled the non specific bands to be identified 










Walla3 ZAP634 ZAP637 












Walla3 ZAP634 ZAP637 
Cyt. Mem. Cyt. Mem. Cyt. Mem. 
Walla3 ZAP634 ZAP637 
Cyt. Mem. Cyt. Mem. Cyt. Mem. 
Fig.62 Western blot analysis of the strains Walla3 escU < >escUc : HA (ZAP634), 
Walla3 escR < >escR : :HA (ZAP637) and Walla3 grown in 500mIs supplemented 
MEM- HEPES. Detection of HA fused proteins with two different commercially 
available antibodies in the cytoplasmic fraction (Cyt.) and the membrane fraction 
(Mem.). A. Anti HA antibody from Sigma B. Anti HA antibody from Abcam C.The 
boxed area in B is magnified and shown. 
The Sigma (Dorset, UK) anti HA antibody did not show any bands unique to the Walla3 
escR < >escR : :HA strain compared to the Walla3 wild type strain. This antibody reacts to 
produce a non specific band at 30kDa that would mask the presence of the HA tag fused 
to the large fragment of EscU and there are no bands, at the correct size, in the 
EscR::HA membrane and cytoplasmic protein preparations (Fig.62, Lane3 and Lane4). 
The Abcam (Cambridge, UK) anti HA antibody gives a band of non -specific binding at 
the size for EscR::HA fusion protein making it impossible to judge whether it is 
detected. However, there is a band present at 30kDa in the lanes for the cytoplasmic and 
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membrane fractions of the EscU::HA tagged protein. Although present in both lanes it is 
disproportionately present in the membrane fraction being 5.33 times higher. This result 
indicates that the EscU protein is being detected by the Abcam (Cambridge, UK) anti 
HA antibody and that EscU is being cleaved into a - 30kDa protein and a -10kDa 
peptide, both of which have been detected separately and localised to membrane protein 
preparations. 
Western blot analysis was carried out on the membrane and cytoplasmic protein 
preparations using anti GroEL antibody and anti OmpA antibody. Although not shown, 
the cytoplasmic fractions of all the strains contained more GroEL protein than in the 
membrane fractions (1.3 times more) with the opposite being true for the detection of 
OmpA (1.4 times more in the membrane fraction). As GroEL is a cytoplasmic protein 
and OmpA is a membrane protein, these results confirm that the cytoplasmic fraction is 
biased towards cytoplasmic proteins and the membrane fraction biased to membrane 
proteins. 
Due to the of sensitivity of the HA antibodies in detecting the HA fusion and the 
non specific bands, microscopy with the HA tagged strains was not carried. 
4.8 EspA Filament Staining 
The strains Walla3 escRSTU < >sac /Kan, Walla3 escU < >escU«. :: o), Walla3 
escU < >escUcc: :xt¡, +, Walla3 escU < >escUCn::HA, Walla3 escU < >escU,,t :v , +, Walla3 
escR < >escR : :HA and Walla3 were used to create microscope slides that were fixed with 
PFA and incubated with anti EspA antibody for immunofluorescence antibody staining. 
This was to gauge the disruption the tags had on the secretion of EspA and the strains 
ability to form EspA filaments. Coomassie Blue stained SDS PAGE gels of the secreted 
proteins from the strains Walla3 escU < >escUcc. : :etj Walla3 escU < >escUce1 :gfi, +, and 
Walla3 escU < >escUc ,gfi, +, (gels not shown) indicated that there might be a disruption in 
the secretion of EspB, EspD and EspA. On each 10 well glass microscope slide five 
wells contained a mutant strain and the other five contained the strain Walla3. Four of 
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the five wells for each strain (including Walla3) were incubated with anti EspA primary 
antibody. Then, after washing, all five wells were incubated with the secondary 
antibody: goat Alexa Fluor 488 conjugate to anti -rabbit IgG. Fluorescence microscopy 
was carried out on the slides; representative frames were selected (Fig.63), which 
highlight the difference between the Walla3 strain and the mutant ZAP strains. 
The Walla3 strain showed EspA filamentation in a heterogeneous population (as 
previously described Roe, A., et al 2003). When incubated with only the secondary 
antibody the Walla3 strain lost these fluorescent foci. All the other strains, including the 
strain ZAP1140 which has the genes escRSTU substituted for the sac/Kan cassette, did 
not show any EspA filamentation. This, along with the Coomassie Blue staining of the 
secreted proteins, indicates that the tags are having a serious effect on the T3SS's ability 











































































































































































































The tagging of EscU and EscR created the opportunity to study the expression and 
localization of two TTSS proteins in the bacterial cell. The method used created a single 
copy gene fusion that replaces the native gene on the wild type Walla3 chromosome. 
Having the gene under its own promoter in its original genetic context means the genes 
expression should be similar to that of the wild type gene, allowing better understanding 
in the regulation and timing of these basal apparatus proteins. 
The low level expression of GFP from the chromosome decreased the likelihood of 
artifacts and misleading results due to high levels of the fluorescent protein. However, 
for the fluorescence from the GFP to be detectable by fluorescence microscopy there 
needs to be a group of GFP molecules in close proximity to allow emitted photons to be 
detected. If too few molecules of GFP are present the number of photons emitted can be 
below the threshold of the camera used in fluorescence microscopy (Niswender, K., et al 
1995). It was hoped that this would not be a problem during this project as the basal 
apparatus proteins chosen have been shown, by yeast two hybrid system, to interact with 
each and with themselves (Creasey, E., et al 2003) indicating that more than one of the 
each molecule is present in each basal apparatus. 
The fluorescent constructs (those that contain GFP protein fusions) were grown in a 
T3SS promoting media and the fluorescence of the population measured using the 
FLUOstar OPTIMA apparatus and plotted against the 0D600nn, of the culture. The 
fluorescence of the tagged strains did not increase far from the base line of fluorescence 
set by the wild type Walla3 strain. The GFP+ protein fusions did record marginally 
higher fluorescence values than the eGFP fusions. Although this small increase was 
encouraging, fluorescence microscopy was needed to deduce whether the constructs 
allowed visualization and localization of the EscU protein at a single cell level. 
Microscopy with strains Walla3 escU < >escU,.,. egtp, Walla3 escU< >escU(.(.;;stl,+ and 
Walla3 escU < >escU,,,;:.,t» +,, all containing EscU GFP protein fusions, showed that after 
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high levels of exposure and contrast enhancement fluorescent foci could be visualized. 
The observation of these fluorescent foci in the Walla3 strain, containing no fluorescent 
tag, demonstrated that it was an auto fluorescence phenomenon, but did not discount that 
it was auto fluorescence from the T3SS basal apparatus. To exclude this possibility the 
strain ZAP1140 (containing a substitution of escRSTU for the sac/Kan cassette) was 
imaged in the same way and the fluorescent foci were seen (data not shown). Panel A. in 
Fig.63 also supports that these observed foci are not due to auto fluorescence of the 
T3SS as the staining with the anti EspA antibody on the Walla3 strain reveals more 
filaments per bacterium and on a greater proportion of bacteria than the observed foci. 
The FLUOstar OPTIMA data demonstrated that on a population basis there is a small 
increase in the level of fluorescence from strains containing a protein fusion to a GFP 
variant but this increase is not detectable at a single cell level by fluorescence 
microscopy, most likely due to the low levels of GFP in each bacterium. 
To overcome the limitation of low levels of GFP an attempt to alter the amount of 
expression from the escU fusion was made using a plasmid containing the gene for the 
positive regulator Ler. FLUOstar OPTIMA data showed no increase in fluorescence in 
strains expressing Ler compared to those that did not. A second construct was then used, 
that contained an inducible copy of grlA, another positive regulator of the LEE. This 
plasmid had previously been published, where it was used to increase the expression of 
genes on the LEE pathogenicity island from the EHEC strain EDL933 (Ando, H., et al 
2007). The expression of grlA did not increase the fluorescence of the strains when using 
the FLUOstar OPTIMA apparatus and microscopy revealed no difference in 
fluorescence at a single cell level. The secreted protein profiles of the strains with and 
without the pGEM -grlA plasmid were used to see whether the plasmid increased the 
amount of secreted proteins. The increased size of the protein pellets from the secreted 
protein preparations of the strains containing the grlA plasmid indicated that the strains 
were secreting at a higher level, however Coomassie Blue staining of the SDS PAGE gel 
of the resuspended secreted protein pellets was hard to interpret due to a lack of secreted 
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proteins from the tagged strains. A Western blot was carried out with the whole cell 
preparations of the strains with and without the grlA plasmid using a monoclonal anti 
GFP antibody (J -L8) to measure any increase in the amount of GFP being produced. The 
Western blot analysis showed that there was a small increase in the amount of eGFP in 
the strain Walla3 escU < >escUcc.::e,sj¡, being produced when grlA was expressed. 
The Walla3 strain was then grown in LB, a non T3SS promoting media, to see whether 
the pGEM -grlA plasmid could increase the levels of EspD secretion. The increase of 
EspD secretion with the grlA plasmid was minimal, measuring a 1.4 times increase in 
comparison to the Walla3 strain grown in LB without the plasmid. 
The Western blot analysis using the anti GFP antibody showed the band detected was 
37kDa and not 66kDa. An amino acid sequence alignment with studied homologues 
from the flagellar system of Salmonella Typhimurium and the T3SS of Yersinia 
pseudotuberculosis showed that a known cleavage site is preserved in the EscU protein. 
This cleavage site (NPTH) cleaves a small 10kDa cytoplasmic peptide from these EscU 
homologues, which is reported to be important in switching from making the needle of 
the T3SS /flagella to making the filament. The eGFP fusion had one band at 35kDa, the 
correct size for the cleaved portion of EscU fused to eGFP. The GFP+ fusion had two 
bands, a strong band at 37kDa and a smaller band at 27kDa, the smaller band being the 
correct size for the GFP+ cleaved from the EscU peptide. These C terminal fusions 
support the idea that EscU is cleaved in a similar way. This means the EscU C terminus 
can be given the same nomenclature as F1hB and YscU proteins. The C and N terminus 











Fig.64 Schematic diagram showing the predicted structure of EscU (based on Lavender, M., 
et al 2002). The diagram is labelled with nomenclature for the C terminus of EscU (EscUc) 
before and after cleavage at the conserved cleavage site NPTH (N= Asparagine P= Proline, 
T= Threonine, H= Histidine.) 
The Western blot of the GFP+ fusion to the large fragment of EscU (at the BstEll site, 
see Fig.65) does not show a band pattern that would be expected. The fusion should sit 
at 57kDa (30kDa for the large cleaved fragment of EscU and 27kDa for GFP +) but 
instead a band at -31 kDa is observed. This band is too small for the fusion and too large 
to be GFP+ by itself. It is most likely that the addition of the large GFP+ protein altered 
the conformation of EscU to such a degree that alternative cleavage happened. This can 
be confirmed by looking at the HA tag in the same position. This tag allows detection of 
the 31kDa EscU fragment (30kDa for the large cleaved fragment of EscU and lkDa for 
the HA tag) due to its small size which does not cause such dramatic conformational 
changes. 
Because microscopy was unsuccessful and attempts to increase the fluorescence levels 
failed, Western blot analysis was used to localize the EscU GFP fusions. The cleaved 
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10kDa fragment was localized to the membrane protein preparation. It could be possible 
that the cleavage in the EscU molecule causes a C terminal conformational change that 
alters its affinity for translocon proteins, as shown in the flagellar system and Yersinia 
T3SS. In both these systems the cleaved portion interacts with the remaining protein it 
was cleaved from and remains anchored to the membrane. The large fragment of EscU 
(labeled with the HA tag) was also localized to the membrane. 
In the strain Walla3 escR < >escR::HA the EscR::HA fusion was not detected with 
Western blot analysis, non specific bands on the gel masked any bands at the correct size 
for the fusion and at higher stringencies no bands were detected. 
EspA filament staining was carried out on all the mutant strains to determine the effect 
the tag had on the T3SS. All the strains showed no detectable EspA filaments (visualized 
by fluorescence microscopy). The presence of GFP and the small HA peptide must 
interfere with the formation of EspA filaments. This result was unexpected and further 
investigation into the extent of the disruption on the T3SS was carried out and is detailed 
in Chapter 5. 
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Chapter 5 
The Effect of Tagging Basal Apparatus Proteins on the 
Type Three Secretion System and Analysis of EscU 
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5. The Effects of Tagging Basal Apparatus Proteins on the Type Three Secretion 
System and Analysis of EscU 
In Chapter 4 the mutant strains that contain a tagged EscU basal apparatus protein 
were unable to be visualised by fluorescence microscopy but were localised to 
bacterial cell fractions by Western blot analysis. This analysis demonstrated that the 
EscU protein is most likely cleaved into a 10kDa peptide and 30kDa protein at a 
conserved cleavage site with the amino acid sequence NPTH. Both the 10kDa 
peptide and the 30kDa protein were independently localised to the membrane 
fraction of the bacterial cell. The cleavage of the homologous proteins in the flagellar 
system of Salmonella Typhimurium (F1hB) and in the Yersinia pseudotuberculosis 
T3SS (YscU) is thought to be involved in a switching mechanism that controls the 
timing of secreting needle proteins and secreting filament proteins (Minamino, T., et 
al 2000, Lavander, M., et al 2002). To investigate the role of this cleavage in the 
EscU protein a deletion of the EscUcc domain was made in the Walla3 strain. This 
strain was added to the repertoire of strains to be studied in order to determine 
whether a functioning T3SS could be formed. The EscUcc deletion strain allows the 
elucidation of the role of the EscUcc domain in the construction of a T3SS, the 
secretion of filament proteins and the secretion of effector proteins. 
5.1 Strategy for Creating ZAP633 (Walla3 escU < >escUocc) 
To delete the EscUcc domain in the Walla3 strain the plasmid pJRE10 first had the 
ler gene and the partial LEE1 promoter removed in an identical manner to that of 
pJRE11, which created the plasrnid pJRE20. This increased plasmid yield, making it 
easier to manipulate (Fig.66). pJRE20 was restriction digested with the REase BstEII 
(upstream from the NPTH cleavage site) and the REase AatII (the REase site added 
at the 3' end of the escU gene). The digestion removed a 1069bp fragment from the 
012E20 plasmid, between the BstEII restriction site and the 3' end of the escU gene. 
The restricted plasmid was treated with the DNA polymerase I (Klenow) large 
fragment, and the blunt ends formed were ligated together, which reformed the 
BstEll site (Fig.65), making the plasmid pJRE21 (Fig.66). The wild type sequence 
from the BstEII site to the cleavage site was added to the pJRE21 plasmid to create 
the pJRE22 plasmid. The PCR product was digested with the REase BstEII and the 
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reaction mixture purified using the QlAquick PCR purification kit (QIAGEN, West 
Sussex, UK). It was ligated with the pJRE21 plasmid, which had also been digested 
with BstEII and purified by the QlAquick PCR purification kit (QIAGEN, West 
Sussex, UK). The pJRE22 plasmid was sent to MWG for sequencing showing that 
the EscUcc domain successfully deleted up to the NPTH cleavage site, which was 
replaced by the codons for NPVT -Stop (Fig.65). 
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BstEII site 
ACT GATG,GT AAC CCT GAA 







TAC AAG IGAC GTIC TAA TCG 
ATG TTC1cdTG CAG ATT AGC 
q 




G'GT AAC TAA TCG 







GIST AAC CITA ATC 




ACT GAT LAGT AAC T GAA 
TGA CTA CCA TTG GA CTT 
BstEII site 




N P V T Stop 
AAA AAC C q GTA ACC ITAA TCG 
TTT TTG GdC CAT TCPG ATT AGC 
BstEII site 
Fig.65 Creating the plasmid pJRE22. 1. pJRE20 was digested by the REase BstEll and 
AatIl. 2. The plasmid was treated with the klenow fragment to form blunt ends. 3. The 
plasmid was ligated with itself to reform the recognition site for the REase BstEll and make 
the plasmid pJRE21. 4. The pJRE21 plasmid was digested with BstEll and 5. ligated with 

































Fig.66 Vector NTI maps of the plasmid 
pJRE20, the intermediate plasmid pJRE21 and 










5.2 Construction of Plasmids pJRE20, pJRE21 and pJRE22 




Fig.67 Rsal digest of pJRE20 and pJRE21. The digestion mixture was run a 1% agarose gel 
with a positive clone for pJRE21 having bands at 2841 bp, 1967bp, 1433bp, 1146bp, 713bp, 
and 538óp. 
Lanai: Rsal digest of pJRE20 expected band pattern (bp): 2841, 1700, 1433, 1182, 1146, 
713, 538, 149, 39, 26 
Lane2: Rsal digest of pJRE21 expected band pattern (bp): 2841, 1967, 1433, 1146, 713, 538, 
39, 26 
Lane3: 1Kb DNA ladder (Invitrogen, Paisley, UK) 
The PCR product from primers 48, 49 was run on an agarose gel (Fig.68). 
1 2 3 4 5 6 7 8 9 10 11 12 
4- 200bp 
f-100bp 
Fig.68 PCR product from primers 48, 49 run on a 1.2% agarose gel. 
Lane1 and 12: 100bp DNA ladder 
Lane2 -11: Ta of PCR increases in one degree increments from 55 -65 °C 
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The PCR product from this reaction was purified and digested with the REase BstEII, 
ligated with the pJRE21 plasmid and transformed into 185 chemically competent 
cells. Successful transformations had the plasmids extracted by the QIAprepTM spin 
plasmid miniprep kit (QIAGEN, West Sussex, UK) and were screened for the 
creation of pJRE22 by diagnostic digestion with the REase BstEII, which removed 
the added PCR fragment (Fig.69). Four positive clones for the pJRE22 plasmid were 
sent for sequencing. 
3 4 10 11 12 13 14 15 
16 17 18 19 20 21 22 23 24 25 26 
Fig.69 Diagnostic digestion screen with the REase BstElI for positive clones of pJRE22 - 
run on a 1.2% agarose gel. Lanes3, 6, 18 and 21 were sent for sequencing. 
Lane1: 1Kb DNA ladder 
Lane2 -11: Possible clones of pJRE22 
Lane15 -16: 1Kb DNA ladder 
Lane17 -25: Possible clones of pJRE22 
Lane26: 1 Kb DNA ladder 
5.3 Allelic Exchange to Create the Strain Walla3 escU < >escUocc (ZAP633) 
The pJRE22 plasmid was transformed into the strain Walla3 escRSTU< >sac /Kan and 
exchanged onto the chromosome to replace the sac/Kan cassette with the esc genes 
on the plasmid, including escUA.. The colonies from the allelic exchange were PCR 
screened for the creation of the strain Walla3 escU< >escUA(.(. using primers specific 
for the sac/Kan cassette, the pIB307 plasmid and for the genes escR, escT, escS and 
escUA,C (gels not shown). 
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5.4 FLUOstar OPTIMA with the Strains Walla3, Walla3 escRSTU < >sac /Kan 
(ZAP1140) and Walla3 escU < >escUocc (ZAP633) Containing LEE1 -5 Promoter 
Fusions to egfp 
To determine whether deleting the EscUcc domain had an effect on the expression of 
LEE1, 2, 3, 4 and 5 and to further investigate the effect of deleting the genes 
escRSTU, plasmids containing promoter regions for the LEE1-5 operons fused to 
egfp (pAJR71- pAJR75) were transformed into the strains Walla3, Walla3 
escRSTU< >sac /Kan and Walla3 escU < >escUocc. The transformed colonies were 
grown in 10m1 supplemented MEM -HEPES and regular FLUOstar OPTIMA 
readings taken. The relative fluorescence was plotted against the OD600nm of the 
culture and the Walla3 strain containing no egfp plasmid was used as a negative 
control (Fig.70, 71, 72, 73, and 74). 
The FLUOstar OPTIMA data showed that the expression of LEE2 and LEE3 was 
almost identical in the strains Walla3 escRSTU< >sac /Kan (ZAP1140) and Walla3 
escU < >escUU (ZAP633) and Walla3. The LEE1, LEE4 and LEES promoters fused 
to egfp show that the Walla3 strain has lower values of fluorescence than the two 
mutant strains. In these cases the relative units of fluorescence of the Walla3 strain 
had started at a lower value than the ZAP 1140 and ZAP633 strain. If the values for 
the units of fluorescence for the Walla3 strain are increased by the difference 
measured from the starting fluorescence then the trend lines on the graph overlap one 
another. The level of fluorescence at the beginning of the experiment was variable 
and appeared to depend on the fluorescence and expression from the overnight 
culture. Although the experiments were repeated in a hope to eliminate this variation 
the initial fluorescence of the cultures could not be standardised. Even after taking 
this small variation into account it appeared that there was no feedback from either 
removing the genes escRSTU or the escU . domain on the expression from the LEE 
promoters. It has previously been shown that there is no observed feedback to the 
LEE after deleting genes for the basal apparatus in Citrobacter rodentium TTSS 
when looking at whole cell detection of Tir and EspB (Deng, W., et al 2004). 
173 
It was observed earlier in this project that substituting the LEE1 genes escRSTU for 
the sac/Kan cassette (Walla3 escRSTU< >sac /Kan) had no effect on the detectable 
amount of EspD in the whole cell protein fraction of the mutant compared to the wild 
type (Fig.23) and no EspD was detected in the supernatant of Walla3 
escRSTU< >sac /Kan. The high levels of EspD detected in the Walla3 supernatant 
were not observed in the whole cell protein fraction of the Walla3 
escRSTU<>saclKan strain i.e. there is no build up of EspD inside the cells of Walla3 
escRSTU< >sac /Kan bacteria due to its inability to be secreted. The promoter fusions 
show that this feedback is not at the transcriptional level. In the wild type strain it is 
proposed that the LEE4 mRNA is produced and transported to the TTSS where 
translation and translocation are coupled (Roe, A., et al 2003). When there is no 
functioning TTSS, as in Walla3 escRSTU<>saclKan, translation would not take 
place as translocation can not occur. This means the EspD levels inside the cell 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.5 Secreted Protein Profiles of the Strains Walla3, Walla3 escU < >escUocc 
(ZAP633), Walla3 escU < >escUcc::e p (ZAP1141), Walla3 escU < >escUcc : :gfp+ 
(ZAP1142), Walla3 escU < >escUcn::HA (ZAP634) and Walla3 escR < >escR::HA 
(ZAP637) 
When looking at the effect of the expression of grlA in the strains Walla3, Walla3 
escU < >escUcc: :ems,, Walla3 escU< >escUcc::j,+ and Walla3 escU < >escUcn::,+ the 
supernatants were run on a SDS PAGE gel and Coomassie blue stained (gel not 
shown). This revealed that the strains secreted less protein into the supernatant when 
compared to the wild type Walla3 strain. To further elucidate the effect of tagging 
EscU or deleting the EscUcc domain the strains Walla3, Walla3 escU < >escUnc , 
Walla3 escU < >escUcc : :eg fi, and Walla3 escU < >escUcc ::i fi,+ were screened for their 
ability to secrete Tir and EspD and their secreted protein profiles were observed by 
Coomassie blue staining (Fig.75, A). The strains Walla3 escU < >eSCUCn::HA and 
Walla3 escR < >escR::HA were also screened for their ability to secrete EspD and had 
their secreted proteins Coomassie blue stained (Fig.76, A). The mutant strains ability 
to secrete EspD or Tir were measured by Western blot analysis using anti EspD 
mouse monoclonal antibody and anti Tir mouse monoclonal antibody on supernatant 
protein preparations and compared to the supernatant of the wild type Walla3 strain 
(Fig.75, B, C and Fig.76, B, C). 
The Coomassie blue stained SDS PAGE gels (Fig.75, A and Fig.76, A) show that the 
mutant strains secrete less proteins compared to the Walla3 strain. In the strains 
measured for Tir (Fig.75, B) only the wild type Walla3 strain had detectable levels in 
the supernatant. The secretion of EspD is also effected by the tagging of EscU or 
deletion of the EscUcc domain. Only the Walla3 strain and the Walla3 
escU < >escU,c....d,+ strain have detectable amounts of EspD in the supernatant protein 
fractions. Interestingly the EspD detected in the Walla3 escU< >escUcc :.. p+ strain is 
approximately 12 times less than that detected in the Walla3 strain (determined by 
the ImageJ software, section 2.7.8.1) and may be present due to the cleavage of 
GFP+ from the EscUcc domain (Fig.75, C). This cleavage may allow some of the 
EscUcc peptide to function unhindered and account for the small amount of EspD 
detected. The lack of secretion in the HA tagged strains (ZAP634 and ZAP637) was 
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interesting as the HA tag is only nine amino acids in length and was chosen as it 
should have caused the least interference with the function of the protein being 
tagged. 
The strain Walla3 escU < >escUAC was also screened by fluorescence microscopy for 
















Fig.75 The secretion profiles of Walla3, Walla3 escU < >escUocc (ZAP633), Walla3 
escU < >escUcc..egfp (ZAP1141) and Walla3 escU < >escUcc:gfp+ (ZAP1142). A. 12% 
SDS PAGE gel of supernatants from Walla3, ZAP633, ZAP1141 and ZAP1142 was 
stained with Coomassie blue. B. Western blot analysis of the same supernatant 
protein samples with the anti Tir antibody. C. Western blot analysis with the 














Fig.76 The secretion profiles of Walla3, Walla3 
escU < >escUc,,::HA(ZAP634) and Walla3 escR < >escR::HA 
(ZAP637). A. 12% SDS PAGE gel of secreted proteins from 
the strains Walla3, ZAP634 and ZAP637 stained with 
Coomassie blue. B. Western blot analysis of the same 
secreted protein samples with the anti EspD antibody. 




5.6 Detection of EspD in Bacterial Cell Fractions of the Strains Walla3, Walla3 
escU< >escUACe (ZAP633), Walla3 escU < >escUcc : :egfp (ZAP1141), Walla3 
escU < >escUcc::gfp+ (ZAP1142), Walla3 escU < >escUen::HA (ZAP634), Walla3 
escR < >escR::HA (ZAP637), Walla3 escRSTU < >sae /Kan (ZAP1140) and Walla3 
escU < >esc Ucn::g fp+ (ZAP635) 
Following this analysis the strains Walla3, Walla3 escU < >escUA, Walla3 
escU< >escUcc. ; ;egfp, Walla3 escU < >escU,(: :gfp +, Walla3 escU< >escU,n. HA, Walla3 
escR < >escR::HA, Walla3 escRSTU < >sac /Kan and Walla3 escU < >escUc,,;;gtp+ were 
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screened for the presence of EspD in the supernatant protein fraction, cytoplasmic 
protein fraction and the membrane protein fraction. Western blot analysis was carried 
out with anti EspD antibody on the cell fractions (Fig.77). The Walla3 strain shows 
some EspD detected in the cytoplasmic fraction, 1.9 times more detected in the 
membrane fraction and at least 1.3 times more detected in the supernatant fraction. 
All the mutant strains have wild type levels of EspD in the cytoplasmic fraction. The 
mutant strains then have less EspD detected in the membrane fraction than the 
Walla3 membrane fraction (Walla3 escRSTU < >sac /Kan (ZAP1140) 3.1 times less, 
Walla3 escU< >escUA (ZAP633) 15.1 times less, Walla3 escU< >escUc.c ;:ed, 
(ZAP1141) 3.8 times less, Walla3 escU < >escUCC;sf /,+ (ZAP1142) 4.1 times less, 
Walla3 escU< >escUc,,:;gf¡,+ (ZAP635).3 times less, Walla3 escU < >escUC71..HA 
(ZAP634) 2.4 times less and Walla3 escR< >escR::HA (ZAP637) ZAP637 2.4 times 
less). The amount detected in the membrane of the mutant strains is also an average 
of 5.1 times less than the amount detected in the mutant strains cytoplasmic fraction. 
Only two strains have any EspD detected in the supernatant, ZAP 1142 and ZAP634. 
The EspD detected in ZAP634 is most likely signal detected from the cytoplasmic 
and membrane fractions in the neighbouring SDS PAGE gel wells as the band is 
faint and undefined. The strain Walla3 escU < >escUcc ::gf»+ (ZAP1142);, however, has 
already been shown to secrete EspD, although the level of EspD detected is at least 4 
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Fig.77 EspD secretion detected by Western blot analysis using 1:2000 dilution of anti EspD 
antibody after running 12% SDS PAGE gel of cell fractions from the strains Walla3, Walla3 
escU < >escUocc (ZAP633), Walla3 escU < >escUcc..egfp(ZAP1141), Walla3 escU < >escUcc : :g /p+ 
(ZAP1142), Walla3 escU<>escUcn::HA (ZAP634), Walla3 escR < >escR::HA (ZAP637), Walla3 
escRSTU< >sac /Kan (ZAP1140) and Walla3 escU < >escUcn::gfp +(ZAP635). Lane1,4,7: 
Cytoplasmic fraction. Lane2,5,8: Membrane fractions. Lane3,6,9,: Supernatant fractions. 
5.7 Complementation of Strains Walla3 escU< >escUocc (ZAP633), Walla3 
escU < >escUcc : :esfp (ZAP1141), Walla3 escU < >escUcc ::sfp+ (ZAP1142), Walla3 
escU < >escUc : :HA (ZAP634) and Walla3 escRSTU< >sac /Kan (ZAP1140) with the 
pJRE02 Plasmid 
To see whether the reduction of EspD secretion observed with the mutant strains can 
be attributed to the modifications made in the LEE1 sequence the strains Walla3 
escU < >escUA,.(, Walla3 escU < >escU,, :,c,,f,, Walla3 escU < >escU,.,.::gfp +, Walla3 
escU < >escUc,j. :HA and Walla3 escRSTU< >sac /Kan had the pJRE02 plasmid 
transformed into them. This was to determine whether this plasmid could 
complement the mutants and restore EspD secretion. The pJRE02 plasmid contains 
6.3Kó of the LEE1 sequence, which includes the LEE1 promoter up to the -10 
region. Although expression from this plasmid was not demonstrated colonies of 
TOP10 cells carrying pJRE02 grew to a smaller colony size and yielded less plasmid 
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than expected, a phenotype that was reversed when the sequence encoding the ler 
gene and the partial LEE1 promoter was removed (to form pJRE 11). 
pJRE02 was transformed into the strains and colonies from each transformation were 
grown in 50m1 supplemented MEM -HEPES with ampicillin and secreted protein 
preparations were made. Western blot analysis was carried out on the samples with 
anti EspD antibody. 
Western blot analysis showed that with the pJRE02 plasmid there was partial 
complementation in all the strains tested (Fig.78). The Walla3 escU < >escUcc:: ,+ 
strain did secrete less EspD than previously observed (14.6 times less than the 
Walla3 strain), however the strains Walla3 escRSTU< >sac /Kan, Walla3 
escU < >escUU,,, Walla3 escU < >escUcc. : :ej, and Walla3 escU< >escUcn::HA all secreted 
a detectable amount of EspD (1.9, 5.7, 3.1 and 2.7 times less than Walla3 
respectively), which had not been detected in previous EspD Western blots. The 
ability of the strain Walla3 escRSTU< >sac /Kan to secrete EspD when the pJRE02 
plasmid was introduced was encouraging as the strain contains no escRSTU and has 
been fully complemented by allelic exchange with the sequence present on the 
pJRE02 plasmid. Having only a partial LEE 1 promoter on pJRE02 may be the reason 
the complementation was not to wild type levels. Also strains containing tagged 
versions of the EscU protein have had the tagged protein localised to the membrane 
where it may be competing with the EscU produced from the pJRE02 plasmid, 
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Fig.78 Complementation of strains Walla3 escU < >escUocc (ZAP633), Walla3 
escU < >escUcc::egfp(ZAP1141), Walla3 escU< >escUcc::gfp +(ZAP1142), Walla3 
escU< >escUc,,::HA (ZAP634) and Walla3 escRSTU < >sac/Kan (ZAP1140),, with the 
pJRE02 plasmid. Western blot analysis carried out with 1:2000 dilution of anti 
EspD antibody after running the samples on a 12% SDS PAGE gel. 
A 
Lane1: Walla3 supernatant proteins 
Lane2: Empty well 
Lane3: ZAP1140 supernatant proteins 
Lane4: ZAP633 supernatant proteins 
Lanes: ZAP1142 supernatant proteins 
B: 
Lane1: Walla3 supernatant proteins 
Lane2: Empty well 
Lane3: ZAP1140 supernatant proteins 
Lane4: Empty well 
Lanes: ZAP634 supernatant proteins 
Lane6: ZAP1141 supernatant proteins 
5.8 Complementation of Walla3 escU < >escUocc (ZAP633) with the EscUcc 
Peptide 
In order to further understand the deletion of the EscUcc domain in the strain Walla3 
escU < >escUAce a plasmid copy of the domain was used to complement the ability of 
the strain to secrete EspD. PCR primers were designed to amplify the escU. 
sequence from the Walla3 strain. One set of primers (50, 51) contained the sequence 
for the HA tag in the 5' primers non complementary tail which was preceded by the 
codon for a methionine as the start codon for transcription. The second set of primers 
(52, 51) contained no HA tag and started with the codon for a methionine (Fig.79). 
Both pairs of primers were designed to allow the PCR product to be cloned into the 
plasmid pKC21 using the REases KpnI and Hindlll. pKC21 is a pACYC184 based 
plasmid that contains the pTac promoter, inserting a gene between the KpnI REase 
recognition site and the Hindlll recognition site places the gene in front of the pTac 
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pKC21 (N terminal HA tag) 
Fig.79 Diagram of the deleted amino acids in the strain Walla3 escU < >escUA (ZAP633) 
and the two peptides used to complement the strain (M = Methionine, N= Asparagine 
P= Proline, T= Threonine, H= Histidine, V= Valine). 
5.8.1 Creating the Plasmids pJRE23 and pJRE24 
The PCR reactions using the primer pairs 50, 51 and 52, 51 were carried out (Fig.80, 
A and B). 
The two PCR products were purified using the QlAquick PCR purification kit 
(QIAGEN, West Sussex, UK) and restriction digested with the REases Kpnl and 
HindIII. The plasmid pKC21 was extracted from the AAEC185 strain by the 
QJAprepTM spin plasmid miniprep kit (QIAGEN, West Sussex, UK) and also 
digested by the REases Kpnl and HindIII. After the restricted plasmid and the 
digested PCR products were purified from the digestion mixture with the QlAquick 
PCR purification kit (QIAGEN, West Sussex, UK) the plasmid was ligated 
separately with each PCR product. The ligation mixtures were transformed into 
chemically competent AAEC 185 cells. 
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Fig.80 PCR reactions using primer pairs 50, 51 and 52, 51 for cloning into the pKC21 
plasmid. Using 1µl of a 1:150 dilution of Walla3 CTAB extracted genomic DNA for 
template. Both sets of primers annealed at each 1 °C temperature increment between 55 °C 
and 65 °C to produce a small -300bp product 
A Lane1: 1Kb DNA ladder 
Lane2 -11: One degree increments in Ta (55 -65 °C) for PCR with primers 50 and 51 
(containing no HA tag sequence) 
B Lane1 -10: One degree increments in Ta (55 -65 °C) for PCR with primers 52 and 51 
(containing the HA tag sequence in the 5' primer tail) 
Lane11: 1Kb DNA ladder 
The transformants were screened by removing plasmid DNA with the QIAprepTM 
spin plasmid miniprep kit (QIAGEN, West Sussex, UK) and diagnostic restriction 
analysis was carried out with the REases Kpnl and HindlII. This removed the PCR 
fragment from successful clones and linearized the pKC21 plasmid (Fig.81). 
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Fig.81 Kpnl and Hindlll REase digestion of pJRE23 and pJRE24 to excise the PCR 
product - a successful clone for the complement plasmid with the HA tag (A) and for 
the complement plasmid without the HA tag (B), also included is the parent plasmid 
pKC21 digested with the same REases (A Lane2).. 
A Lane1: pJRE23 digestion 
Lane2: pKC21 
Lane3: 100bp DNA ladder 
B Lane1: pJRE24 digestion 
Lane2: 100bp DNA ladder. 
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Both the clones were sent to MWG for sequencing. Vector NTI maps for each 
construct are shown in Fig.82. 
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Fig.82, A) Vector NTI map of pJRE23: escUcc with a 5' HA tag expressed from the 
pTac promoter. 
B) Vector NTI map of pJRE24: escUcc expressed from the pTac promoter. 
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5.8.2 Western Blot Analysis Detecting ESCUCC::HA in the Strain Walla3 
escU < >escUocc (ZAP633) 
Both pJRE23 and pJRE24 were transformed into the Walla3 escU < >escUACL strain. 
Initially three 50m1 cultures in supplemented MEM -HEPES (with chloramphenicol 
where appropriate) were set up; one containing Walla3 escU < >escUACC with no 
plasmid and the remaining two cultures containing ZAP633 with pJRE23. At an 
OD600nm of 0.1 one of the Walla3 escU < >escUA,.( cultures with pJRE23 had IPTG 
added to a final concentration of 1 mM to induce expression from the pTac promoter. 
Whole cell preparations were made from all the cultures and Western blot analysis 
carried out with anti HA mouse monoclonal antibody (Sigma, Dorset, UK). The 
Western blot analysis demonstrated that the small EscUcc 10kDa fragment was being 
produced and detected in the Walla3 escU< >escUA,. strain (Fig.83). 
1 2 3 
10kDa 
Fig.83 Western blot analysis of the HA peptide fused to the N terminus of EscUcc 
(from the pJRE23 plasmid). Using 1:1000 dilution of anti HA antibody after using a 
18% SDS PAGE gel 
Lane1: Walla3 escU < >escU, (ZAP633) 
Lane2: ZAP633 with pJRE23 (uninduced) 
Lane3: ZAP633 with pJRE23 (induced). 
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5.8.3 Western Blot Analysis Detecting EscUcc::HA in Walla3 escU< >escUAcc 
(ZAP633), Walla3 escU < >escUcc : :egp (ZAP1141), Walla3 escU < >escUcc::gp+ 
(ZAP1142), Walla3 escU < >escUc,t : :HA (ZAP634), Walla3 escRSTU < >sac /Kan 
(ZAP1140) and Walla3 
The strains Walla3, Walla3 escU< >escUAcc, Walla3 escU < >escUcc : :e,tt,, Walla3 
escU< >escUcc::stj, +, Walla3 escU< >escU,,,::HA and Walla3 escRSTU< >sac /Kan were 
transformed with the pJRE23 plasmid in an identical manner as the Walla3 
escU < >escUACC strain. All the strains containing the plasmid and the Walla3 strain 
without the plasmid were used to prepare cytoplasmic, membrane and supernatant 
fractions. The fractions were used in Western blot analysis with the anti HA mouse 
monoclonal antibody (Sigma, Dorset, UK). Fig.84 shows the results for Walla3 with 
and with out the plasmid and the two strains, Walla3 escU< >escUA.,. and Walla3 
escRSTU< >sac /Kan, which produced detectable amounts of the EscUcc::HA peptide. 
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Fig.84 Western blot analysis of the cytoplasmic fractions, membrane 
fractions and supernatant fractions of the strains Walla3 without pJRE23 
and Walla3, Walla3 escU < >escUocc (ZAP633) and Walla3 
escRSTU< >sac /Kan (ZAP1140) with pJRE23. Samples were run on an 
18% SDS PAGE gel and incubated with 1:1000 dilution of anti HA antibody 
A Lane1: Walla3 without pJRE23 cytoplasmic fraction 
Lane2: Walla3 without pJRE23 membrane fraction 
Lane3: Walla3 without pJRE23 supernatant fraction 
Lane4: Walla3 with pJRE23 cytoplasmic fraction 
Lanes: Walla3 with pJRE23 membrane fraction 
Lane6: Walla3 with pJRE23 supernatant fraction 
Lane 7: ZAP633 with pJRE23 cytoplasmic fraction 
Lane8: ZAP633 with pJRE23 membrane fraction 
Lane9: ZAP633 with pJRE23 supernatant fraction 
B Lane1: ZAP1140 with pJRE23 membrane fraction 
Lane2: ZAP1140 with pJRE23 cytoplasmic fraction 
Lane3: ZAP1140 with pJRE23 supernatant fraction. 
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The results in Fig.84 show the EscUcc peptide was only detected in the strains 
Walla3 escRSTU< >sac /Kan and Walla3 escU < >escUA ,. Interestingly, in both strains 
the peptide is localised to the membrane fraction of the bacteria. This is intriguing as 
the Walla3 escRSTU< >sac /Kan strain does not contain the genes escRSTU so the 
EscUcc peptide is not being anchored to the membrane by interacting with the 
ESCUCN domain in this strain. 
5.8.4 Western Blot Analysis Detecting EspD Secretion with pJRE23 and 
pJRE24 Complement Plasmids in the Walla3 escU < >escUAcc (ZAP633) Strain 
The ZAP633 strain was used to see if the EspD secretion was restored by the 
presence of EscUcc. The supernatant fractions from the preparations when 
EscUcc::HA was detected in the membrane of ZAP633 had Western blot analysis 
carried out using anti EspD mouse monoclonal antibody (Fig.85). A supernatant 
fraction from the strain Walla3 escU< >escUA(.( (ZAP633) transformed with the 
pJRE24 plasmid, grown and prepared at the same time and in an identical manner to 
the induced pJRE23 plasmid was also used (Fig.85). The samples from Walla3 
escU < >escUAC( with pJRE24 were screened for their ability to restore EspD secretion 
in case the HA tag disrupted the function of the EscUcc peptide. 
Fig.85 shows that the production of the HA tagged EscUcc peptide does not restore 
secretion of EspD to wild type levels and if the EscUcc untagged protein is being 
produced, this also does not restore secretion. Empty wells in this Western blot 
(Fig.85, Lane2 and Lane4) contain signal from the detection of EspD from the 
Walla3 strain. Upon repeating the Western blot this artefact was observed again and 
is most likely due to the wells on the SDS PAGE gel leaking. In each repeat of this 
Western the final lane, containing the secreted proteins of the Walla3 escU < >escUA(,. 
strain with the induced pJRE24 plasmid, did have a small amount of detectable EspD 
that was not from the well containing the Walla3 sample. The presence of the 
EscUcc domain by itself is not enough to restore EspD secretion to a wild type level. 
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Fig.85 EspD secretion from the Walla3 and Walla3 escU < >escUocc (ZAP633), strains 
with and without pJRE23 and pJRE24 (induced and uninduced). 12% SDS PAGE gel 
used, with 1:2000 dilution of anti EspD antibody 
Lane1: Walla3 supernatant protein 
Lane2: Empty well 
Lane3: ZAP633 supernatant protein 
Lane4: Empty well 
Lane5: ZAP633 with pJRE24 (uninduced) supernatant protein 
Lane6: ZAP633 with pJRE23 (uninduced) supernatant protein 
Lane7: Empty well 
Lane8: ZAP633 with pJRE24 (induced) supernatant protein 
Lane9: ZAP633 with pJRE23 (induced) supernatant protein 
Attempts to clone the whole of escU into the pKC21 plasmid, the pWSK29 plasmid 
(Wang, R. et al 1991) or into the tetracycline gene of the pBR322 plasmid (NEB, 
Hertfordshire, UK) failed. This may have been due to toxicity problems. 
5.9 Anti EscJ Antibody: Western Blot Analysis 
Anti EscJ and anti EscF antibodies were kindly supplied by Professor Akio Abe from 
Kitasato University, Tokyo, Japan. The antibodies were used on strains containing 
EscU mutants to determine whether EscJ and EscF were located in the correct 
location (i.e. the membrane fraction of the cell). The location of EscF and EscJ in the 
mutant strains indicates whether the mutants are capable of forming a T3SS basal 
apparatus, as EscF and EscJ insertion into the membrane requires other basal 
apparatus proteins to be present (Gauthier, A., et al 2003b). In essence, they provide 
evidence that the formation of the basal apparatus is not being hindered due to the 
mutations in EscU. The anti EscJ antibody was checked for specificity using 
membrane preparations from the strains Walla3, ZAP193AescN, 148a and Walla3 
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escRSTU < >sac /Kan (ZAP1140). The strains were grown in supplemented MEM- 
HEPES and membrane preparations were made from the cultures. The samples were 
used in Western blot analysis with anti EscJ rabbit polyclonal antibody (Fig.86). 
The EscJ Western blot (Fig.86) showed that the Walla3 strain had a band at the 
correct size for EscJ as did the ZAP193AescN strain whilst the 148a strain (which 
does not contain the escJ gene) had no EscJ detected. The Walla3 
escRSTU< >sac /Kan had 1.6 times less EscJ detected in the membrane compared to 
the Walla3 strain. The results seem to verify the antibody is for EscJ and indicate that 
the ATPase EscN might be required for wild type levels of EscJ, whilst the basal 
apparatus proteins EscR, S, T and U do not need to be present for EscJ to be 
localised to the membrane 
1 2 3 4 
Fig.86 1:1000 dilution of anti EscJ antibody used in Western blot 
analysis of membrane preparations from the strains Walla3, 
ZAP193AescN, 148a and Walla3 escRSTU <>sac/Kan (ZAP1140) 
run on a 12% SDS PAGE gel. 
Lane1: Walla3 membrane preparation 
Lane2: ZAP193AescN membrane preparation 
Lane3: 148a membrane preparation 
Lane4: ZAP1140 membrane preparation 
The anti EscJ antibody was used with cytoplasmic, membrane and secreted protein 
fractions of all the strains to see whether EscJ can be detected. All the strains were 
grown in 50m1 supplemented MEM- HEPES. Membrane, cytoplasmic and secreted 
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Fig.87 Western blot analysis on the cytoplasmic, membrane and secreted protein 
fractions of Walla3, Walla3 escU < >escUA (ZAP633), Walla3 escU < >escUcc..ûgfp 
(ZAP1141), Walla3 escU < >escU,c :::gfp +(ZAP1142), Walla3 escU < >escUcl.:HA 
(ZAP634), Walla3 escRSTU < >sac /Kan (ZAP1140), Walla3 escU < >escUcr, :gfp+ 
(ZAP635) and Walla3 escR< >escR::HA (ZAP637) using 1:1000 dilution of the anti 
EscJ antibody. Lanesl , 4 and 7 are cytoplasmic fractions, Lanes2, 5 and 8 are 
membrane fractions and Lanes3, 6 and 9 are supernatant fractions. 
A Lanesl -3: Walla3 
Lanes4 -6: ZAP633 
Lanes7- 9:Zap1140 
B Lanesl -3: ZAP1142 
Lanes4 -6: ZAP1141 
Lanes7 -9: ZAP635 
C Lanesl -3: Walla3 
Lanes4 -6: ZAP634 
Lanes7 -9: ZAP637 
Western blot analysis (Fig.87) showed that EscJ was detected in the membrane 
fraction of all eight strains, and detected in the cytoplasmic fractions of six strains. 
The amount of EscJ detected in the membrane fractions was variable, with less being 
detected in the strains Walla3 escRSTU<>saclKan (2.1 times), Walla3 
escU< >escU.:: h,+ (3.5 times) and Walla3 escU< >escUc c ..egt¡, (1.2 times) when 
compared to the Walla3 strain. In the Walla3 strain there is at least 10 times more 
EscJ detected in the membrane preparation than the cytoplasmic preparation, this 
ratio of the amount of EscJ detected in the membrane fraction compared to the 
cytoplasmic fraction remains fairly constant in all the strains. 
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All the Western blots containing membrane and cytoplasmic fractions were verified 
by Western blot analysis with both anti GroEL and anti OmpA antibodies. The 
results for all the gels (not shown) show a bias of OmpA in the membrane fraction 
and a bias of GroEL to the cytoplasmic fraction. 
5.9.1 Anti EscJ Antibody: Fluorescence Microscopy 
The antibody was used for fluorescence microscopy to detect EscJ in the bacterial 
membrane /periplasm. The Walla3 strain (positive control) was used alongside the 
148a strain (negative control) to test whether the antibody was effective at labelling 
bacteria for fluorescence microscopy. Microscopy slides were made using the 
methanol fixation /permeabilistaion method. The slides were incubated with a 1:25 
dilution of the anti EscJ antibody then incubated with the secondary antibody goat 
Alexa Fluor 488 conjugate to anti -rabbit IgG. Examples of the microscopy are shown 
in Fig.88 and Fig.89. 
Fig.88 Microscopy with the anti EscJ antibody labelling the Walla3 strain. The slides 
were visualised using a DM LB2 microscope (Leica, Milton Keynes, UK) with a 100X 
objective lens and an exposure time of 500ms. The panel 'S' contains bacteria 
visualised after incubation with only the secondary antibody. 
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Fig.89 Microscopy with the anti EscJ antibody labelling the 148a strain. The slides 
were visualised using a DM LB2 microscope (Leica, Milton Keynes, UK) with a 100X 
objective lens and an exposure time of 500ms. The panel `S' contains bacteria 
visualised after incubation with only the secondary antibody. 
Microscopy with the anti EscJ antibody gave varying images. Although grown in an 
identical manner the images for the Walla3 strain did not repeat. The number of 
fluorescent bacteria and the nature of the fluorescence were not constant; 
occasionally the fluorescence was in fine focused spots and other times it appeared 
more dispersed. In the 148a the majority of the repeats showed images with no 
staining, but some microscopy slides showed fluorescence with groups of bacteria 
having fluorescent foci. 
The results led to the conclusion that the antibody, although good for Western blot 
analysis, was not suited for labelling strains for fluorescence microscopy. 
5.10 Anti EscF Antibody: Western Blot Analysis 
The anti EscF antibody was first screened using membrane preparations of Walla3, 
ZAPl93AescN and Walla3 escRSTU<>saclKan (ZAP1140). These preparations were 
used for Western blots where they were incubated with anti EscF antibody (Fig.90). 
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Fig.90 Western blot analysis using 1:1000 dilution of the anti EscF 
antibody on membrane preparations from the strains Walla3, 
ZAP1986.escN Walla3 escRSTU< >sac /Kan (ZAP1140), after samples 
were run on an 18% SDS PAGE gel. 
Lane1: Walla3 membrane preparation 
Lane2: ZAP198AescN membrane preparation 
Lane3: ZAP1140 membrane preparation 
Western blot analysis detected three main bands when using the anti EscF antibody 
on membrane preparations. The most intense band was between the 10kDa marker 
and the dye front of the SDS PAGE gel, a promising candidate for the 8kDa EscF 
monomer. The other two bands may have been dimers and trimers of the EscF 
protein. This result indicated that EscF could be detected in large amounts in the 
membrane fraction of the three strains screened. Due to filament shearing EscF may 
have been detectable in the supernatants of the strains. Supernatant protein 
preparations were easier to prepare and contain fewer proteins for cross reactivity, so 
supernatant proteins of the escU mutant strains and the Walla3 strain were screened 
by Western blot analysis for EscF. The strains Walla3, Walla3 escU < >escUAcc., 
Walla3 escU < >escUcc.:egf,, Walla3 escU < >escUc: : :xtp +, Walla3 escU < >escUC,,;;HA, 
Walla3 escRSTU< >sac /Kan and Walla3 escU < >escUcn::gfp +, were grown in 50m1 
supplemented MEM -HEPES and supernatant preparations were made and run on a 
10 -20% gradient gel (Bio -rad, Hertfordshire, UK). These gels were used in the 





Fig.91 Western blot analysis with the anti EscF antibody on supernatant 
proteins from Walla3, Walla3 escU < >escUocc (ZAP633), Walla3 
escU < >escUcc:egfp (ZAP1141), Walla3 escU<>escUcc::gfp+ (ZA P1142), 
Walla3 escU < >escUC _;HA(ZAP634), Walla3 escRSTU < >sac /Kan 
(ZAP1140) and Walla3 escU < >escUcn::gfp+ (ZAP635) 
Lane1: Walla3 supernatant proteins 
Lane2: ZAP1141 supernatant proteins 
Lane3: ZAP1142 supernatant proteins 
Lane4: ZAP635 supernatant proteins 
Lanes: ZAP634 supernatant proteins 
Lane6: ZAP633 supernatant proteins 
Lane7: ZAP1140 supernatant proteins 
Western blot analysis of the supernatant proteins showed that the anti EscF antibody 
was detecting a double band below the lOkDa marker. This could be two forms of 
EscF, one form modified to increase the molecular mass or one form cleaved to 
decrease it. The Western blot also shows a large increase in the amount of EscF 
detected in the Walla3 escU< >escUc.,. ::,t¡,+ strain. If the antibody is specific for EscF 
then fusing GFP+ to the C terminus of EscU has a dramatic effect in the amount of 
EscF being secreted. 
5.10.1 Creating a Walla3 LEE4 Deletion Strain (ZAP636) 
Before any conclusion could be reached about the effect of modifying EscU on the 
amount of EscF being secreted the anti EscF antibody was verified. To confirm the 
antibody was detecting the EscF protein a LEE4 deletion in the Walla3 strain was 
created (deleting the entire LEE4, including escF). The plasmid pHY 10 was 
transformed and used to replace the LEE4 sequence for the sac/Kan cassette by 
allelic exchange. Colonies from the allelic exchange were screened by PCR for the 
presence of escF. PCR screening was also used to verify the pIB307 plasmid had 
been cured and the sac/Kan cassette was present in the strain (gels not shown). 
Successful allelic exchange created the Walla3 LEE4< >sac /Kan strain, which 
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contained no escF and acted as a negative control for the Western blots with the anti 
EscF antibody. 
5.10.2 Anti EscF Antibody: Western Blot Analysis with the Walla3, Walla3 
LEE4 < >sac /Kan (ZAP636) and Walla3 escU < >escUcc::gfp+ (ZAP1142) Strains 
Initially the strain Walla3 LEE4< >sac /Kan was compared with the Walla3 strain. 
Both strains were grown supplemented MEM -HEPES and cytoplasmic, membrane 
and supernatant protein fractions made. Western blot analysis was carried out on 
these samples using the anti EscF antibody (Fig.92). 
1 2 3 4 5 6 
Fig.92 Western blot analysis of membrane, cytoplasmic and supernatant protein fractions of 
Walla3 and Walla3 LEE4< >sac /Kan (ZAP636) with 1:1000 dilution anti EscF antibody. 
Samples were initially run on a 10 -20% SDS PAGE gel (Bio -rad, Hertfordshire, UK). 
Western blot analysis was carried out in low stringency condiditons 
Lane1: Walla3 cytoplasmic fraction 
Lane2: Walla3 membrane fraction 
Lane3: Walla3 supernatant fraction 
Lane4: ZAP636 cytoplasmic fraction 
Lanes: ZAP636 membrane fraction 
Lane6: ZAP636 supernatant fraction. 
Fig.92 shows that the Walla3 LEE4< >sac /Kan mutant strain, which contains no 
escF, has the double band below the 10kDa marker. This indicates that the 
previously detected band was not EscF. EscF may still be detected on the Western 
blots but masked by the cross reactivity with another small peptide. To minimise 
cross reactivity the anti EscF antibody was absorbed using the Walla3 
LEE4< >sac /Kan strain. The strains Walla3, Walla3 LEE4< >sac /Kan and Walla3 
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escU < >escU.c. : :d,+ were grown in supplemented MEM -HEPES and cytoplasmic, 
membrane and supernatant protein fractions made. The strain Walla3 
escU < >escU.c : :s0,+ was used as it showed an increase in the protein detected by the 
anti EscF antibody. If this is indeed an increase in EscF then the Walla3 
escU < >escUc : :gj»+ strain may produce enough EscF to be seen after the cross 
reactivity has been removed. The samples were run on a 10 -20% SDS PAGE gel 
(Bio -Rad, Hertfordshire, UK) and a 1:10 dilution of the absorbed antibody used in a 
low stringency Western blot to detect EscF (Fig.93) 
A 
B 
1 2 3 4 5 6 7 8 9 
Fig.93 Western blot analysis of membrane, cytoplasm and supernatant protein preparations 
of Walla3, Walla3 LEE4 < >sac /Kan (ZAP636) and Walla3 escU < >escUcc : :gfp ,.(ZAP1142) 
using a 1:10 dilution of absorbed anti EscF antibody. The boxed area in A. is shown from a 
longer exposed X -ray film in B. The box in B. highlights a small and faint band which may be 
EscF. 
Lanai: Walla3 cytoplasmic protein fraction 
Lane2: Walla3 membrane protein fraction 
Lane3: Walla3 supernatant protein fraction 
Lane4: ZAP636 cytoplasmic protein fraction 
Lane5: ZAP636 membrane protein fraction 
Lane6: ZAP636 supernatant protein fraction 
Lane7: ZAP1142 cytoplasmic protein fraction 
Lane8: ZAP1142 membrane protein fraction 
Lane9: ZAP1142supernatant protein fraction 
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5.10.3 Anti EscF antibody: Antibody Absorption and Tricine Gels 
The absorbed antibody did reduce the intensity of the two bands detected below the 
lOkDa marker in the supernatant protein fractions, however, the bands were still 
observed in the Walla3 LEE4< >sac /Kan strain (Fig.93, B Lane6). Below these bands 
but before the dye front for the SDS PAGE gel, was another band detected only in 
the Walla3 escU< >escUcc...sfi,+ strain; which could be the EscF monomer detected by 
the antibody. 
To determine whether the absorbed anti EscF antibody is detecting EscF tricine gels 
(Bio -Rad, Hertfordshire, UK) were run with the Walla3 and Walla3 LEE4< >sac /Kan 
membrane, cytoplasm and supernatant protein samples and purified EscF. The 
purified EscF was supplied by Sean McAteer from the ZAP lab, CID, the University 
of Edinburgh. The EscF was purified using a 6 His tag expression system and had 
been detected by Western blot analysis in the final elution using anti His antibody. 
The Walla3 and Walla3 LEE4< >sac /Kan samples were run on the tricine gel with a 
whole cell sample from the expression strain with the EscF -His tag plasmid which 
had not been induced, a whole cell sample of the strain when the plasmid had been 
induced and 5p1 of the final column elute (Fig.94). 
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Fig.94 Western blot analysis of the cytoplasmic, membrane and supernatant proteins of 
Walla3 and Walla3 LEE4 < >sac /Kan (ZAP636) and whole cell fractions from the expression 
strain with the EscF -His tagged expression vector induced and not induced and the final 
elution of purified EscF. The Western blot was carried out in low stringency conditions with a 
1:10 dilution of the absorbed antibody. 
Lane1: Walla3 cytoplasmic protein fraction 
Lane2: Walla3 membrane protein fraction 
Lane3: Walla3 supernatant protein fraction 
Lane4: ZAP636 cytoplasmic protein fraction 
Lane5: ZAP636 membrane protein fraction 
Lane6: ZAP636 supernatant protein fraction 
Lane7: Uninduced expression vector (whole cell) 
Lane8: Induced expression vector (whole cell) 
Lane9: Final column elute, purified EscF. 
The tricine gel never detected the purified EscF using the anti EscF antibody and 
there were no differences observed between the Walla3 strain and the LEE4 deletion 
strain Walla3 LEE4< >sac /Kan. 
5.10.4 Anti EscF Antibody: Fluorescence Microscopy 
The anti EscF antibody was used in fluorescence microscopy to determine whether it 
could directly label EscF on bacterial cells. Fluorescence microscopy was carried out 
on the strains Walla3, Walla3 escU< >escUAL.C, Walla3 escU < >escU,.c..e tp, Walla3 
escU< >escLJ :. fi, +, Walla3 escRSTU< >sac /Kan Walla3 LEE4< >sac /Kan and Walla3 
escRSTU < >saclKan and using the PFA fixation technique. The anti EscF antibody 
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was the primary antibody with the Alexa Fluor 488 conjugate to anti -rabbit IgG the 
secondary. Eexamples of the images obtained are presented in Fig.95- Fig.98. 
Although the quality of the antibody staining varied, fluorescence microscopy using 
the anti EscF antibody on the Walla3 strain did produced discrete fluorescent foci on 
a subset of bacteria. When the antibody was used to stain the Walla3 
LEE4 < >sac /Kan strain the discrete foci were replaced with a more diffuse 
fluorescence that did not consistently repeat (Fig.95 panel D and F). The Walla3 
escRSTU< >sac /Kan strain appeared to have less staining with the anti EscF antibody, 
which occasionally produced faint foci and the Walla3 escU < >escUA strain had foci 
similar to Walla3 (Fig.96). Panels A -C (Fig.97) show the strain Walla3 
escU<>escUcc::egii, had brighter fluorescent foci than the wild type strain and rings of 
fluorescence (particularly noticeable in panel A). Finally in the strain Walla3 
escU < >escUcc :: ,+ (Fig.97, Panels D -F) there was an average increase of over 6 
times in the amount of fluorescence detected from individual bacterium when 
compared to the Walla3 strain. Only in Fig.97 panel F can foci be distinguished, the 
other panels contain bacteria where the level of fluorescence is too high to visualise 
individual foci. This is interesting as the strain Walla3 escU < >escUcc : :xfi+ had 3.2 
times more signal detected when using the anti EscF antibody in Western blot 
analysis when compared to the wild type strain (Fig.91). Fig.108 is the secondary 
antibody only, used as a negative control for the staining method. 
Although the microscopy images were variable it would appear that the antibody did 
bind to bacteria which had an escF deletion. The wild type strain produces 
fluorescent foci in a subset of bacteria. Although deleting the EscUcc peptide had 
little effect on staining with the anti EscF antibody the addition of eGFP to the 
EscUcc domain increases the amount of fluorescence detected, and the addition of 
GFP+ increases it further. This is unlikely to be due to the fluorescence from these 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The tagged strains provided the tools to investigate the function of the EscU protein 
in more detail. The work demonstrated that like its homologues in the Yersinia 
pseudotuberculosis T3SS and Salmonella Typhimurium flagellar system (Minamino, 
T., et al 2000, Lavander, M., et al 2002), the EscU protein in EHEC T3SS is most 
likely cleaved into a 10kDa and a 30kDa protein at the conserved cleavage site 
NPTH. For EscU it was unclear whether this cleavage played a role in the switching 
from secreting needle protein (EscF) to secreting filament protein (EspA). 
The REase recognition site added to the escU sequence was used in a cloning 
strategy that removed the C terminal region of EscU from the cleavage site NPTH. 
This was used to generate a strain that produced only a truncated EscU protein 
(ZAP633). Analysis of this strain and the previously created mutants demonstrated 
that all (apart from the strain Walla3 escU < >escUcc : :kr,+ [ZAP1142]) did not secrete 
EspD into the supernatant at detectable levels with Western blot analysis and the 
EspD secreted by Walla3 escU < >escUct: :,,+ was more than 4 times less when 
compared to the wild type level. The strains Walla3 escU < >escUAc , Walla3 
escU < >escUcc : :eR , and Walla3 escU<>escUcc:..gfp, also secreted no detectable Tir into 
their supernatant protein fractions. It was seen whether the substitution in the strain 
ZAP 1140 of escRSTU for the sac/Kan cassette and the deletion of EscUcc domain in 
the ZAP633 strain effected the transcription from the LEE1 -5 promoters. A negative 
feedback mechanism may have existed that stopped the transcription of the TTSS 
genes when the basal apparatus could not be formed. However, this was not the case 
as both the ZAP 1140 and ZAP633 strains had LEE promoter expressions that 
matched that of the Walla3 strain. 
The strains Walla3 escU < >escUoee, Walla3 escU < >escUcc. : :e¡,, Walla3 
escU < >escUcc : :x , +, Walla3 escRSTU < >sac /Kan and Walla3 escU < >escUc,,::HA had 
their secretion of EspD partially complemented after transformation with the pJRE02 
plasmid. Although it contains the sequence that was substituted for the sac/Kan 
cassette in the Walla3 escRSTU< >sac /Kan strain it does not carry a full LEE1 
promoter, which may explain the partial complementation. However, this result did 
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confirm that the strains were not secreting EspD due to the modifications made to 
this LEE1 sequence. 
The EscUcc peptide was artificially expressed from plasmids in the Walla3 
escU < >escLIA strain to determine whether EspD secretion could be restored. Two 
versions of the plasmid were constructed, one containing the EscUcc peptide N 
terminally labelled with the HA tag, enabling detection to confirm it was being 
translated. The other version was without the HA tag, in case the tag interfered with 
the function of the peptide. EscUcc::HA from the pJRE23 plasmid was expressed in all 
the strains but only detected in Walla3 escU < >escUoc c and Walla3 
escRSTU < >sac /Kan, where it was localised to the membrane fraction of the cell. 
This was interesting as it was assumed that the EscUcc peptide localised to the 
membrane via an interaction with the EscUcN domain after cleavage but the Walla3 
escRSTU< >sac /Kan strain contains no EscR, S, T or U. The peptide may still localise 
to the membrane via EscUcN, but in the absence of EscU it may be free to bind to 
another molecule which is also anchored to the membrane. The EscUcc::HA may have 
only been detected in strains not containing a chromosomal copy of the peptide 
because the peptide produced by this chromosomal EscU gene may interact at the 
membrane leaving EscUcc::HA to be denatured in the cytoplasm. 
The detection of EscUcc::HA in the Walla3 escU < >escUA strain enabled the secreted 
proteins from these samples to be tested for EspD secretion. The EspD Western blots 
showed that the peptide could not fully complement the Walla3 escU < >escUocc 
strain. The complementation may have failed because the whole EscU protein is 
needed for the secretion of EspD. In the EscU homologues cleavage is a timing 
mechanism and a switch to stop secreting hook proteins and start secreting filament 
proteins. If the cleavage of EscU has a similar function then not having the whole 
EscU protein present could lead to no EscF being secreted. It could be the case that 
without EscF then no EspD or EspA can be secreted through the T3SS as its 
assembly is not complete. 
210 
An anti EscJ antibody was used to detect EscJ in preparations of protein fractions 
from the mutant strains. It showed that EscJ was present in the mutant strains and 
localised to the membrane fraction. This means that EscJ is present in the right 
bacterial cell compartment for its TTSS function, which is not surprising as it is 
thought to be transported to the periplasm in a Sec -dependent manner (Gauthier, A., 
et al 2003b). It was known that all the strains, except Walla3 escU < >escUcc : :xfi+ , do 
not secrete EspD or EspA, but it was not known at what stage the TTSS process 
stops functioning. The presence of EscJ in the membrane fraction of the mutants 
could mean that the TTSS basal apparatus can form but the mechanism for secretion 
of EspD and EspA has been affected by the addition of the tags. If the Sec -dependent 
secreted proteins are present in the membrane then EscV, EscC and EscJ (Gauthier, 
A., et al 2003b) would be localised there as well as tagged EscU, which was shown 
to be present in the membrane fraction. The EscJ antibody was used with the Walla3 
strain to try and visualise the TTSS by fluorescence microscopy. The strain 148a 
containing no escJ was used as a negative control. Although the antibody yielded 
clean Western blots the fluorescence microscopy had non specific binding in the 
148a mutant, which appeared as discrete fluorescent foci. This meant it was not able 
to be used for fluorescence microscopy with the mutant strains. 
The anti EscF antibody was used to see whether the EscU mutants were effecting the 
secretion of EscF, the needle component of the TTSS. The initial Western blots were 
promising, showing an intense band at -10kDa that was resolved further in the 
supernatants of the strains to two bands, possibly a modified and unmodified EscF. 
The strain Walla3 escU< >escUcc : :Kt¡,+ showed a large increase in the secreted protein 
that was being detected. The Walla3 escU < >escU. : :sh,+ strain is also the only strain 
that has a detectable amount of EspD in the supernatant and has been shown to 
cleave the GFP+ from the C- terminus. This cleavage could produce a small number 
of functioning TTSS apparatus which are altered in their timing of switching 
between secreting EscF and secreting filament proteins, secreting EscF for longer. 
However, when a LEE4 substitution was made, replacing the LEE4 genes (including 
escF) for the sac/Kan cassette, Western blot analysis did not detect a difference 
between the LEE4 substitution strain (ZAP636) and the Walla3 wild type strain. The 
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Walla3 LEE4 < >sac /Kan strain was then used to absorb the antibody to reduce non 
specific binding, but this had little effect. Tricine gels were run which contained the 
wild type strain, the Walla3 LEE4< >sac /Kan strain and purified EscF, but no bands 
at the right size were detected. Fluorescence microscopy was also carried out with 
the anti EscF antibody; it showed discrete foci of fluorescence in the strains, which 
were present but more diffuse in the LEE4 substitution strain and not as bright in the 
Walla3 escRSTU<>saclKan strain. Interestingly the Walla3 escU < >escUcc::gt¡,+ strain 
had an average bacterial fluorescence that was over 6 times higher than the Walla3 
strain, with rings of fluorescence around the bacteria. This confirmed the Western 
blot analysis, which showed a higher amount of protein being detected in the 





6. General Discussion 
The project's objective was to label the basal apparatus of the T3SS of EHEC 
O157:H7 with variants of the fluorescent protein GFP or the immunogenic 
haemagglutinin (HA) tag. This was to create a tool to help answer questions 
concerning timing, regulation and location of T3SS proteins. The approach required 
the introduction of REase sites at the 3' end of the genes for predicted inner 
membrane proteins of the basal apparatus. The tag sequences were introduced using 
these sites. Allelic exchange was used to replace the wild type copy of the gene from 
the bacterial chromosome to avoid problems associated with artificial promoters, 
genetic context and fluorescent artefacts from over expression. 
The cloning strategy was designed, in detail, for six proteins; EscR, S, T, U, V and 
N, all predicted to be part of the inner membrane basal apparatus (apart from EscN, 
which is predicted to be associated with the inner membrane). The cloning was 
carried out for EscR and EscU and tags were introduced. EscR and EscU tags were 
used to create five derivatives of EHEC O157:H7 Walla3, two of which were strains 
containing EscU that had been labelled in a naturally occurring REase site before the 
predicted NPTH cleavage sequence (Table 7). 
Table 7. Table showing the different fusion proteins and the corresponding strain. 
Wild Type Protein Fusion Protein Strain Name 
EscU ESCUCC::eGFP ZAP1141 
EscU EscUcc::GFP+ ZAP1142 
EscU ESCUCN::HA ZAP634 
EscU ESCUCN::GFP+ ZAP635 
EscR EscR::HA ZAP637 
Despite the use of the expand long template PCR system (Roche, Burgess Hill, UK), 
which contains a high fidelity DNA polymerase, there were base pair changes added 
by PCR error that created substitution mutations in some of the genes. Strains with 
two substitutions had them at ORF3: V 107F and EscU: F167S, whilst strains with 
four substitutions had also acquired two at EscU: G235E and rORF3: T53A (Table 
8). 
214 
Table 8. Table showing which mutant strains contained two substitutions and which 
contained four. 
Strains with Two Strains with Four 
Substitutions Substitutions 
ZAP632 ZAP1141 




Even with these amino acid substitutions the complemented strain (ZAP632) was 
able to secrete EspD to wild type levels, indicating it contained a functioning T3SS. 
This meant the strains Walla3 escU < >escElAce, Walla3 escRSTU < >sac /Kan restored 
TTSS strain, Walla3 escU < >escUcn 
: :HA, Walla3 escU < >escU,...0)+ and Walla3 
escR < >escR:: HA contained unintentional amino acid substitutions that did not effect 
the ability of the T3SS to secrete EspD and so were taken forward for further 
analysis. For the strains Walla3 escU < >escUcc : :exfj, and Walla3 escU < >escL / .:sr¡,+ , 
that contained two additional sequence errors, the ability for the strains to secrete 
EspD with these substitutions was partly confirmed by the secretion of small levels 
of EspD after some of the GFP+ was cleaved from the EscUcc::GFP+ fusion. This 
demonstrated that the small amount of EscU that was now unlabelled, yet still in the 
background with all four substitutions, was able to form a functioning T3SS 
apparatus. However, it is acknowledged that to fully discount these substitutions as 
having an effect on the T3SS, a complement should be made containing all four PCR 
errors and screened for its ability to secrete EspD. 
Strains containing EscU labelled with variants of GFP were examined by 
fluorescence microscopy to detect the fusion protein. With an exposure time of one 
second and contrast manipulation on the OpenLab software (Improvision, Coventry, 
UK) foci were observed. However, these foci were also observed in the wild type 
Walla3 strain and the Walla3 escRSTU<>saclKan strain, so they were attributed to 
autofluorescence of proteins, detected because of the long exposure time and contrast 
enhancement. This result was disappointing as the GFP labelled EscU strains had 
higher population fluorescence than the Walla3 wild type strain. Unfortunately the 
relative fluorescence units (rfu) for the strains, measured on the Flurostar fluorimeter 
(FLUOstar Optima, Bath, UK), did not exceed 5000rfu at a gain of 1750. This level, 
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especially when compared to strains containing protein fusion of GFP on plasmids, is 
extremely low and may explain the inability to visualize the proteins directly. 
An attempt was made to increase the low level of fluorescence by increasing the 
expression from the LEE 1 promoter. This was done by transforming the strains with 
a plasmid containing either the positive regulator ler or grlA under an inducible 
promoter. This was unsuccessful and further analysis of Walla3 with and without the 
grlA plasmid showed little effect on the level of EspD secretion. This may be 
because the Walla3 LEE regulation network is at a maximum level of secretion and 
the addition of extra Ler or Gr1A cannot increase this further, or because high levels 
of Ler act as a negative regulator on LEE1 promoter expression (Berdichevsky, T., et 
al 2005). 
Western blot analysis was used to try and detect the HA tagged fusions of EscR and 
EscU with commercial anti HA antibodies from two separate companies. Only when 
high levels of protein were loaded, coupled with low stringency Western blot 
conditions, was the EscUcN : :HA fusion protein detected. The EscR::HA fusion was not 
detected in any of the Western blots. 
At this stage it was clear that the initial aims of the project could not be fulfilled as 
the tagged fusions were not detectable at the single cell level. This indicated that the 
amount of EscU and EscR in the basal apparatus is likely to be low and certainly 
insufficient for direct detection. Interestingly the work to this point had shown that 
all the strains containing tagged proteins (except strain Walla3 escU< >escU.::K,+ ) 
were unable to secrete detectable amounts of EspD. The inability to visualize the tags 
and their apparent disruption on the T3SS led to the decision to analyze the tagged 
proteins to determine the effect the presence of the tag was having on the function of 
EscU. 
It was also noted during Western blot analysis that the EscU protein appeared to be 
cleaved into two fragments, a -l0kDa peptide and a -30kDa peptide, both of which 
were independently localized to membrane fractions. Sequence alignments with the 
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previously studied homologues YscU and F1hB showed the presence of a conserved 
cleavage site (NPTH) in the EscU sequence. The cleavage of the YscU and F1hB 
homologues plays an important role in regulating the length of the needle and the 
secretion of hook proteins in the Yersinia T3SS and the flagellar system, 
respectively. 
A cloning strategy was used to delete the portion of the escU gene that encodes the 
10kDa cleaved peptide. This was allelic exchanged to replace the wild type escU 
sequence. This strain was added to the repertoire of mutants to be screened for their 
ability to secrete proteins via the T3SS. The strains were screened for the secretion of 
EspD and the effector protein Tir. None of the strains had detectable levels of Tir in 
the supernatants and only Walla3 escU < >escUcc : :¡,+ had a small amount of secreted 
EspD. This demonstrated that introducing the tags, at the C terminus of EscR and in 
EscU at either the C terminus or before the NPTH cleavage site, led to a T3SS that 
was not fully functional. This phenotype was also seen when the cleaved portion of 
the EscU protein (EscUcc) was deleted. The strains were unable to secrete T3SS 
proteins but were still localized to the membrane fraction of the cell. This may not be 
surprising with the GFP tagged proteins as GFP is 27kDa and may interfere with the 
function and interactions of EscU. Indeed it was shown that when GFP+ was fused to 
EscU before the NPTH cleavage site (strain Walla3 escU < >escUcn : ;gfn +) the fusion 
protein was cleaved at alternative sites, possibly due to conformational changes in 
the EscU protein. However, the HA tag at the same position in EscU was localized to 
the membrane at the correct size (without alternative cleavage), but this fusion 
protein was still not able to produce a functional T3SS. This implies that either the 
HA tag was located in a domain important in the formation of the basal apparatus or 
secretion of T3SS proteins or, despite its small size, it altered the conformation of 
EscU. All of the escU mutants (except strain Walla3 escU < >escUcn ::gi¡, +) were 
screened for the ability of the pJRE02 plasmid to complement EspD secretion. The 
plasmid contains the genes escRSTU and gave a small degree of complementation to 
the mutant strains, with some EspD detected in the supernatants. The low level of 
complementation could have been due to the lack of a full LEE1 promoter, however, 
their partial complementation added to the body of evidence that the observed 
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phenotypes were due to the sequence changes created by adding the tags to, or 
deleting portions of, the EscU protein. Attempts to clone the escU gene failed, 
possibly due to toxicity issues. This meant that complementing the mutants with only 
escU was not possible. 
All the mutants had EscJ present in the membrane at wild type levels. This indicated 
that the basal apparatus proteins that require Sec -dependent insertion into the inner 
membrane were present (EscJ, EscV and EscC in the presence of EscN (Gauthier, A., 
et al 2003b)). 
Plasmids containing the LEE promoters fused to egfp were transformed into the 
Walla3, Walla3 escRSTU < >sac /Kan and Walla3 escU< >escUA, strains. FLUOstar 
OPTIMA readings demonstrated that the level of expression from these promoters 
remained the same in the two mutant strains when compared to Walla3. However, 
the large amount of EspD seen in the Walla3 supernatant was not detected in the 
strains unable to secrete EspD. Because the expression from the LEE promoters was 
the same yet the total amount of EspD detected was different, it implied regulation at 
a posttranscriptional stage, if this is coupled with translocation (as previously 
described in Roe, A., et al 2003b) then the lack of a functioning T3SS basal 
apparatus (due to the interference caused by the tags) would explain the decrease in 
EspD translation. 
The deletion of the cleaved EscUcc portion and the strains inability to form a 
functioning T3SS demonstrated the need for the peptide for the secretion of EspD, 
Tir and the formation of EspA filaments. Supplying the peptide in trans did not 
complement the strain, indicating the whole EscU protein is needed. In the 
homologous flagellar system the F1hB protein is needed for secretion of rod and hook 
proteins and its cleavage acts as a timing mechanism that slows down rod and hook 
protein secretion, allowing F1hB to interact with FliK. This causes a conformational 
change in F1hB and increases its affinity for filament proteins (Moriya, N., et al 
2006). If this was the case for EscU then deleting the cleaved peptide would create a 
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strain that could not secrete of EscF. Without the formation of a needle structure the 
proteins EspD and Tir would not be translocated. 
When the deleted EscUcc 10kDa peptide was supplied in trans it was only detected 
in strains where the peptide had been deleted from the chromosome (Walla3 
escU< >escUA, and Walla3 escRSTU < >sac /Kan) and it was only detectable in the 
membrane fractions. This may be because in strains like Walla3 escU< >escUcc::e811, , 
where an eGFP labelled version of the EscUcc peptide was produced from the 
chromosome and localized to the membrane, the plasmid copy of the peptide could 
not interact at the membrane and was degraded. The peptide's localization to the 
membrane in the Walla3 escRSTU< >sac /Kan strain was unexpected; this would 
indicate that the peptide does not localize to the membrane by interacting with the 
EscUcN domain of EscU or can localize to the membrane in the absence of EscU by 
another interaction that would not normally occur (possibly an interaction of lower 
affinity). 
To see whether the EscU mutant strains effected the level of EscF export (the 
predicted needle protein) an anti EscF antibody was obtained from Prof. Abe (Osaka, 
Japan). This was a published anti EscF antibody used to detect levels of EscF in 
Western blot analysis (Ando, H., et al 2007). Preparations of cytoplasmic, membrane 
and supernatant proteins were made and tested with the antibody. At first the results 
were encouraging but a mutant strain with an escF deletion was needed to check the 
antibodies specificity. After the creation of this mutant it became clear that the initial 
enthusiasm for the specificity of the antibody was misplaced as little difference in the 
Western blot banding pattern was seen between the wild type and the mutant. 
Interestingly the strain Walla3 escU < >escUcc ::xt¡,+ had a higher intensity band in 
Western blot analysis and a higher level of fluorescence when using the anti EscF 
antibody in fluorescence microscopy. If this published anti EscF antibody was 
detecting EscF then it was also detecting another small protein(s) that masked the 
difference in the level of EscF in the supernatants. It is possible that this masking of 
EscF was overcome in the Walla3 escU < >escUcc ::xin+ strain because the tagged 
EscUcc caused the EscU protein to function incorrectly; over secreting EscF and not 
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switching properly to the secretion of EspA filament proteins. This may have been 
observed in the GFP+ fusion and not in the eGFP fusion because of sequence 
differences between the two proteins. It may also have been due to the cleavage of 
GFP+ from some of the EscU molecules, creating a small number of functioning 
T3SS, which secreted increased amounts of EscF. 
Two models exist for the role of F1iK in substrate -specificity switching in the 
flagellar secretion system: a measuring -cup model and a tape- measure model (Ferris, 
H., et al 2006). In the measuring -cup model the F1iK molecule cannot interact with 
F1hB (the EscU homologue) and switch substrate -specificity because the flagellar C- 
ring is blocked by hook protein. It is only when this hook protein has been exported 
that the FliK molecule can interact with FlhB. In the tape- measure theory the F1iK is 
exported through the growing flagellar hook until the hook reaches the correct size to 
allow the C terminus of F1iK to interact with FlhB and the N terminus to interact 
with the tip of the growing hook (Ferris, H., et al 2006). It is likely that a 
combination of these two models, along with the cleavage of FlhB acting as a 
molecular clock (Moriya, N., et al 2006), exist to ensure correct rod /hook secretion 
and substrate -specificity switching. If EscU in the EHEC T3SS has a similar role, 
then having a few functioning T3SSs in the strain Walla3 escU < >escU,.c :.vi,+ could 
overflow the `molecular -cup', not allowing the a homologous, yet still unknown, 
molecular ruler (FliK in flagellar system) access to the needle at the correct time, 
missing the period when the ruler is able to interact with the growing tip of the 
needle and the C terminus of EscU. Another possibility is that the GFP+ cleaved 
from a few EscU molecules allows EscU cleavage to happen but leaves an altered 
peptide that, although present in lower levels, results in the hyper secretion of EscF 
or GFP+ cleavage leaves EscU altered in the time it takes for EscU cleavage to 
occur, resulting in EscF hyper secretion. 
It is clear that tagging the T3SS basal apparatus protein EscU interferes with the 
secretion of EspA, EspD and Tir. Using the experimental data from the project 
models can be created detailing the different mechanisms that may exist in the wild 
type strain and the effect of the EscU mutants on the function of EscU. 
220 
6.1 What Function does EscU Have in the Wild Type Strain? 
From research into the function of the homologous proteins, the role of EscU in 
EHEC can be extrapolated into models where the cleavage of EscU is a timing 
mechanism involved in the switching between EscF and EspA secretion. Uncleaved 
EscU could bind EscF and secrete it through the basal apparatus. EscF has been 
shown to interact with EscJ, EscD and EscC (Ogino, T., et al 2006) and may 
contribute to the inner rod (shown in the diagram as being composed of EscD) as 
well as forming the needle structure. Possibly, its interaction with these proteins 
mediates its passage through the T3SS pore, to the needle where it polymerises. It 
could be that the first few molecules of EscF could interact with EscC, EscJ and 
EscD to stabilize the inner rod, with the subsequent molecules passing through the 
basal apparatus to the needle where they polymerise and extend. This is the simplest 
of models for EscF secretion, involving no chaperone for EscF or interaction with 
molecules such as SepL or SepD that mediate the hierarchy of secretion. It is 
unlikely that EscF does not have a chaperone as it would polymerise within the 
bacterial cell or be degraded. 
In the second model (Fig.99) the EscF interacts with SepL and SepD (Fig.99, A) and 
then it is translocated (Fig.99, B). A recent hypothesis for the role of SepL and SepD 
is that they function as a gate at the T3SS. This gate initially allows translocator but 
not effector proteins to be secreted. Then the completion of the translocon is 
signalled (possibly by a drop in calcium levels) and the SepL -SepD complex 
dissociates or changes to allow effector proteins through (Deng, W., et al 2005). The 
SepL -SepD complex may be associated with the C terminus of EscU and EscF is 
brought to them via a chaperone. It is interesting to speculate that SepL and SepD 
may play a role in the secretion of EscF as a sepD or a sepL deletion does not secrete 
translocon proteins, indicating they are involved at this stage of secretion or the next 
(EspA secretion). 
After EscF has been secreted and the needle has reached the required length, EscF 
secretion stops and EspA is secreted. In Fig.100, A, the needle length is measured by 
a protein homologous to the YscP protein in Yersinia (possibly Orf16 from the LEE). 
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This protein translocates through the T3SS and interacts with the tip of the needle. 
When the needle is of the correct size the interaction at the tip of the needle will 
place the C terminus of Orf 16 (YscP homologue) in close enough proximity to 
interact with the EscUc domain, promoting cleavage of EscUc and a change in 
substrate -specificity. After this cleavage has occurred the Orf16 protein leaves the 
T3SS (Fig.100, B). The cleaved portion remains at the basal apparatus interacting 
with the ESCUCN peptide and allows the secretion of translocon proteins to proceed. 
The secretion of EspA may be linked to SepL and SepD, although no work to date 
has shown a direct interaction with SepL -SepD and EspA. However, the SepL -SepD 
complex could interact with espADB mRNA, in the presence of a ribosome (Fig.l00, 
C). 
Alternatively the cleavage of EscU may happen auto -catalytically, after a set period 
of time, acting as a timing mechanism. This is independent of a molecular ruler 
molecule such as Orf16 /YscP (Fig.101, A and B). The cleavage alters the substrate - 
specificity and allows the secretion of EspA via SepD and SepL in a coupled 
translation and translocation step (Fig.101, C and D). Of course a combination of 
both models could be possible, the cleavage of EscU could slow down the secretion 
of the needle proteins giving a molecular ruler time to enter the T3SS and measure 
the needle. When the needle is of the correct length the molecular ruler interacts with 
the already cleaved EscU molecule and alters its substrate- specificity, increasing its 













































































































































































































































































































































































































































































































































































































































































































































The next step in T3S is the secretion of effector proteins. From unpublished work in 
our laboratory, SepL was shown to directly bind Tir, independent of its binding to 
SepD and that Tir could potentially be displaced from SepL by EscD. This means 
that SepL, whilst required for the secretion of EspA, B and D, is also potentially 
holding back Tir secretion at this stage. LEE4 and LEES seem to be expressed at the 
same time (Roe, A., et al 2004) in the same cells and this mechanism may exists to 
stop Tir secretion before the secretion of EspA, B and D. Following a drop in 
calcium levels, once a conduit has opened with the host cell (Deng, W., et al 2005) 
the SepL -SepD complex may dissociate and release Tir for secretion. If SepL can 
bind Tir with its chaperone CesT then all the effector proteins relying on CesT as a 
chaperone for export will not be secreted until the SepL -SepD complex dissociates. 
6.2 What is the Effect of Tagging EscU? 
It is hard to understand what is happening in the mutant strains without an accurate 
measure of EscF. It is clear that tags, which remain attached to the C terminus of 
EscU protein, even after cleavage at NPTH, are localised to the membrane. Even so 
strains containing these fusions do not secrete EspA, EspB, EspD and Tir. Possible 
explanations for this include: 
1) The tags do not allow the correct assembly of the T3SS, auto -catalytic 
cleavage still occurs but no proteins are secreted. However, proteins that are 
inserted into the membrane in a Sec -dependent, T3SS independent, manner 
will be present in the membrane. These include EscV in the inner membrane 
and EscC in the periplasm. It has also been demonstrated that EscJ and EscU 
are localised to the membrane in the tagged mutants. In the presence of EscN 
the EscC molecules can be inserted into the outer membrane. This would 
indicate that EscN, EscV, EscJ, EscC and EscU are all localized correctly 
implying that the basal apparatus is formed. The presence of some secretion 
in the GFP+ tagged strain (Walla3 escU < >escU,c ::Xh, +) adds evidence to this 
assumption 
2) The tags are interfering with the function of EscU in the secretion of EscF. 
Conformational changes in EscU from the addition of the tag do not allow 
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EscF to be secreted. If EscF is not secreted then the substrate -specificity of 
EscU cannot be changed, so EscU does not interact with filament proteins 
and the SepL -SepD complex. 
3) EscF is secreted onto the cell surface but cleavage of EscU does not happen 
normally, either earlier or later, and the resulting strain cannot interact with 
the molecular ruler to increase its affinity for filament proteins. 
4) EscF is secreted onto the cell surface and cleavage happens normally, but the 
presence of the tags interferes with the ability of EscU to interact with 
filament proteins and the SepL -SepD complex. 
It is apparent that a number of check points exist for the T3SS and multiple protein 
interactions occur with varying and changeable affinities to control sequential 
secretion. The T3SS has evolved to be tightly regulated and timed so that the basal 
apparatus are in place before the needle is formed, then the filament proteins secreted 
followed by the effector proteins. Proteins that regulate expression, chaperones, 
gating proteins and calcium signals all aid to form the T3SS in logical steps. It is not 
surprising that EscU may function as a switch and timing mechanism in this process, 
as it is important for the bacteria to form the complete T3SS in a precise manner at 
the right time and correct place. 
This project was unsuccessful in realising its initial aims. Instead it went on to 
demonstrate that the amount of EscR and EscU in the basal apparatus of the T3SS is 
too low to make GFP +, eGFP and HA fusions a viable approach for microscopy or 
single cell work. It also highlighted the fact that even a nine amino acid addition into 
one of these proteins is enough to disrupt function. This may not be an unexpected 
result when considering how conserved the basal apparatus genes are amongst T3SSs 
in Gram negative bacteria. The project evolved to look at the tagged strains 
containing escU mutants, which has interesting homologues in the flagellar system 
and Yersinia T3SS. However, even this analysis was rife with problems including 
antibody specificity and complementation issues. The results can be interpreted to 
form models where EscU may act in a similar manner to its homologues but more 
work is needed to validate its role. 
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6.3 Future Work 
The work with EscU and its role in the secretion of EscF inspires most of the future 
work for this project and is ongoing in the ZAP lab. 
The anti EscF antibody did not function as hoped, even after attempts to absorb it 
against the escF deletion. Although previous published attempts to make anti EscF 
antibodies have failed (Wilson, R., et al 2001); it remains an avenue to consider as a 
good anti EscF antibody would be invaluable to this work. A His tag fusion to EscF 
has been created in the ZAP laboratory, with the intention to use it for the production 
of antibodies. Also an anti EscF antibody, published by Cook, S., et al 2007, will 
hopefully be acquired for use in the ZAP laboratory. The antibody will be used to see 
whether tagging EscU or EscU deletions have an effect on the amount of EscF 
secreted into the supernatant. It would be good to verify that the increase seen in 
Walla3 escU < >escU(.(. ::gib,+ is EscF. If the protein is not EscF it would be interesting 
to find out what protein has been effected so dramatically. It may be possible to 
MALDI -TOF the band from an SDS PAGE gel to identify the protein, or run 
samples on two dimensional SDS PAGE gels to better clarify its mass and pI. 
Obviously the antibodies, if successful will be used for microscopy. This would give 
an insight into whether the formation of the EscF needle is phase variable, only 
happening in a subset of bacteria, or whether all the bacteria, in T3SS permissive 
conditions, contain EscF needles. 
Unfortunately, research in our laboratory (by Mr. Dai Wang) has shown that when 
EscF is fused to a His tag and artificially expressed it cannot be detected. The EscF 
fusion was not detected in the cytoplasm or the supernatant of strains with the 
plasmid, indicating the mRNA was unstable and not translated. Fusions to bla were 
also created with an identical outcome. If a plasmid fusion to EscF could be 
constructed and the protein detected, it could be expressed in the wild type strain to 
see if there is an increase in secretion of EscF from the cell. It would be interesting to 
see whether increasing the amount of EscF in the cell has the same phenotype as 
secreting wild type levels of EscF through fewer T3SS (as may be the case for 
Walla3 escU < >escU. :gib, +). This would help determine whether there is a timing 
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mechanism that stops EscF secretion no matter how much EscF is in the bacterial 
cell, or whether the controls for the EscF secretion can be by- passed with increased 
cellular EscF. If EscF continues to be secreted from a wild type strain with an EscF 
plasmid and no switching occurs to filament proteins then it may indicate that EscF 
is secreted until the `pool' of EscF runs out. However, in the strain Walla3 
escU < >escUcc::,+ the `pool' of EscF is the same as in the wild type, yet EscF 
secretion is higher, indicating a more complex mechanism than this. 
Our laboratory's inability to create an EscF plasmid fusion that works may indicate 
the need for a single copy approach; however, personal communication with Prof. 
Gad Frankel's group in Imperial College, London indicated that tagging EscF 
disrupts its ability to polymerise and form the needle structure. This may not be 
surprising, given the effect of the HA tag on EscU, combined with the small size of 
EscF. This needs to be kept in mind when manipulating the gene and stresses the 
need for a working antibody. 
If the Walla3 escU < >escU....gfi,+ strain is secreting more EscF, forming longer 
needles and secreting some EspA/DB, then it could be possible to stain the 
ZAP1142 strain with anti EspA antibody (Crepin, V., et al 2005) and use gold 
conjugated secondary antibody for electron microscopy. If there were T3SSs with 
long needles and small filaments the T3SS could be detected by the EspA antibody 
and the needle distinguished from the filament by the lack of gold labelling. 
However, if the strain produced long needles without EspA filaments then the 
needles would still have to be identified as T3SS associated, which would be difficult 
with the current antibodies available. Alternatively the method for basal apparatus 
preparations (Ogino, T et al 2006) could be used to isolate the basal apparatus and 
compare needle length with electron microscopy. 
Creating defined EscF mutants that polymerised slower than wild type EscF and 
exchanging the genes for these mutants onto the chromosome, replacing the wild 
type sequence, could help answer questions about the timing mechanism of EscF 
secretion. If EscU cleavage acts as a molecular clock then the slower polymerising 
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EscF would lead to shorter needles, a phenotype that may be overcome by over 
expressing the mutant EscF from a plasmid. 
Fusions to escU could be created on a plasmid and the autoradiogram method 
(described in Minamino, T., et al 2000) used to see if the fusions effect the timing of 
the cleavage, a possible explanation for the potential increase in the amount of EscF 
secreted in Walla3 escU < >escUcc::gfi+ . This method requires making the fusion gene 
on a plasmid under an inducible promoter and expressing it in the presence of 
radioactively labelled amino acids for a set length of time. Determining what 
proportion of the protein is in the uncleaved form compared to the cleaved form 
indicates the time it takes for the protein to undergo cleavage. 
His tag protein column purification experiments could be carried out with the 
cleaved peptide EscUcc, running whole cell preparations of the Walla3 strain, the 
Walla3 escU < >escUAcc strain (without the EscUcc peptide) and the Walla3 
escRSTU < >sac /Kan strain through the column. The proteins eluted from the column 
that interact with the EscUcc peptide could help explain its observed membrane 
localisation. SepD and SepL localize to the membrane independent of escRSTU 
(work carried out by Mr. Dai Wang). It could be the case that SepD and SepL 
mediate EspA secretion in conjunction with EscU by interacting with the EscUcc 
peptide and in the absence of the EscU molecule the EscUcc peptide is localised to 
the membrane by an interaction with SepD and SepL. The co- purification 
experiments, in the absence of the genes escRSTU, may shed light on the process of 
the EscU switching from EscF to EspA secretion by identifying other proteins the 
EscUcc domain is capable of interacting with. 
As mentioned in the introduction, the LEE encoded gene orfl6 may be the EHEC 
0157:H7 homologue to YscP and FliK (the molecular rulers that interact with YscU 
and FlhB, respectively) (Pallen, M., et al 2005). If this was the case then the Orf16 
protein would be expected to interact with EscF and EscU. It would be interesting to 
see whether the Orf16 protein is expressed and where it localizes during T3S. Orf16 
could also be used in His tag protein column purifications to see what proteins co- 
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purify with the His tagged Orf16. If Orf16 is a molecular ruler then can it be 
lengthened to created longer needles in EHEC? This was carried out with great 
success in Yersinia T3SS, proving a direct link between YscP length and the length 
of the needle (Journet, L., et al 2003). It would be assumed that an orfl6 deletion 
would not secrete EspA and carry on secreting EscF, if it acted as a molecular ruler, 
as there would be no mechanism for substrate -specificity switching. Deleting orf16 
and characterising the mutant phenotype, especially if an anti EscF antibody was 
available, would be an interesting experiment to carry out to determine its role in 
needle length. 
The literature for F1hB and YscU contain numerous examples of defined mutants that 
helped clarify FlhB and YscU as molecular timers and switches in secretion (see 
section 1.3.5.9). This literature could be used to create similar mutants in EscU and 
observe the effect these have on EscF secretion and needle formation, once a 
measure for EscF secretion has been devised. Some of the most interesting mutants 
used in YscU work substituted amino acids in the NPTH cleavage site and altered the 
proteins ability to cleave (Lavander, M., et al 2002). 
It is possible that other tags could be used to label the basal apparatus, or alternative 
positions found to place the tags. For example, an HA tag fused to the C terminus of 
the EscU protein may be able to secrete, as a similar plasmid construct in Yersinia 
was able to exert an effect on the Yersinia T3SS (Lavander, M., et al 2002). Other 
tags that exist include a tag that binds specifically to a CC -XX -CC motif in a protein 
(where C is a cysteine and X is any amino acid) (Selvin, P., 2002) and the Flash and 
ReAsh tagging method (Lebrasseur, N., et al 2002). However, the results from this 
project indicate that all tags added to the basal apparatus would interfere with T3S. 
Possibly a more productive route would be using the basal apparatus proteins, or 
parts of them, to create antibodies. A good repertoire of antibodies raised against 
soluble fractions or small peptides from the basal apparatus proteins may lead to a 
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ABSTRACT 
s work we describe protocols for the generation of gene deletions and gene replacements using a temperature 
live plasmid in Escherichia coli 0157:H7. This technology requires flanking DNA to be cloned into a temperature 
ive vector but the resulting clone allows great flexibility for further modification of the target sequence. It is 
lore highly suited to the study of genes in which several rounds of changes are envisaged. A number of examples 
,ed to illustrate the flexibility of the system which has been used to create novel gene replacements including 
is for protein localisation work and reporters for transcriptional analyses. In this paper we describe protocols 
scan be used with a high degree of success when applied to E. coli 0157. The deletion and replacement of the 
operon of E. coli 0157 is detailed to show the advantages and limitations of the technology. 
INTRODUCTION 
ability to generate directed gene deletions and 
replacements is a central technique used to 
?nstrate gene function and fulfil Molecular Koch's 
lates in any study (1). The past two decades have 
the development of a variety of molecular 
vques to achieve such chromosomal modifications 
coli K -12, including F' homogenotization, the 
lion and resolution of ColE1 plasmid cointegrates 
solAl background, transformation and mating via 
tir cross, and the use of temperature sensitive 
As with selection for homologous recombination 
.More recently, the phage a, red recombinase has 
successfully applied to allow rapid, one step 
ivation of genes (4). However, these techniques 
Adler from the requirement of specific genetic 
founds (often mutants themselves), and are 
ed for efficient use in E. coli K -12 laboratory 
The application of these techniques to "wild - 
strains including pathotypes of E. coli is, 
'ore, often problematic. Furthermore, using 
vrature sensitive plasmids provides a number of 
ivantages compared with other methods. Firstly, 
although lambda red is probably the most rapid system 
for inactivation of genes it does suffer from the fact that 
transient expression of the recombinase system enhances 
the frequency of unwanted genetic rearrangements. 
Secondly, the lambda red approach is also highly suited to 
creation of gene deletions, delivery of gene replacements, 
as we describe for the temperature sensitive based system, 
is less straightforward. Additionally, as the temperature 
sensitive allelic exchange system does not rely on any 
conjugation step, for example when using lambda Pir- 
dependent iroR6K plasmids, strains that produce 
bacteriocins or capsule can also be successfully modified. 
In the case of E. coli 0157, the complete genome 
sequencing of two strains has revealed an additional 
1.4MB of DNA when compared with the E. coli K -12 
genome (5). These sequences include numerous putative 
adhesin clusters, the complete LEE pathogenicity island, 
shiga -like toxins encoded on prophages and other 
putative virulence factors (6). Genetic manipulation of E. 
coli 0157 to selectively disrupt these factors is therefore 
highly desirable. Two approaches have been widely 
adopted to achieve this goal: a modified lambda red 
protocol and the use of temperature sensitive plasmids 
by the author(s). This paper is Open Access and is published in Biological Procedures Online under license from the author(s). Copying, 
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and selection for allelic exchange (7, 8). Here we 
describe a modified protocol for use with temperature 
sensitive plasmids. This protocol reliably yields allelic 
exchange constructs, works well to replace large DNA 
fragments (we have deleted /modified up to 7KB), and 
gives excellent flexibility for further modifications. This 
flexibility is demonstrated by our use of the system to: 
1) knockout a specific operon and then complement the 
knockout by allelic exchange back at the site of 
deletion. 2) Engineer whole gene or sequence deletions. 
3) Introduce marker genes for single copy reporter 
fusions. 4) Introduce specific tags to track or visualise 
the resultant recombinant proteins. 
OUTLINE OF ALLELIC EXCHANGE 
METHODOLOGY 
In this paper we describe a modified allelic exchange 
method that allows the exchange of genetic information 
into a wild -type E. coli strain background. Firstly an 
intermediate strain is constructed in which the wild - 
type chromosomal sequence is replaced by a DNA 
cassette. This sacB -kan cassette contains the sacB gene 
from Bacillus subtilis and the neomycin (kanamycin) 
gene from TnS. The method has two distinct rounds of 
allelic exchange. The sacB -kan cassette is cloned into a 
temperature sensitive chloramphenicol resistant 
plasmid in between homologous flanking regions of 
DNA. This is used in the first round of allelic exchange 
to create an intermediate strain containing the cassette 
on the chromosome in replace of wild -type sequence 
(Fig. 1). The selection for plasmid integration occurs at 
42 °C in the presence of chloramphenicol while plasmid 
excision occurs at 28 °C in the presence of kanamycin. 
In the second round of allelic exchange, for example to 
create a complete deletion, the temperature sensitive 
plasmid containing only the homologues flanking 
regions is used (Fig. 2). Alternatively DNA cloned in 
between the flanking regions can be exchanged onto 
the chromosome e.g. to complement the mutant or to 
introduce different alleles. During this allelic exchange 
the plasmid is transformed into the intermediate strain. 
Growth at 42 °C in chloramphenicol selects for plasmid 
integration, whilst growth at 28 °C in the presence of 
sucrose selects for bacteria in which the inserted 
cassette has been exchanged for the target sequence 
and then the plasmid lost through lack of selective 
pressure. The selective pressure results from the action 
Emmerson et al. - Generation of gene deletions and gene replacements 
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of the sacB gene that encodes levansucrase, an enzyme 
! 
that cleaves sucrose resulting in toxic levels of levans inl 
many E. coli strains. 
MATERIALS AND METHODS keyreag( 
id pIB: 
ed from 











The allelic exchange method was used to delete and then'modifiec 
repair the entire LEE4 operon from E. coli 0157:H7 voter (to 
(ZAP198), generating strains ZAP984 and ZAP985, 'ap19 as 
respectively. A step by step protocol for the allelic majority 
exchange procedure is listed under the protocols section ease the 
of this work. These methods were used to create ZAP984 mosomal 
(ALEE4), using plasmid pHY10 and the complemented 
strain, ZAP985, using plasmid pAJR162. The detailed Tanking 
construction of these plasmids and strains including 1000óp c 
oligonucleotide sequences are covered in Naylor et al., sizes 
2005 (9). In this work, we aim to provide an overview of eise the 
the steps involved in the cloning, the allelic exchange '1ng regi 
methodology and our experience with the technology. og regi 
le cross( 
RESULTS AND DISCUSSION cexchan 
ing regi 




The allelic exchange method has been used for a number 
of studies in which defined deletions or gene 
replacements were made. In this paper, the deletion and 
complementation of the LEE4 operon of Escherichia col. 
0157 is used as a specific example to illustrate the 
technique. A number of further examples are used to 




Factors affecting co- integrate formation 
cork bu 
Two key factors play a role in determining the frequency ankin 
of co- integrate formation: 1) degree of DNA homology l 
y 
ied an 
and 2) size of the flanking regions. We have observed a 
ed an' 
dramatic reduction in efficiency of primary integrate 
formation with even a few base pair mismatched between 
betwe 
flanking region DNA and target region on the 
.chop sits 
chromosome. This is a drawback as sometimes it results in 1pnent 
the requirement of cloning specific flanking regions for 
creati 
each strain being studied. For example, we have used an 
vantage 
allelic exchange system at the lac locus in several wild- 
low sub; 
type 0157:H7 strains that created a number of promoter was a 
lacZ fusions (8). However, we observed extremely low 07 to 
In Escherichla coil 0157 :H7 using a temperature sensitive allelic exchange 
et at. 
@calprc 
nzymOencies of allelic exchange when plasmids were 
ans in with any strain other than the one from which the 
fling regions were cloned. 
key reagent we use for the knockout strategy is the 
mid pIB307. The replicon from this plasmid is 
Lumber sed from the large antibiotic resistance plasmid R6- 
gene i). This replicon and a tetracycline resistance gene 
on and manipulated to form a smaller plasmid termed 
hia coli :101. pSC101 has undergone in vitro mutagenesis 
ate the 
i hydroxylamine, creating distinct mutants that 
ised to d in their temperature dependent replication (11). 
L other 
ie induded pH01, a pSC101 replicon mutant that 
unable to replicate at 42 °C but could replicate 
vented 
pally at 28 °C. The replicon from pH01 was 
wed and ligated to the chloramphenicol resistance 
from pBR325. The resulting plasmid, pMAK705, 
-id then' modified by the addition of the lacZ gene and its 
)157:H7 voter (to facilitate screening) and the polylinker 
'AP985, mp19 as a multiple cloning site (12). At a later date 
alleliclmajority of the lac sequences were removed to 
sectionase the plasmid's size and homology with 
ZAP984 mosomal DNA, thereby creating pIB307 (13). 
mented 
detaileding regions we routinely use between 600óp 
eluding 1000óp of DNA, and find it is important to have 
r et al., ir sizes of left and right hand flanking regions to 
view of'sise the efficiency of exchange. Grossly differing 
xchange'. Ilg regions will favour recombination at one 
hing region thereby reducing frequency of the 
le crossover event that is required for successful 
cexchange. The deletion of LEE4 used a left hand 
' g region of 958 bp and a right hand flanking 
of 610 bp. Smaller flanking regions (200 -300óp) 
work but will reduce the efficiency of exchange. 
equency 
,flanking region for the LEE4 knockout was PCR 
mology 
ified and cloned into the temperature sensitive 
served a 
ntegrate 
. pIB307 creating pHY3. A sacB -kan cassette was 
between 
between the flanking regions at the BamHI 
on the 
`,ion site to create plasmid pHY10 (8). Again, the 
esults in'ement of cloning three separate DNA fragments 
ions for ' creation of the allelic exchange vector is a 
used an . antage compared with the lambda red approach. 
ral wild- ,ow subsequent 'repair' of any deletion, the LEE4 
romoter- }n was amplified by long -range PCR and cloned 
rely 
)gy. 
low 1307 to create construct pAJR162. 
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An alternative method is to amplify the whole region 
including the flanking regions and the gene(s) to be 
deleted using long -range PCR. This can be cloned into the 
pIB307 vector and restricted by endonucleases at naturally 
occurring restriction sites to replace the gene(s) to be 
deleted with the sacB -kan cassette. This plasmid can then 
be used in the allelic exchange process. 
Optimising conditions for generation of large deletions 
For large deletions of several kilobases or problematic 
deletions we have found that increasing the temperature 
from 42 °C to 44 °C will aid the selection of primary 
integrates. Furthermore, we also find it useful to plate out 
dilutions of the primary integrates on LBC plates at 44 °C, 
enabling single colonies to be analysed for the primary 
integration event by PCR. This "primary positive" colony 
can then be cultured at the lower, permissive temperature 
of 28 °C to allow the generation of resolution products. 
This approach is particularly useful if any construct 
results in low levels of primary integrates at 42 °C, often 
indicated by a subsequent failure to culture at 28 °C. 
Location of the sacB gene 
The sacB gene offers a powerful tool for the selection of 
allelic exchange events that do not occur frequently. The 
stage at which the sacB gene carries out this function in 
the allelic exchange strategy can vary depending on its 
location on the exchange plasmid. For the creation of the 
LEE4 deletion strain the exchange plasmid contained the 
sacB gene as part of a cassette that was situated in between 
the homologous flanking regions. For the 
complementation of LEE4 the sacB gene was used to select 
for bacteria that had lost the sacB -kan cassette from the 
chromosome after it was used to replace the genetic 
material, i.e. on the second round of allelic exchange. If 
the sacB gene is located outwith the homologous flanking 
regions then it can be used as a negative selective marker 
for the loss of the plasmid during the first round of allelic 
exchange. The colonies that do not contain the sacB gene 
successfully grow in the presence of sucrose and can then 
be screened for the correct resistance profiles (if any) and 
verified by PCR. In one study the sacB gene was situated 
on the allelic exchange plasmid outside the flanking 
regions. In between the flanking regions was a cassette 
that replaced the genetic material of interest for a genetic 
element containing lacZ, the aph gene (encoding resistance 
In Escherichla coli 0157:H7 using a temperature sensitive allelic exchange 
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to kanamycin) and the lac promoter. This cassette was 
flanked by FRT sites, so it could be excised from the 
chromosome by the Flp recombinase provided in trans, 
creating a clean deletion (14). 
Exchange frequencies 
During the first round of allelic exchange when the 
sacB -kan cassette is inserted into the chromosome, we 
have found that >80% of colonies plated on LBC after 
48 hours selection are primary integrants suitable for 
resolution (ascertained by PCR). Following culture at 
28 °C, the success of the allelic exchange can vary 
widely, from 5 -90 %. Therefore, we typically replica 
plate about 100 colonies and expect to find a successful 
exchange clone. The removal of the sacB -kan cassette 
during the second round of exchange has a higher 
frequency of success due to the negative selective 
screening offered by the sacB gene. 
Construct validation 
Following the allelic exchange process and, assuming a 
clone has been obtained with the correct antibiotic 
resistance profile; two key checks should be carried out 
on any construct. Firstly, the loss of the plasmid is 
verified using PCR primers designed to amplify the pIB 
plasmid (Table 1). Secondly, the region that has been 
exchanged is PCR amplified (usually in 2 or more 
sections) including DNA that is outside the flanking 
region, i.e. was unmodified during the exchange 
process. This shows that the allelic exchange is indeed 
at the target site and that the cloned DNA does not 
contain any sequence errors. 
Table 1: Strains and oligonucleotide primers used in 
the study. 
Strains Description 
ZAP198 E. coli 0157:H7 (Walla3) VT1 -VT2- 
ZAP984 ZAP198 0 LEE4 
ZAP985 ZAP784 LEE4 complement 
Primers Primer Sequence 
PIB sp.5 AGACAAATGGATCTCGTAAGCG 
PIB sp.3 GCTGTAACAAGTTGTCTCAGGTGT 
Plasmids Description 
pfB307 pMAK705 based plasmid for allelic 
exchange. Temperature sensitive replicon. 
pAJR162 pIB307 vector with cloned LEE4 
Emmerson et al. - Generation of gene deletions and gene replacements 
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APPLICATION OF THE METHOD have n 
ate chrc 
Examination of EspD secretion phenotype in wild -type, jsecretic 
deletion and complemented strainsies we 
gated 
The ability of strains to secrete EspD protein in the wild- educe 
type, and LEE4 deletion strain (ZAP984) and the 
complement (ZAP985) was confirmed by Western iotial l 
analysis. As expected, deletion of LEE4, the operon that 
encodes EspD, leads to a loss of secretion phenotype. lur ex 
Complementation of the deletion mutant by allelic ' the 
exchange using the LEE4 operon resulted in restoration of ,mid 
the secretion phenotype. Clearly, complementation using perati 
plasmids is far easier than the approach described. all ini 
However, the approach has a number of limitations, :cultua 
including plasmid stability and copy number. We peratu 
subsequently used the LEE4 deletion strain and ' the 
complement to assess the importance of this operon ranter( 
during colonization of the terminal rectum of cattle (9). ser d 
The LEE4 complement strain was capable of adhering to 
d reac 
bovine epithelium in vitro and colonising the terminal aid is 
rectum of cattle, indicating that the type III secretion tit is 
system plays a key role in the animal host. In such an llems. 
animal model, plasmid selection using antibiotics is not npted 
always possible and many studies therefore avoid initial 
performing any form of complementation. We consider and 
that single -copy chromosomal complementation is more s) V 
desirable, as it can replace the region of interest into its aique 
original site thereby fulfilling molecular Koch's postulates 'ipulat 
opatl 
C) an 
Further applications say 1 
Carr 
We are currently using the described allelic exchange bed 
system to deliver a number of hybrid protein fusions into esce 
the structural components of the type three secretion lility 
system. This approach includes delivery of an EscU::eGFP )C01. 
fusion (EscU being a ty pe three secretion apparatus 
protein) into the chromosome and subsequent hybrid ! also 
protein localisation using fluorescence microscopy and Idary 
Western analyses. Ongoing work is also replacing the lids i 
eGFP protein with brighter variants such as GFP+ and óe is 
alternative tags such as haemagglutinin (HA) to 
determine the most appropriate detection system in terms for 
of sensitivity and stability. Again, the flexibility of the 1em 
system allows easy replacement of the sacB -kan cassette )ogea 
with any construct cloned between the flanking region ngeh 
DNA. rage 




have made extensive use of the described system to 
fe chromosomal lacZ fusions to fimbrial genes, type 
.ype secretion genes and regulators (15 -17). In these 
ies we observed that once the sacB -kan cassette is 
gated into the chromosome, it is straightforward to 
wild- educe single copy fusions at this target site 
the 
stern lntial problems areas 
that 
;type iur experience, there are two inherent problems 
allelic the method. Firstly, the pSC101 replicon based 
ion of 'mid vector can be susceptible to loss of 
using perature sensitivity. Care must be taken to ensure 
ribed. all initial cloning steps, transformation recoveries 
lions, cultures are carried out at 30 °C or less. Loss of 
. We ierature sensitivity will result in the inability to 
and ' the strain of the plasmid. We have even 
peron ;untered this problem following particularly hot 
le (9). mer days when the temperature of the laboratory 
ing to reach >28 °C. Secondly, the copy- number of the 
.urinal aid is approximately 6 to 10 per cell. For certain 
retion -sit is possible that this could result in gene dosage 
Ich an !;ems. This may explain our observation when we 
is not opted to delete a DNA methylase gene but found 
avoid initial transformants cultured very slowly in LBC 
nsider'nand did not produce primary integrates (data not 
more al). With regards to which strains of E. coli the 
nto its aique can be applied to, we have successfully 
tulates ipulated several E. coli 0157 strains, 
sopathogenic E. coli (EPEC), uropathogenic E. coli 
C) and K -12 strains. The only strain- specific factor 
may limit the application of the technique is if the 
ncarries a sucrose utilisation system that has been 
:hang ibed in certain isolates of E. coli (18). Clearly the 
ns into ince of such loci would negate the selective 
cretion ability of the sacB gene used in the allelic exchange 
f ::eGFP 0l 
)aratus 
hybrid also important to appreciate that unintended 
y and adary mutations can occur when using suicide 
ng the rids to create a deletion (19). Before a phenotypic 
p+ an4te is attributed to the deleted gene the strain 
[A) to `la be checked. PFGE has been shown to be a useful 
n terms for detecting these unwanted changes and 
of the 1Pm blotting is also advisable to show that no 
cassette ngements have occurred proximal to the site of 
region egeted modification. Alternatively, reverse allelic 
age can restore the wild -type allele to the 
157 
genome; if the phenotype is restored then the changes 
observed can be attributed to the deletion. 
Summary 
Allelic exchange is an invaluable tool for creating defined 
deletions of chromosomal DNA sequences. In this paper 
we describe protocols that ensure a high degree of success 
when using temperature sensitive plasmids for generating 
deletions in Escherichia coli 0157:H7. Our experience in 
creating defined knockouts and complements at several 
loci is discussed as are potential problem areas. Further 
applications of the technology are covered including the 
creation of chromosomal gene fusions to markers such as 
green fluorescent protein and haemagglutinin. 
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Step 3 & 4: Plasntid Curing an. selection of the mitant: 
&own at 28 C in LBK. Selected on 
LBK and LBC agar plates. Bacteria 
J, that only grow oat LEK havre be 4 
successfully exchanged. 
Crown st 28 Con 
LBKanILBC 
agar phtes . 
Positive clones are 
verne dby P CR. 
Homologous reglow of flanking DNA 
Successful strain Original S train 
constructed 
Fig. 1: (Adapted from Blomfleld et al. 1991). The transfer of the sacB -kan cassette into the chromosome requires two recombination events leading to 
plasmid integration followed by plasmid excision. Step 1: plasmid integrates into the wild -type strain at the non permissive temperature for plasmid 
replication (42 °C). Steps 2 and 3: plasmid integrates are grown at 28 °C in the presence of kanamycin to enrich for bacteria that have excised and cured 
the plasmid, leaving the cassette on the chromosome. Step 4: Growth on media containing LBC or LBK. Bacteria that can only grow on LBK are 
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Step 1: Flasmid Integration Removing the sacB -Ann Cassette: 
r°0-1 
A. x X B. 
or 
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CYwwn 01 28 C in 
LE 
Plastid is able to 
replicate so itis 
excised fromtbe 
2. chromosome 
Successful allelic Abortive allelic 
exchange exchange 
Step 3 & 4: Plasmid Curing and s election of the mutant: 
MI 
Colonies that grow on LB sucrose 
are thenplate d on LEK, LEC and 
LB agar. Those that ong grow on 
LB haie be en exchanged. 
1 
o lionnologous regions of flanldng DNA 
Grown at 23 Con 
LB sucrose agar 
plates. Than 
patch plated or to 
LBC,LBK ani 
LB agar plates. 
159 
Clean Deletion created Original S train contanir 
srnB -km cass ette in 
chromos orne 
(Adapted from Blomfield et al. 1991). Step 1: Plasmid integration in the intermediate strain is selected at the non permissive temperature for 
replication (42 °C). Steps 2 and 3: Plasmid integrates are grown at 28 °C in the absence of antibiotics to enrich for bacteria that have excised 
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exchange process relies on a series of sub -culturing steps. Each time 100 µl of the culture is used to inoculate 100 




rting the sacB -kan cassette into the chromosome: 
coli 
d a One: 
obiol Transform the exchange plasmid into the appropriate strain 
Plate 250 pl of the recovered transformation onto LB (Luria -Bertani) agar plates containing chloramphenicol (25 
1 of ug /ml) 
teríol Recover at 28 °C in a static incubator for -48 hours 
and Three: 
richia Inoculate 100m1 of LBC broth (Luria- Bertani broth containing 25 pg /ml of chloramphenicol) with -10 colonies 
from the recovered transformation plate 
m of Incubate at 42 °C and 200 RPM in a shaking incubator for --16 hours 
a coli 
Four: 
both Sub the culture into 100 ml LBC broth, incubate for -8 hrs at 42 °C and 200 RPM 
richia After 8 hrs repeat the sub -culturing step into LBC and incubate for -16 hrs at 42 °C and 200 RPM 
tither 
Five: 
crose Duplicate the sub -culturing step into LBC broth and incubate for -8 hrs at 42 °C and 200 RPM 
ttives ,after 8 hrs sub the culture into 100 ml of LBK (Luria -Bertani broth containing 25 µg /ml of kanamyacin) and 
Iviron Incubate for --16 hrs at 28 °C and 200 RPM 
Before discarding the culture used for the LBK sub create serial dilutions and plate 250 pl of the 10-4 and 10-5 
idary dilutions onto LBC agar plates. Incubate at 28 °C in the static incubator for 16 hours. These can be used to screen 
range ix primary integrants if later steps in the allelic exchange process fails 
richia 
Six: 
Sub the culture into 100 ml of the LBK broth and incubate for -8 hrs at 28 °C and 200 RPM 
Repeat the sub -culturing step into LBK broth and incubate for --16 hrs at 28 °C and 200 RPM 
Seven: 
Repeat the sub -culturing step into LBK broth and incubate for -8 hrs at 28 °C and 200 RPM 
Oter 8 hrs create serial dilutions of the culture and plate out 250 pl of the 10-3, 10-4, 10-5 and 10-6 dilutions onto LBK 
Igar plates and incubate for -16 hrs in a static incubator at 28 °C 
Right: 
Jse the colonies from the serial dilution LBK agar plates to create patch plates. Each colony screened should be 
?ached on an LBC agar plate first followed by an LBK plate. Only those colonies that grow on LBK and not LBC 
Hill be correct. On average 100 - 200 colonies are screened. 
the colonies that can only grow on the LBK patch plate are further checked by PCR. They can be screened by 
sing pIB specific primers. Primers that sit inside the deleted genetic material can also be used. The correct strain 
hould only grow on kanamyacin. 
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Removing the sacB -kan cassette from the chromosome, leaving a clean deletion: 
Day 1: 
Transform the exchange plasmid (containing the flanking regions and no sacB -kan cassette) into the intermediate 
strain with the sacB -kan cassette in the chromosome 
Plate 250 pl of the recovered transformation onto LB (Luria -Bertani) agar plates containing chloramphenicol (25 
pg /ml). 
Recover at 28 °C in a static incubator for -48 hours 
From this the steps are identical to inserting the sacB -kan cassette into the chromosome, up until day four, where the 
subs go from LBC to LB (not LBK). This is grown and sub -cultured (into LB) in the same way until day seven when 
the dilutions are plated onto LB agar plates containing 6% sucrose and no NaCl. This is a selective media where any 
bacteria still containing the sacB -kan cassette will not be able to grow; the colonies that do grow are patched onto LBK, 
LBC and LB (or replica plated). Only those colonies that grow on LB and not LBK or LBC are correct and can be 
verified by PCR. 





9 Cloning Strategies not Taken Forward 
9.1 Strategy for escN 
Wild type sequence 
(sense strand) 
Sequence changed by 
overlapping primers 
A B C 




ATT GAA AGO CTA TTC AAA GTG GTT 
ATT GAA AGO CCT AGG AAA GTG GTT 
Pro Arg Y) 
Avril site 
3 amino acids to 
stop codon of escN 
Fig.7 Diagram showing the REases to be used in the strategy for escN to add an 
Avril recognition site. The nucleotides in blue will be changed in the wild type 
sequence to form the recognition sequence for Avril (shown in red). 
For the gene escN primer 1 (primer F1 from Fig.5) sits over the REase recognition site 
NruI, whilst primer 2 sits over Agel (primer R2 from Fig.5) and primers 3, 4 add the AvrII 
site (Fig.7). Agel is not unique; it is also present in the pIB307 vector. This means that 
either a partial digest will have to be carried out or the Agel site in the pIB307 vector will 
have to be removed. Removal of this site is an option as it is in non essential pIB307 
sequence. The site chosen to manipulate is 4 amino acids from the stop codon of the escN 
gene. This position was chosen as it is 17bp from the start of the next gene in the operon, 
allowing this distance means the addition of a restriction site and a tag will hopefully not 
interfere with the ribosome binding site for the downstream gene. The non 
complementary sequence in the 5' primer used to amplify the tag will contain the 
sequence for the four amino acids from the AvrII site to the stop codon of escN. This 
means that when the tag is cloned into the AvrII site the whole of the escN coding 
sequence (without the stop codon) will be transcribed before the start of the fused tag. 
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9.2 Strategy for escV 
A B C 




Thr Val Asn 
Wild type sequence 
(sense strand) GTA TTA GGA ACG GTA AAT 
Seq uence changed b yGTA TTA GGA TTT AAA TAT 
overlapping primers 




4 amino acids to 
stop codon of escV 
Fig.8 Diagram showing the REases to be used in the strategy for escV to add a 
Swal recognition site. The nucleotides in blue will be changed in the wild type 
sequence to form the recognition sequence for Swal (shown in red). 
The strategy for escV has primer 5 (primer F1) situated over the B1pI recognition site and 
primer 6 (primer R7) over the PmII site with primers 7, 8 overlapping to add a Swal 
recognition site (Fig.8). The strategy is made slightly more complicated as the ATG start 
of escN is l5bp before the 3' end of escV. This means that the 5' primer for the tag will 
contain the sequence for the 5 amino acids from the added Swal site to the 3' end of escV. 
The 3' primer for the tag will also contain 9bp after the stop codon for the tag and before 
the Swal site in the 3'primer, which will recreate the sequence that may contain the 
ribosome binding site for escN. When the tag is cloned into the Swal recognition site the 
9bp in the 3' primer tail for the tag will be repeated; once naturally in the coding region 
for escV before the added Swal site and then again after the stop codon for the tag as non - 
coding DNA before the start codon of escN. 
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9.3 Strategy for escS 
A: Nsil 







Wild type sequence 
TTT GAA ATG ATT CCG AAG GTG AAC (sense strand) 
Sequence changed by TTT GAA ATG CGG CCG AAG GTG AAC overlapping primers 
Arg Pro 
Eagl site 
3 amino acids to 
stop codon of escS 
Fig.10 Diagram showing the REase to be used in the strategy for escS to add an 
Eagl recognition site. The nucleotides in blue will be changed in the wild type 
sequence to form the recognition sequence for Eagl (shown in red). 
The primers over the unique restriction sites for escS are the same as the primers for escR 
(primers 9, 10) (Fig.10). To tag both escR and escS in the same strain either one of escS or 
escR would have to be made first and cloned into the pIB307 plasmid containing the 
escRSTU genes. This plasmid would then be used as the DNA template for the PCR 
reactions needed to create the second tagged gene. When this is cloned the plasmid will 
contain tagged versions of both escS and escR. The ATG start codon of escT is 14bp from 
where primers 13, 14 overlap to add an EagI REase site and the site is 4 amino acids from 
the stop codon of escS. The 5' primer tail for the PCR of the tag should contain the 12bp 
for these 4 amino acids. 
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9.4 Strategy for escT 
A 
A: Ach 
Wild type sequence 






Sequence changed by 
overlapping primers ATT GAT AGA 
C: BstEll 
Ser Leu 
TCG TTA CCG AGC ATG 
TGC GCAI COG AGC ATG 
Cys Ala 
Fspl site 
5 amino acids to 
stop codon of escT 
Fig.11 Diagram showing the REases to be used in the strategy for escT to add an 
Fspl recognition site. The nucleotides in blue will be changed in the wild type 
sequence to form the recognition sequence for Fspl (shown in red). 
Primer 15 for escT is over the unique REase recognition site AcII, and primer 16 over 
BstEII. The added REase recognition site is FspI, added by primers 17, 18 and is 6 amino 
acids from the stop codon of escT (Fig.11). The ATG of escU is 5bp upstream from the 
stop codon for escT. This means there are 13bp from the ATG of escU and the added 
restriction site. These six amino acids will be added in the non complementary sequence 
in the tail of the 5' primer used in the PCR for the tag that will be added at the Fspl site. 
The distance on the chromosome between the added REase recognition site and the start 
of escU should be enough not to interfere with the ribosome binding site for escU. 
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